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SUMMARY
There is increasing evidence that IL-6  may function as a bone-active cytokine. 
IL-1, which itself exerts potent effects on bone cells, is a potent stimulator of 
IL-6  release in several connective tissue cell types. Furthermore, these 
cytokines exhibit strikingly similar biological activities in other tissues. It is 
therefore possible that IL-6  may mediate the effects of IL-1 in bone. In this 
thesis, the synthesis and factors regulating the production of IL-6  protein and 
mRNA by human osteoblast-like cells was investigated. In addition, the effects 
of IL- 6  on human osteoblast-like cell function was determined. A rat 
osteosarcoma cell line was used as a comparative osteoblast-like model.
The cytokines IL-1 and TNF, but not the osteotropic hormones PTH and 
l,25(OH)2D3, induced the synthesis of IL-6  mRNA and protein from human 
osteoblast-like cells whereas PTH was the most potent stimulator of IL-6  
protein release in the rat osteosarcoma cells. Despite the high levels of 
production of IL-6 , this cytokine exerted no effect on various osteoblast cell 
activities including cell proliferation, cytokine and prostaglandin release and 
expression of differentiated phenotype.
Although human osteoblast-like cells apparently lacked responsiveness to IL-6 , 
Northern and dot blot analysis of IL- 6  receptor mRNA showed that the 
transcript was constitutively expressed but not modulated by any of the factors 
above. Lack of effects of IL-6  on osteoblasts could be due to the expression of 
non-functional receptors.
To provide a clearer understanding of the possible role of IL-6  in bone 
physiology in vivo, IL-6  mRNA production in actively remodelling human 
bone tissue was studied by in situ hybridisation. Expression of this cytokine 
was observed in many cell types including cells with the appearance of newly 
formed osteoblasts as well as osteoblasts and osteoclasts adjacent to the bone 
surface and marrow stromal cells. The demonstration of the presence of IL-6
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in bone sections shows that IL-6  production by osteoblasts in culture is not 
artifactual. Further in situ hybridisation studies are required to co-localise IL-6  
mRNA with osteoblast and osteoclast markers in order to gain more information 
about the role of this cytokine in vivo. That several cell types are apparently 
capable of synthesising IL-6  in the bone microenvironment provides strong 
evidence that IL-6  may co-ordinate certain cellular events within bone such as 
hematopoiesis. However, the failure of IL-6  to affect osteoblast activity 
in vitro may discount a direct role in bone formation. The importance of 






Apart from the obvious structural and supporting properties, bone has a number of 
other important functions. Bone provides an attachment site for tendons and 
ligaments and is protective for internal body organs such as the heart and central 
nervous system. Bone also serves as a reservoir for several mineral ions such as 
calcium, phosphorus and magnesium which are capable of being released into the 
circulation during the process of bone remodelling. Bone therefore plays an active 
part in mineral homeostasis.
Bone structure
There are three types of bone, cortical, trabecular (or cancellous) and woven bone. 
Cortical bone
Cortical bone constitutes approximately 80% of the total bone mass. It lines the 
external surfaces of all bones and is most abundant in shafts of long bones where 
trabecular bone is sparse. Cortical bone is composed of Haversian systems (or 
osteons) containing osteogenic cells and canals formed by the remodelling cycle and 
through which blood vessels run. Haversian systems form a tightly packed, 
longitudinally aligned conformation surrounded by a cement line that canaliculi are 
unable to penetrate. The outer and inner most layers of the cortical bone have no 
Haversian systems but instead contain lamellae deposited in parallel to the periosteal 
and endosteal surfaces.
Cortical bone mainly exerts a structural and protective role. As it is only slowly 
remodelled, it does not play a major role in mineral homeostasis.
Whether cortical and trabecular bone communicate with each other has yet to be 
determined.
Trabecular bone
Trabecular bone, with its lattice-like structure, comprises 20% of the skeleton and is 
found predominantly in the long bones and the vertebrae.
Trabecular bone contains a more loosely arranged Haversian system particularly 
because of the high degree of porosity in trabecular bone. Instead, the trabeculae 
consist of a series of perforated interconnecting plates of bone surrounded by blood 
vessels, hematopoietic marrow and fat. This type of bone provides mechanical 
strength as orientation of trabeculae reflect the pattern of stress that a particular area 
of bone is subject to.
Trabecular bone is highly cellular and so it is associated with all cells involved in 
the remodelling cycle. It is therefore more metabolically active than cortical bone 
and possesses a higher bone turnover rate. As this bone is remodelled more 
frequently, its role in mineral homeostasis is of major importance.
Woven bone
This immature bone represents the initial bone laid down in the foetus and around 
sites of active fracture repair. It is not structurally organized and the collagen fibrils 
are layed down in an irregular random fashion. Woven bone is temporary and is 
eventually remodelled to form either cortical or trabecular bone.
Bone histiogenesis
Bone is derived from the mesoderm during embryonic development. There are two 
types of bone formation; intramembranous ossification for flat bones and 
endochondral ossification for long bones, the difference being the presence or
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absence of a cartilagenous template.
Intramembranous ossification
During intramembranous ossification, a group of mesenchymal cells within the 
connective tissue divide and differentiate into osteoblast precursors and mature 
osteoblasts. Osteoblasts then deposit immature woven bone with its disordered 
collagen fibrils. Furthermore, calcification does not proceed in an orderly fashion. 
The bone becomes invaded with blood vessels and hematopoietic bone marrow and 
is eventually remodelled to form mature lamellar bone.
Endochondral ossification
Mesenchymal connective tissue differentiates into prechondroblasts and 
chondroblasts. Once these cells have secreted the cartilagenous matrix and become 
embedded, they are known as chondrocytes. Unlike osteocytes (embedded in 
trabecular bone and formed from osteoblasts), chondrocytes retain the capacity to 
divide. New matrix is synthesized between the chondrocytes referred to as 
interstitial growth and the chondrocytes are arranged as regular columns within the 
growth plate. This is known as the proliferation zone and together with 
differentiation, is responsible for the increased length of tubular bone. The 
chondrocytes enlarge in the hypertrophic zone and progressively lose their 
intracytoplasmic glycogen and show increased vacuolation. This prepares the 
matrix for calcification. The hypertrophic chondrocytes die in the region of matrix 
that selectively calcifies. Once calcified, the matrix is partially resorbed by 
osteoclasts and becomes invaded by blood vessels in a region termed the 
metaphysis. Osteoblasts form woven bone over the cartilagenous remnants. The 
trabeculae formed are further remodelled lower in the growth plate to attain the 
mature state known as secondary spongiosa.
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Cells of bone
Bone turnover in the adult skeleton is continually occurring at discrete sites along 
the bone surface. The cells responsible for dissolution of matrix are known as 
osteoclasts and represent a completely different lineage and phenotype from the 
bone forming cells, the osteoblasts. The necessity for remodelling is evident during 
fracture repair thereby 'knitting' the bones together. Other reasons are mineral 




Osteoclasts are derived from hematopoietic mononuclear cells in bone marrow 
(Roodman et al 1985). Mononuclear osteoclast precursors can circulate in the 
blood and proliferate and fuse at endosteal surfaces to produce multinucleated 
osteoclasts. The majority of evidence supports the view that the precursors are 
derived from a pluripotent stem cell able to differentiate into a granulocyte, 
monocyte or osteoclast. The most likely progenitor is therefore CFU-GM (colony 
forming unit-granulocyte/macrophage). Osteoclasts are not derived from more 
mature monocytes and macrophages (Vaes 1988, Chambers 1989). For a review 
of this subject refer to Skjodt and Russell (1991).
Structure
Osteoclasts are large multinucleated cells of approximately 50-100 um diameter and 
are located on endosteal bone surfaces associated with calcified bone matrix at the 
interface with bone marrow (Baron 1989). In normal adult bone, osteoclasts are 
not frequendy detected but are more readily found at sites of bone undergoing active
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remodelling. Under these circumstances, osteoclasts can contain up to 100 nuclei, 
although 1 0 -2 0  nuclei of heterogeneous size and shape are evident under more 
normal conditions. Osteoclasts also possess a strongly basophilic cytoplasm 
containing primary lysosomes, numerous mitochondria (Holtrop and King 1977) 
and golgi complexes (Baron et al 1985). One of the most striking features of the 
osteoclast is the possession of a highly folded membranous area known as the 
ruffled border, which is in intimate contact with the bone surface (reviewed by 
Jones et al 1985). The ruffled border is surrounded by a clear zone which is free of 
organelles and contains actin filaments which anchor and seal the ruffled border to 
the bone surface (Holtrop and King 1977). Osteoclasts are motile cells and so once 
they have completed the resorption of a pit, are capable of subsequent resorption 
activities (Ali et al 1984).
Function
Osteoclasts are capable of solubilizing the mineral content of matrix and causing the 
dissolution of organic matrix components (Ali et al 1984, Vaes 1988). The area 
under the ruffled border that is enclosed by the clear zones, is responsible for the 
resorption of bone. Lysozomal enzymes are synthesized by the osteoclast and are 
found in the endoplasmic reticulum, golgi and secretory vesicles. The enzymes are 
secreted across the ruffled border into the extracellular bone resorbing compartment 
(Gay and Mueller 1974). Hydrogen ions are formed within the cell by the enzyme 
carbonic anhydrase (isoenzyme II). Osteoclasts also possess a proton pump 
(Baron et al 1985) which is capable of exporting the hydrogen ions into the 
resorbing compartment thereby creating an acidic environment which is optimal for 
the proteolytic enzymes (Vaes 1968). Tartrate-resistant acid phosphatase (TRAP) 
(Minkin 1982) and lysosomal enzymes such as cathepsins (Delaisse et al 1984) are 
produced by osteoclasts. Delaisse et al (1984) observed that excretion of lysosomal
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cysteine proteases by PTH-stimulated embryonic mouse calvariae in culture 
correlated with the extent of resorption which was evaluated by increased serum 
hydroxyproline and calcium levels. Osteoclasts are capable of degrading the bone 
matrix extracellularly (Baron et al 1985) and it appears that the mannose 6 - 
phosphate receptor is involved in the directional release of the lysosomal enzymes 
(Baron et al 1988).
Although TRAP activity may not be exclusive to osteoclasts, its degree of 
expression is certainly far higher in osteoclasts associated with the bone surface 
(Dodds and Gowen 1991). Since TRAP is a hydrolytic enzyme which may be 
involved in the dissolution of matrix, these findings provide good evidence that 
TRAP may be active during resorption.
Osteoblasts
Lineage
Using diffusion chambers implanted in vivo, stromal tissue within bone marrow 
rather than hematopoietic tissue was found to be the origin of the osteoblast 
(reviewed by Owen 1985). It is likely that a pluripotent stem cell within stromal 
marrow can give rise to osteoblasts, fibroblasts, chondroblasts and other stromal 
cells of the marrow cavity (Owen 1985).
Tritiated thymidine pulse treatment in rabbits has been used to follow the 
development of cells throughout the osteogenic lineage (Kember 1960, Owen 
1963). Radiolabelled nuclei were first detected in preosteoblasts within 30 minutes, 




These tire committed progenitor cells capable of proliferation and expressing low 
levels of alkaline phosphatase enzyme. They are usually present close to where 
active mature osteoblasts are synthesizing bone and the preosteoblasts become more 
mature as they reach the bone surface (Puzas 1990).
Osteoblasts
Osteoblasts do not appear to function individually but as members within a team, 
where they are seen as clusters of plump cuboidal cells along the bone surface 
lining a layer of osteoid.
Osteocytes
Approximately 10-20% of the osteoblasts eventually become encased in calcified 
bone (Menton et al 1984). The cells are then known as osteocytes. They are 
metabolically less active than osteoblasts but possessj processes, which may form a 
communication and nutrient system (Menton et al 1984).
Lining cells
These cells line the majority of surfaces on mature bone. They are flattened and 
contain few organelles unlike osteoblasts (Jones et al 1985). It is possible that 
lining cells can transform into osteoblasts although substantial evidence is still 
required (Parfitt 1987).
Osteoblast structure
Osteoblasts are mononuclear cells, 20-30 um in diameter, and contain polarized 
intracellular organelles. These include an extensive network of rough endoplasmic 
reticulum containing large amounts of ribosomes associated with the high synthetic
activity of osteoblasts. They also contain an intricate golgi apparatus and other 
intracellular components reflecting the high metabolic activity of these cells. 
Osteoblasts are capable of extending cytoplasmic processes and may therefore be 
able to communicate with other cells within the bone microenvironment (Vesely et 
al 1992). The osteoblasts are also in contact with the stomal cells of the marrow 
cavity (Deldar et al 1985).
Osteoblasts synthesize substantial levels of alkaline phosphatase which is located in 
the plasma membrane. The function of this enzyme is unclear but may be 
associated with bone formation. For a review on osteoblast phenotype refer to 
Rodan and Rodan (1983).
Function
Osteoblasts lay down matrix in resorption lacunae previously formed by 
osteoclastic activity. Initially the matrix is not calcified and is known as osteoid. 




Within bone 80-90% of the total bone matrix protein is comprised of type I 
collagen. The collagen fibrils are extensively cross linked to form a highly 
insoluble complex (Urist et al 1983). The type I collagen molecule consists of a 
triple helix containing two identical al(I) chains and an a2(I) chain. These are 
tightly supercoiled because of the presence of a glycine at every third residue. In 
the matrix, individual collagen fibrils are packed in an organized conformation with
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small spaces located between the ends of the molecules and the mineral phase is 
initially deposited within and subsequently between the collagen fibrils. Collagen 
type I is produced by the osteoblasts (Canalis 1983a) and it undergoes several post- 
translational modifications during its biosynthesis and secretion. Amino and 
carboxy terminal peptidases cleave the procollagen molecules to form the mature 
protein. In normal mature bone, the collagen fibrils are arranged in parallel, 
whereas in woven bone the fibrils are randomly deposited. The developing 
collagen fibril becomes the focus for the association of non-collagenous bone 
proteins. Several of these proteins are also produced by osteoblasts.
Osteocalcin
This bone matrix protein is also known as bone gla protein (BGP) because of the 
three vitamin K-dependent amino acids, y-carboxyglutamic acid, (gla). Osteocalcin 
is a small (6  kD), highly conserved, abundant bone matrix protein. Osteocalcin is 
produced by osteoblasts from several species including human (Beresford et al 
1984b). Its biosynthesis is dependant on vitamin K for gla formation from three 
glutamic acid residues, vitamin C for hydroxylation of the proline residues and 
vitamin D for the stimulation of synthesis. It exerts a weak association with 
calcium (Hauschka et al 1982) but has strong affinity for hydroxyapatite via the gla 
residues which are vital for mineral binding (Poser and Price 1979). The 
physiological function of osteocalcin is unknown. Long-term warfarin treatment in 
rats can induce the abnormal mineralization of the growth plate and premature 
epiphyseal closure (Price et al 1982). In humans however, vitamin K depletion has 
not been shown to be associated with adverse bone alterations (Piro et al 1982). 
Osteocalcin has been shown to have a role in bone resorption since it has been 
proposed to function as a chemotactic factor for osteoclast precursors (Mundy and 
Poser 1983). In addition, bone implants from warfarin-treated rats are poorly
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resorbed in vivo when compared to normal bone (Lian et al 1984).
Matrix gla protein
Matrix gla protein (MGP) is a second gla-containing protein in bone and is slightly 
larger than osteocalcin having a molecular weight of 10 kD. MGP contains 5 gla 
residues (Price and Williamson 1985) and possesses some degree of homology 
with osteocalcin which would indicate a possible common ancestor. MGP is 
expressed at early stages of bone formation and precedes the accumulation of 
osteocalcin (Fraser et al 1988). Unlike osteocalcin, MGP is not bone specific as it 
is also found in cartilage. Fraser et al (1988) detected either MGP or osteocalcin in 
various clonal osteoblast lines which could indicate that osteoblasts are expressing 
these proteins at different stages of development
Osteonectin
Osteonectin is the most abundant non-collagenous bone matrix protein which is an 
acidic phosphorylated glycoprotein of 32 kD molecular weight. Osteonectin 
possesses high affinity for binding ionic calcium and hydroxyapatite (Termine et al 
1981). Its binding domains for collagen and mineral are separate and this may be 
indicative of a role for osteonectin in the promotion of mineral deposition between 
type I collagen fibrils. Osteonectin is synthesized by a number of different cell 
types including osteoblasts and is produced by a number of species including 
human (Gehron-Robey and Termine 1985). Osteonectin is associated with rapidly 
growing tissues including non bone tissue (Holland et al 1987) and therefore may 




This is a 44 kD bone phosphoprotein which may be involved in the promotion of 
attachment and spreading of osteoblasts, via an arg-gly-asp amino acid sequence, 
to the bone surface (Oldberg et al 1986). Osteopontin contains nine aspartic 
residues which may confer hydroxyapatite binding (Oldberg et al 1986). 
Previously osteopontin has been immunolocalized on osteoblasts and their 
precursors, however recently it has been demonstrated by in situ hybridization to 
be expressed by osteoclasts as well as osteoblasts (Littlewood et al 1991a, Merry et 
al 1992b). Heinegard and Oldberg (1989) demonstrated the presence of 
osteopontin at the clear zone of the osteoclast binding to the mineral and postulated 
that osteopontin, also present in the matrix, may be involved in the attachment of 
the osteoclasts to the bone surface via the vitronectin receptor.
Sialoproteins
Bone sialoprotein was so called because of its high sialic acid content (20% by 
weight). It is a 23 kD protein and is considered to be bone specific. It is not 
located in any other tissue in vivo except for low levels in dentine (Fisher et al
1983). Bone sialoprotein is produced by osteoblast-like cells (Heinegard and 
Oldberg 1989) yet its function is unknown although it binds calcium and so may be 
involved in the bone mineralization process. In other tissues, similar highly acidic 
proteins have been shown to affect cell adhesion (Edelman 1983) and so bone 
sialoprotein may have a similar function. Also, like osteopontin, it contains the arg- 
gly-asp sequence (Oldberg et al 1986) which enables attachment to the vitronectin 
receptor which is expressed by osteoclasts (Horton 1990).
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Proteoglycans
These are macromolecules with acidic polysaccharide side chains known as 
glycosaminoglycans (GAG) attached to a central protein core. The two types of 
GAG found in bone are chondroitin sulphate and heparan sulphate. The latter may 
be involved in the interaction of osteoblasts with the extracellular macromolecules 
(Beresford et al 1987). They possess a negative charge and are able to bind several 
growth factors, eg heparan sulphate is capable of binding fibroblast growth factor 
(FGF). Furthermore, in order for FGF to bind to its receptor, prior association of 
FGF with heparan sulphate is required (Ruoslahti and Yamaguchi 1991). Most 
GAGs are attached to two small proteoglycan core proteins in bone, namely 
biglycan and decorin. Biglycan is especially abundant in developing bone and is 
capable of binding two GAG molecules whereas decorin is found throughout the 
many stages of bone development and only binds one GAG. Decorin is capable of 
binding to collagen fibrils and may control the rate of formation and the size of the 
collagen fibrils. Decorin is capable of binding Transforming growth factor beta 
(TGFp) (discussed on page 31) which can neutralize the growth factor activity. In 
addition, TGFp induces the synthesis of decorin and so this may represent a 
negative feedback mechanism for controlling TGFp activity (Ruoslahti and 
Yamaguchi 1991). As certain proteoglycans are capable of binding various factors, 
the extracellular matrix may act as a store for growth factors. Growth factors act on 
target cells over a short range only and so the immobilization at the cell surface or in 
the extracellular matrix through binding to proteoglycans, may achieve this goal. 
Beresford et al (1987) demonstrated that human osteoblast-like cells produced 
proteoglycans. For a review of proteoglycans, refer to Ruoslahti and Yamaguchi 
(1991).
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Other non collagenous bone matrix proteins
Several other proteins have also been isolated such as thrombospondin which again 
contains the arg-gly-asp sequence (Gehron-Robey et al 1989).
Osteoid also contains a number of plasma proteins including a2 HS glycoprotein 
and albumin. Their function is as yet unknown. For a review refer to Triffitt 
(1987).
Growth factors
Osteoblasts deposit a number of proteins in the bone such as TGFp, bone 
morphogenetic proteins (BMPs), insulin-like growth factor I (IGF-I) and FGFs. 
For a review, refer to Canalis et al (1989). These factors are associated with 
osteoblast function and proliferation as well as exerting effects on osteoclasts. 
They are discussed in more detail later in this chapter.
Mineralization
The osteoid therefore contains tightly packed collagen fibrils complexed with a 
number of non collagenous proteins. The principal mineral constituent is 
hydroxyapatite. Other minerals such as magnesium ions are associated with 
extracellular matrix. The process of mineralization is still a matter of contention. 
Bone cells are probably involved in this process. Alkaline phosphatase, produced 
by osteoblasts, may promote mineralization by reducing levels of free 
pyrophosphate which is an inhibitor of hydroxyapatite formation (Fleisch and 
Bisaz 1962). Matrix vesicles are likely to be involved in initial calcification 
(Anderson 1976). Matrix vesicles are not normally evident in the upper 
proliferating zone of the growth plate where cells are actively dividing but are 
observed in clusters in the lower proliferative region. Vesicles associated with the 
hypertrophic zone contain needle-like hydroxyapatite crystals. These crystals
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eventually disrupt the vesicles and grow to form nodules of hydroxyapatite which 
are deposited between the collagen fibrils. Several factors may control this process. 
For a review refer to Anderson (1976).
The remodelling cvcle
| The processes of bone resorption and bone formation are linked or 'coupled' in 
normal bone turnover in what is termed the bone remodelling cycle (Fig. 1.1).
I
I
The bone remodelling cycle was first described by Frost (1964) who observed that 
remodelling occurred at discrete sites along the bone surface. Osteoclasts resorbed 
a quantity of the bone and this was then replaced with new matrix by the 
osteoblasts. These events were more closely studied during tooth egression in rats
) (Tran Van et al 1982).
Activation is initiated by the presence of mononuclear cells around the site of bone 
that is to be resorbed. These cells contain enzymes characteristic of the 
mononuclear phagocytic lineage eg. non-specific esterase. Flattened lining cells, 
possibly derived from osteoblasts, then may retract their cytoplasm to expose the 
matrix underneath and to which the mononuclear cells extend cytoplasmic processes 
to establish contact (Jones and Boyde 1976). These mononuclear cells start to fuse 
to become multinucleated osteoclasts and form ruffled borders against the bone 
surface. During the resorption phase, these cells erode a quantum of bone of 
characteristic size and depth, known as a resorption lacuna. This phase is only 
short lived, approximately 2  days after which the osteoclasts are replaced by large 
TRAP positive mononuclear cells of unknown origin. This initiates the reversal 
phase, a period of about 4 days, during which these cells lay down a cement line 
rich in glycoproteins and GAGs. Osteoblasts then attach to the cement line and 
there follows a much longer formation phase whereby osteoblasts lay down osteoid 
which is then eventually mineralized. It is possible that the osteoblasts then
16
transform to the flattened morphology of lining cells.
These cyclical events observed in remodelling must be tightly controlled both 
through systemic factors, and as discrete remodelling foci are present, some local 
signalling between the cells and matrix of bone must also exist.
Bone cell coupling
The term coupling essentially describes the cellular linkage between bone resorption 
and formation processes that occur at each resorption site. Successful coupling 
results in the replacement of the resorbed area with new bone associated with 
osteoblast activity. Although the mechanisms associated with this process are 
unknown, there are many ways in which coupling can proceed.
To account for the coupling phenomenon, Howard et al (1981) proposed that an 
osteoblast-stimulating factor is released during the process of osteoclastic bone 
resorption and that the stimulation of osteoblast activity leads to new bone 
formation. The source and identity of these local osteotropic factors is at present 
unknown. It is possible that they are released from the actively resorbing osteoclast 
or related cells. Alternatively, these factors could be incorporated into the bone 
matrix during bone formation and subsequently released during the phase of 
osteoclast resorption. The products of re sorbed bone have been reported to act as 
chemotactic agents for the osteoblast lineage. Local factors such as TGFp, released 
from the matrix during resorption, may mediate this chemotactic effect (Pfeilschifter 
et al 1990b). Similar functions may also apply to additional growth factors and 
cytokines that are active on bone. An alternative theory is that the factor which 
stimulates resorption also acts directly, although more slowly, on the osteoblast to 
cause their activation and subsequent new bone formation. Parathyroid hormone 
(PTH) is an example of a factor that stimulates both bone resorption and formation 
in vivo (Tam et al 1982).
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Factors which influence the remodelling process
Systemic hormones 
Parathyroid hormone (PTH)
PTH regulates the levels of calcium and phosphate in the blood by acting on bone 
and kidney. When calcium levels are low PTH stimulates the release of calcium 
from bone and increases reabsorption of calcium from the glomerular filtrate. PTH 
can also activate the la  hydroxylase enzyme in the kidney to stimulate the 
production of 1,25-dihydroxyvitamin D3 (l,25(OH)2D3) which can then increase 
the intestinal absorption of calcium. Blood calcium can also influence PTH levels 
since an increase in calcium level decreases the secretion of PTH. All these events 
serve to maintain a constant serum calcium level irrespective of the contribution of 
the diet, bone metabolism and fluctuation in renal function. PTH is involved in the 
stimulation of bone resorption, thereby releasing calcium into the blood. This can 
be demonstrated in a number of bone organ culture systems including fetal rat long 
bones (Raisz 1963, Raisz 1965, Mundy et al 1976, Lorenzo et al 1983) and 
neonatal mouse calvariae (Feldman et al 1980). PTH is capable of synergising with 
a number of agents such as interleukin 1 (IL-1) (Dewhirst et al 1987, Sato et al 
1989) and vitamin A (Raisz 1965) to further increase bone resorption. Several 
groups have observed that the action of PTH results in an increase in osteoclast 
number in these systems (Raisz 1963, Feldman et al 1980). Lorenzo et al (1983) 
reported that PTH-induced resorption occurred independendy of the replication of 
osteoclast precursors, which would indicate that PTH exerts its effects through the 
fusion of pre-formed precursors. Teti et al (1988) observed that PTH did not 
induce the fusion of blood monocytes with osteoclasts concluding that the 
precursors may be committed in the bone marrow. Many groups have investigated
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the effect of PTH in human, feline and primate long term marrow cultures. The 
cells within these cultures are capable of being induced by PTH to form 
multinucleated cells which possess several osteoclast characteristics such as TRAP 
activity, reactivity with a monoclonal antibody 23C6, calcitonin receptors and 
production of resorption lacunae on bone or sperm whale dentine (Ibbotson et al 
1984, Roodman et al 1985, MacDonald et al 1987, Takahashi et al 1989). In a 
contrasting study, Kurihara et al (1991) demonstrated that PTH stimulated the 
proliferation of early osteoclast precursors rather than promoting the fusion of late 
precursors.
PTH is capable of stimulating already formed osteoclasts to resorb the medullary 
bone of Japanese quail (Miller 1978). Miller (1978) demonstrated that after 20 
minutes infusion, PTH induced ruffled border and clear zone formation on inactive 
osteoclasts which was subsequently followed by increased plasma calcium levels. 
PTH stimulates carbonic anhydrase activity in mouse calvarial osteoclasts 
(Anderson et al 1985) and increases acid phosphatase and hyaluronate synthesis 
(Wong et al 1977), another indication that PTH activates pre-formed osteoclasts.
A possible mechanism by which PTH can mediate its bone resorptive effect is by 
stimulating the production of latent collagenase as visualised in mouse calvarial 
osteoblasts (Heath et al 1984), rat calvarial osteoblasts (Shen et al 1988) and 
UMR106-01 cells (Partridge et al 1987). Plasminogen activator, an enzyme 
capable of activating collagenase via an enzyme cascade, is also released by rodent 
(Hamilton et al 1984, Partridge et al 1987) and human (Evans et al 1990b) 
osteoblasts. Activated collagenase may degrade the osteoid layer thereby exposing 
the mineralized bone matrix for resorption by osteoclasts. Osteoblasts are capable 
of producing a variety of inhibitors for these enzymes indicating the involvement of 
a complex regulatory control mechanism in this potential process.
PTH is capable of inducing shape changes in bone cells (Lomri and Marie 1988)
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and Rodan and Martin (1981) proposed that shape changes in osteoblasts could 
cause a mild retraction of cells leading to the exposure of the underlying matrix to 
the osteoclasts.
A related peptide (rp) called PTHrP is also capable of inducing bone resorption in 
organ culture (Raisz et al 1990). Bone resorptive effects of PTHrP are also 
observed in vivo when nude mice are transplanted with human esophageal 
carcinoma cells which produced IL-la and PTHrP (Sato et al 1989). These mice 
developed hypercalcemia. Separate experiments were performed in order to assess 
the relative contribution of each agent. Both IL-la and PTHrP increased 45Ca 
release from prelabelled forearm bones of fetal mice but only PTHrP consistently 
increased serum calcium levels. Sato et al (1989) postulated that the effects of 
PTHrP on hypercalcemia were due to a combination of the stimulation of both bone 
resorption and calcium readsorption in the kidney (Sato et al 1989). Murrills et al
(1990) observed that osteoclasts disaggregated from neonatal rat bone were 
stimulated to resorb devitalized bone with both PTH and PTHrP which resulted in 
an increased number of pits, although mean area of pit excavated was decreased. 
Studies in vivo have demonstrated that long-term treatment with PTH is anabolic. 
Trabecular bone calcium is increased after daily sub-cutaneous injection of PTH for 
twelve days into rats (Hey et al 1988). Tam et al (1982) injected 
thyroparathyroidectomized rats with PTH and observed that the daily injection 
increased bone apposition while continuous infusion resulted in increased bone 
formation and resorption. In rats injected daily with PTH, the amount of cancellous 
bone eventually increased and this was accompanied by an increased number of 
osteoblasts and a decreased osteoclast number (Liu and Kalu 1990). Hock et al 
(1989) used a combination of pulsatile PTH with calcitonin or a bisphosphonate, 
dichloromethylene disphosphonate (CI2MDP), in rats to successfully block the 
stimulation of resorption induced by PTH. This resulted in an increase in bone
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formation by PTH independently of the need for previous bone resorption. In a 
more recent study, Hock et al (1992) observed that intermittent PTH administration 
was significantly more anabolic than continuous PTH. Furthermore, Hock and co 
workers (1992), using a combination of continuous PTH and CI2 M D P 
demonstrated that PTH induced formation independently of its effects on bone 
resorption.
The combination therapy of nasal calcitonin spray and intermittent PTH injection 
has been used to increase the trabecular bone mass of osteoporotic patients (Hesch 
et al 1989). Thus from an anabolic aspect, intermittent treatment with PTH appears 
to be more beneficial than a continuous infusion.
Osteoblasts, unlike osteoclasts, are capable of directly responding to PTH. This is 
related to the fact that receptors for PTH have been localized on osteoblasts but not 
osteoclasts. Isolated osteoclasts do not respond to PTH (McSheehy and Chambers 
1986a). It has been postulated that a soluble factor is released from PTH-stimulated 
osteoblasts which stimulates osteoclast activity. In an attempt to characterise this 
factor, McSheehy and Chambers (1986b) observed that it was smaller than 1 kD, 
stable to freeze thawing but inactivated at 65°C after 30 minutes. In contrast, Perry 
et al (1989), employing similar techniques, isolated a 110 kD protein which was 
dependent on a divalent cation for retention of its activity. Furthermore, the 
stimulation of resorbing activity of isolated osteoclasts with this 110 kD factor was 
not blocked by treatment with indomethacin which therefore indicates that this 
factor exerts its effects via prostaglandin-independent mechanisms. It must be 
noted however, that PTH can induce prostaglandin E2 (PGE2) in human osteoblasts 
(MacDonald et al 1984) and enhances IL-1 elevated PGE2 in rat calvarial 
osteoblasts (Tatakis et al 1988).
The effects of PTH on osteoblasts at least in the short term are mainly de­
differentiating and proliferative changes are variable. These effects may be related
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to the initial differentiation status of the osteoblast-like cells used in addition to 
differences in culture conditions such as cell density, serum concentration and time 
of exposure. For a summary of effects of PTH on the proliferation of osteoblasts 
and alkaline phosphatase and collagen type I expression, refer to table 1.1.
Canalis et al (1990) observed that PTH and PTHrP were able to induce the 
proliferation of cells in fetal rat calvariae. MacDonald et al (1986a) reported that 
PTH induced the proliferation of human osteoblast-like cells over long-term culture. 
A proliferative effect on osteoblasts in vivo would account for the increase in 
trabecular bone volume observed in rats following intermittent infusion of PTH.
A characteristic effect of PTH on osteoblast-like cells is the stimulation of the PTH 
receptor-linked adenylate cyclase and cAMP formation in human (MacDonald et al
1984), murine (Heath et al 1984), rat ROS 17/2.8 (Shigeno et al 1988) and human 
SaOS-2 (Fukayama and Tashjian 1990) osteoblasts. Many of the effects of PTH 
are mediated via the stimulation of adenylate cyclase although there are reports of 
PTH receptors which are coupled to protein kinase C (Hesch et al 1988, Rao and 
Murray 1989, Mitchell and Goltzman 1990). Recently the cDNA for the PIH- 
PTHrP receptor has been expressed and cloned in monkey COS-7 cells (Juppner et 
al 1991). The expressed receptor was capable of binding both PTH and PTHrP 
with equal affinity and intracellular signaling was linked to the G protein thereby 
activating adenylate cyclase and cAMP (Juppner et al 1991). The authors reported a 
significant homology between the PTH-PTHrP and the calcitonin receptor, another 
G protein-linked receptor. Since both PTH and calcitonin are involved in calcium 
homeostasis, Juppner and co workers postulated that these novel receptors could 
represent a new family of G protein-coupled receptors which share functional 
features that distinguish them from other G protein-linked receptors.
Receptors for PTH have been localised in an embryonic avian bone cell population, 
the identity of which are likely to be osteoblasts (Pliam et al 1982). Silve et al
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(1982) using light microscope autoradiography localised PTH receptors on 
osteoblasts and progenitor cells but not in osteoclasts or osteocytes in embryonic 
chick calvariae. Rouleau et al (1988) using a similar isotopic technique in vivo 
detected binding of PTH to a certain population of cells within rat long bones that 
were distinct from mature osteoblasts. Further studies characterised the target cell 
for PTH as a slowly dividing cell which may represent an osteoblast precursor 
although these cells were histologically distinct (Rouleau et al 1990).
1.25-dihvdroxwitamin (1.25(OHDD^l
l,25(OH)2D3 is the other majoijcalciotropichormone along with PTH which 
regulates calcium homeostasis in the intestine, bone and kidney. l,25(OH)2D3 is 
considered to represent the hormonally active metabolite of vitamin D3 . 
l,25(OH)2D39 like PTH also stimulates the production of latent collagenase in rat 
(Shen et al 1988) and mouse (Heath et al 1984) calvarial osteoblast-like cells. 
Hamilton et al (1984) and Partridge et al (1987) demonstrated that l,25(OH)2D3 
increased plasminogen activator production from UMR106-01 cells. 
l,25(OH)2D3 is also a potent resorbing factor in both fetal rat long bones (Holick 
and DeLuca 1972, Vargas et al 1990) and neonatal mouse calvariae (Reynolds et al 
1973, Linkhart and Keffer 1991) and stimulates the formation of osteoclast-like 
cells in a variey of long-term marrow culture systems (Ibbotson et al 1984, 
Roodman et al 1985, MacDonald et al 1987, Takahashi et al 1989, Kurihara et al 
1991). Abe et al (1983) observed that l,25(OH)2D3 was capable of inducing the 
fusion of mouse alveolar macrophages into multinucleated cells, although these did 
not resorb bone. Holtrop et al (1981) studied the effects of l,25(OH)2D3 in 
thyroparathyroidectomized rats maintained on a vitamin D-deficient diet and 
demonstrated that independendy of PTH, intravenous injection of l,25(OH)2D3 
increased osteoclast number. These osteoclasts had prominent ruffled borders,
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clear zones and nuclei. Furthermore, this hormone also increases other osteoclast 
characteristics such as acid phosphatase and hyaluronate synthesis (Wong 1977). 
l,25(OH)2D3 is a potent maturation factor, that is capable of promoting the 
differentiation of a number of cells along the macrophage lineage. These include 
human monocytic leukemia U937 cells (Amento et al 1984), HL-60 cells (Bar- 
Shavit et al 1983, Reichel et al 1987), bone marrow cells (Miyaura et al 1982) and 
murine myeloid Ml cells (Miyaura et al 1989a). In one of these studies, HL-60 
cells differentiated into multinucleated cells which were capable of bone resorption 
(Bar-Shavit et al 1983). Thus, many lines of evidence suggest that l,25(OH)2D3 
may be involved in osteoclastogenesis by promoting cell differentiation. 
l,25(OH)2D3 also promotes the differentiation (Table 1.2) of the markers of the 
osteoblast phenotype including upregulation of alkaline phosphatase activity and 
osteocalcin expression. The effects of l,25(OH)2D3 on the synthesis of type I 
collagen are variable and may be species related. Contradictory reports with repect 
to the effects of l,25(OH)2D3 on alkaline phosphatase activity may reflect the 
density and/or maturity status of the osteoblast cell cultures (Majeska and Rodan 
1982, Fritsch et al 1985). Furthermore, Owen et al (1991) detected variable effects 
of l,25(OH)2D3 on all three parameters in rat osteoblasts. This was dependent on 
the proliferative and differentiative state of the osteoblasts and also the duration of 
exposure of the cells to hormone treatment. Osteocalcin, alkaline phosphatase and 
collagen genes all contain a 5' upstream sequence which contain l,25(OH)2D3 
responsive elements and AP-1 binding sites (Owen et al 1991). Owen et al (1991) 
observed that during the proliferative phase of osteoblasts, a fos-jun nuclear 
complex bound a region in the 5’ sequence which inhibited the expression of 
osteocalcin. l,25(OH)2D3 exposure during cell differentiation may cause the 
disassociation of this complex thereby initiating transcription of the osteocalcin 
gene. l,25(OH)2D3 promotes the production of various other matrix components
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from osteoblasts including osteonectin (Thiebaud et al 1989) and osteopontin (Jin et 
al 1989, Owen et al 1991). Merry et al (1992a) demonstrated that l,25(OH)2D3 
induced transforming growth factor-p (TGFp) mRNA expression in human 
osteoblast-like cells. This work was in accordance with a report by Finkelman et al
(1991) who observed that rats maintained on a vitamin D-deficient diet lacked TGFp 
expression in the matrix. Since osteoblasts are known to release this growth factor, 
it was proposed that l,25(OH)2D3 was involved in the promotion of maturation of 
the osteoblast and elaboration of bone matrix proteins (Finkelman et al 1991). 
l,25(OH)2D3 exerts anti-proliferative effects on human osteoblasts (Beresford et al 
1986, Evans et al 1990a), rat and mouse calvarial osteoblasts (Chen et al 1983) and 
ROS 17/2.8 (Majeska and Rodan 1982, Yoneda et al 1984). Skjodt et al (1985) 
observed a biphasic effect of l,25(OH)2D3 on human osteoblasts according to the 
dose used, with high concentrations inhibiting proliferation and low concentrations 
inducing a small though consistent stimulatory effect.
Receptors for l,25(OH)2D3 have not been demonstrated in osteoclasts. This may 
account for the lack of observed effects of l,25(OH)2D3 on isolated osteoclasts 
(Chambers and Dunn 1982, McSheehy and Chambers 1987). However the 
l,25(OH)2D3 receptor has been demonstrated in various osteoblast lines including 
MC3T3-E1 (Kurihara et al 1986), UMR series (Partridge et al 1980), mouse 
calvaria (Chen et al 1979), primary rat (Chen et al 1986), rat calvaria (Kream et al 
1977), chick calvaria (Kream et al 1977) and ROS 17/2 (Petkovich et al 1984). 
Merke et al (1986) demonstrated that the ligand-receptor complex bound to DNA in 
the nuclear fraction of whole bone preparations, a characteristic of steroid receptors. 
Receptor levels are regulated by a number of agents including l,25(OH)2D3 and 
PTH in UMR 106 cells (Pols et al 1988a, Pols et al 1988b) and by l,25(OH)2D3 
and retinoic acid in MG-63 cells (Mahonen et al 1989).
Vargas et al (1990) characterised the effect of the rat l,25(OH)2D3-binding protein
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in serum which was found to block the action of the hormone as visualised by a 
decrease in l,25(OH)2D3-stimulated resorption in fetal rat long bones.
Calcitonin
This small peptide is produced mainly by the C cells in the thyroid.
The characteristic effect of this peptide on bone is the inhibition of basal and 
stimulated resorption by osteoclasts (Wong et al 1977, Gowen et al 1985, Stem et 
al 1985, Bertolini et al 1986, deVemejoul et al 1988, Abe et al 1988, Nishihara et al 
1989, Fujii et al 1990, Raisz et al 1990, Linkhart et al 1991). Furthermore, 
calcitonin inhibits the formation of multinucleated cells in long-term marrow culture 
systems (Ibbotson et al 1984, Takahashi et al 1989, Kurihara et al 1991).
Recently, the cDNA for the calcitonin receptor has been expressed and cloned in 
monkey COS cells (Lin et al 1991). The authors observed that similar to the PTH- 
PTHrP receptor, calcitonin receptors were linked to a G protein that subsequently 
lead to increases of intracellular cAMP upon ligand binding. Lin et al (1991) 
reported that the calcitonin receptor was a unique structure and only exhibited a 
degree of amino acid sequence similarity with the PTH-PTHrP receptor. Therefore 
the calcitonin and PTH-PTHrP receptors appear to represent a new family of G 
protein-coupled receptors.
Receptors for calcitonin have been observed on osteoclasts (Goldring et al 1988, 
Shinar et al 1990, Kurihara et al 1991). Chambers et al (1985) was able to 
demonstrate an inhibition of pit formation by isolated osteoclasts when calcitonin 
was present and deVemejoul et al (1988) demonstrated a similar inhibitory effect as 
assessed by 45ca release from devitalised bone. It appears that the major effect of 
calcitonin on osteoclasts is the rapid inhibition of osteoclast motility and retraction 
of pseudopods (Chambers and Dunn 1982, Dempster et al 1987). Dempster et al
(1987) observed this effect using synthetic chicken calcitonin on disaggregated rat
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osteoclasts, but was unable to demonstrate the same effect on embryonic chicken 
osteoclasts. This group postulated that native chicken calcitonin may be required 
for an effect on the chicken system. Several groups have observed an effect known 
as the 'escape' phenomenon, where the osteoclasts begin to resorb again after a lag 
period of inactivity in the presence of calcitonin. Fujii et al (1990) observed this 
effect after two days treatment of calcitonin on fetal mouse forearm bones. Peterlik 
et al (1985) observed that interferon-y also had a calcitonin-like inhibitory effect, 
but differed from calcitonin in that no escape phenomenon was detected. Clinically 
this phenomenon has been used in combination with PTH for the effective treatment 
of osteoporotic patients whereby salmon calcitonin is administered for the 
functional life span of the osteoclast and PTH is given whilst the osteoblasts are 
actively forming bone (Hesch et al 1989). In a comparative in vitro study, Zaidi et 
al 1987 demonstrated that salmon calcitonin was more potent than human calcitonin 
with respect to inhibition of bone resorption.
Calcitonin gene-related peptide (CGRP) is not as potent as calcitonin but is capable 
of decreasing bone resorption (Zaidi et al 1987) and does not exhibit the escape 
phenomenon (D' Sousa et al 1986).
Calcitonin has also been reported to exert effects on osteoblast-like cells in vitro. 
Klein et al (1991) demonstrated the presence of calcitonin receptors on the 
osteoblast UMR 106-06 cell line and detected a slight decrease in collagen synthesis 
and cell proliferation upon addition of calcitonin whereas Farley et al (1991c), using 
human osteosarcoma SaOS-2 cells observed an increase in cell proliferation and 
alkaline phosphatase activity. CGRP also exerts effects on osteoblast-like cell 
lines, increasing intracellular cAMP content (Burns et al 1991). Calcitonin 
therefore also appears to modulate osteoblast activity although further work is 
required to gain a clearer understanding.
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Glucocorticoids
Glucocorticoids potendy inhibit bone resorption (Raisz et al 1972, Mundy and 
Martin 1982) and decrease osteoclast-like cell formation in long-term marrow 
culture (Suda et al 1983). In addition, glucocorticoids decrease the transcription of 
other agents involved in bone resorption such as IL-1 (Lee et al 1988).
The major action of glucocorticoids however is their potent inhibition of bone 
formation. Glucocorticoids act directly on osteoblast-like cells and these cells have 
been demonstrated to possess the glucocorticoid receptor (Chen et al 1977). 
Canalis (1983a) demonstrated that glucocorticoids decrease the transcription of 
procollagen type I transcription in rat calvarial cells in accordance with a study by 
Gallagher et al (1983) who also demonstrated that osteocalcin transcription was 
inhibited by glucocorticoid treatment in human trabecular bone cells. Since Dietrich 
et al (1979) reported that short-term glucocorticoid treatment caused small increases 
in collagen, it is possible that these steroids have dual effects on sub-populations of 
cells at different differentiation stages. A major effect of glucocorticoids is the 
inhibition of preosteoblast replication which is observed in vivo and in most tissue 
culture systems (Chen et al 1977, Dietrich et al 1979). The overall effect of 
glucocorticoid treatment therefore results in a decrease in available mature 
osteoblasts and a subsequent decrease in bone formation.
Prostaglandins (PG1
In a comparative study, PGE2 was shown to be most potent prostanoid in 
stimulating bone resorption although PGF, PGA and PGB were all active but with 
a reduced potency (Dietrich et al 1975). Other groups have also demonstrated a 
resorptive effect of PG in neonatal mouse calvariae (Katz et al 1983, Peterlik et al
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1985) and fetal rat bones (Klein and Raisz 1970, Rodan et al 1981). PGs are 
thought to mediate the resorption of some agents including epidermal growth factor 
(EGF), FGF (Tashjian and Levine 1978) and possibly IL-1 (Akatsu et al 1991) 
although with respect to the latter, PG-independent effects have also been reported 
(Gowen and Mundy 1986). In long-term bone marrow cultures, the effect of PGE2 
on osteoclast-like cell formation is variable. Ibbotson et al (1984) and Akatsu et al 
(1991) both observed a stimulatory effect, whereas Roodman et al (1985) observed 
no effect. Collins and Chambers (1991) reported that whilst PGE2 alone induced 
osteoclast-like cell formation in long-term bone marrow culture, it had an inhibitory 
effect on l,25(OH)2D3-stimulated osteoclast formation. Hiura et al (1991) 
observed that PGE2 was partially responsible for the decreased formation of 
multinucleated cells in spleen cells of 5-fluorouracil treated mice.
The effect of PGs on isolated osteoclasts was to inhibit resorption (Chambers and 
Dunn 1982, Chambers et al 1985, deVemejoul et al 1988). deVemejoul et al 
(1988) observed calcitonin-like effects with PGE2 in that osteoclast motility was 
decreased. It is possible that accessory cells are required in the vicinity of the 
osteoclast in order for PGs to stimulate osteoclastic bone resorption.
Stimulation of bone resorption induced by PGs can also be demonstrated in vivo. 
Tashjian et al (1972) transplanted mice with a PGE2-producing tumour and 
observed an increase in plasma calcium levels not observed in control mice or in 
mice transplanted with non-PGE2 producing tumours. In addition the 
cyclo-oxygenase inhibitor, indomethacin, blocked the resorptive effect induced by 
the tumour.
Norrdin and Shih (1988) found that in dogs with rib fracture, the long-term 
administration of PGE2 increased bone formation. Whether this is a direct effect of 
PGE2 is not clear since PGE2 is able to induce the production of growth factors 
such as IGF-I from osteoblasts that are associated with stimulating bone formation
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(McCarthy et al 1991).
PGs themselves are produced by osteoblasts stimulated by a variety of agents such 
as IL-1, tumour necrosis factor (TNF), thrombin, haptoglobin (Rodan et al 1981, 
Nolan et al 1983, Gowen 1988, Evans et al 1990b, Frohlander et al 1991) and by 
mechanical strain (Murray and Rushton 1990). Thus the effects of cytokines such 
as IL-1 and TNF to stimulate bone resorption may be mediated via the production 
of PGE2 from the osteoblast. PGs are also capable of inducing the production of 
collagenase (Shen et al 1988, Heath et al 1984) and plasminogen activator 
(Hamilton et al 1984) release from rodent osteoblasts and so this may represent 
another mechanism whereby PGs exert pro-resorptive effects.
Other effects of PG on osteoblasts include the induction of alkaline phosphatase in 
MC3T3-E1 cells (Hakeda et al 1985, Kumegawa et al 1984) and stimulation of 
collagen type I in rat RCT-1 and RCT-3 lines (Ernst et al 1989), chicken pre- 
osteoblasts (Nagai 1989) and fetal rat pre-osteoblasts (Chyun and Raisz 1984). 
Prostanoids are therefore able to promote the maturation of the osteoblast 
phenotype which may account for some of the long-term effects of PGs observed 
on bone formation.
PGs also promote the proliferation of pre-osteoblasts (Chyun and Raisz 1984), 
chicken osteoblasts (Van der plas et al 1985) and RCT-1 and RCT-3 rat osteoblast 
lines (Ernst et al 1989) via IGF-I production.
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Local Factors
Transforming growth factor B (TGFB'l
TGFp represents a member of a growing family of related peptides including 
TGFpi, TGFp2 and bone morphogenetic proteins as well as a variety of other 
proteins. For a review see Mundy and Bonewald (1991).
TGFp has been shown to exert variable effects on bone resorption. It stimulates 
resorption in neonatal mouse calvariae or mouse long bones possibly via the 
induction of PG (Tashjian et al 1985, Pfeilschifter et al 1988, Dieudonne et al 
1991). Others have been unable to demonstrate a resorptive effect of this growth 
factor in a variety of systems including fetal rat long bones (Pfeilschifter et al 1988) 
and isolated avian osteoclasts on sperm whale dentine slices (Oreffo et al 1990). 
Others have demonstrated an inhibitory effect of TGFp on bone resorption in fetal 
mouse long bones where osteoclast fusion and migration into the marrow cavity 
appeared to be inhibited (Dieudonne et al 1991). Furthermore, Pfeilschifter et al
(1988) using fetal rat long bones, demonstrated that TGFp partially or completely 
blocked the induction of bone resorption by IL-1 and l,25(OH)2D3 possibly by 
diverting precursors along a different lineage. This is supported by evidence from 
long-term marrow cultures where TGFp is proposed to divert cells away from the 
osteoclast precursor pool by increasing the number of granulocyte-macrophage 
colony forming units (Chenu et al 1988). Shinar and Rodan (1990) observed a 
biphasic effect of TGFp which was PG and dose-related in long-term mouse bone 
marrow culture. A low concentration of TGFp enhanced l,25(OH)2D3-dependent 
stimulation of osteoclast-like cell formation via PG generation, whereas at a higher 
concentration, TGFp was reported to be directly inhibitory (Shinar and Rodan
1990).
In vivo, persistent or daily injections of TGFp stimulate woven bone formation and
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increase bone thickness in rats and mice and as there were also increased osteoclast 
numbers, this would suggest that TGFp may be a coupling factor (Noda and Rodan 
1986, Mackie and Trechsel 1990). Furthermore, after 19 days the woven bone was 
partially replaced by lamellar bone in the mouse (Mackie and Trechsel 1990). The 
potential involvement of TGFp in stimulating bone formation was further supported 
using vitamin D-deficient rats (Finkelman et al 1991). These rats had a reduced 
skeletal content of TGFp which resulted in reduced osteoinduction as a consequence 
of the less mature cells being unable to elaborate bone matrix (Finkelman et al
1991). TGFp is produced by osteoblasts and chondrocytes in a latent form 
(Gehron-Robey et al 1987, Oreffo et al 1989, Gelb et al 1990, Pfeilschifter et al 
1990a, Pfeilschifter et al 1990b) and some of this can be deposited into the bone 
matrix. Oreffo et al (1989) postulated that the latent form of TGFp in the matrix 
could be activated by osteoclasts during the process of bone resorption. The acidic 
environment is favourable for the dissociation of latent TGFp from a binding 
protein of about 300 kD (Pfeilschifter et al 1990a). Once the TGFp is activated it 
may then serve to inhibit further osteoclastic resorption and to promote the 
formation of osteoblasts and so may function to couple these two phases. This is 
supported by evidence from the work of Pfeilschifter et al (1990b) who observed 
that activated TGFp was transiently chemotactic for osteoblasts.
The proliferative effects of TGFp on osteoblasts are often biphasic with the 
concentration of growth factor being critical ( Centrella et al 1987, O' Keefe et al
1988). This is also seen for collagen type I synthesis (Centrella et al 1987). 
Variable effects on alkaline phosphatase are also observed and may be related to cell 
proliferation (Centrella et al 1987). Centrella and co workers observed that doses 
of TGFp that inhibited alkaline phosphatase expression, maximally stimulated 
proliferation in fetal rat osteoblasts. Conversely, an increase in TGFp concentration 
inhibited proliferation and returned alkaline phosphatase to original levels. Noda
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and Rodan (1986) using murine non transformed MC3T3-E1 cells reported that 
alkaline phosphatase levels, which peak when cells are confluent, were inhibited by 
TGFp. Overall et al (1989) demonstrated TGFp-induced release of plasminogen 
activator inhibitor (PAI) from fibroblasts which would ultimately reduce 
collagenase activity.
Growth factors
Many growth factors, including transforming growth factor a (TGFa), epidermal 
growth factor (EGF), platelet derived growth factor (PDGF), insulin-like growth 
factors (IGFs) and acidic or basic fibroblast growth factors (a or bFGFs) have been 
demonstrated to have effects on bone. For a review on these refer to Canalis et al
(1989), Schmidt and Ernst (1991), and Rodan and Rodan (1991). Growth factors 
are generally mitogenic although they also may affect the differentiated function of 
cells. IGFs have been isolated from bone cultures and are produced by osteoblasts. 
They increase DNA synthesis (Canalis and Lian 1988) and production of collagen 
type I independently (Canalis and Lian 1988, Pfeilschifter et al 1990c) and also 
promote the production of alkaline phosphatase. Canalis and Lian (1988) observed 
that IGF-I and l,25(OH)2D3 synergistically increased osteocalcin expression in 
fetal rat calvarial cells. Ernst et al (1989) observed that IGF-I mediated the 
proliferative effects of oestrogen on RCT-1 and RCT-3 osteoblast like cells. IGFs 
are therefore capable of inducing cell proliferation and differentiation of cells of the 
osteoblastic lineage.
TGFa shares extensive amino acid homology with EGF and competes for the same 
receptor. TGFa, like EGF generally decreases bone formation and stimulates 
resorption via increased prostaglandin production (Tashjian and Levine 1978, Stem 
et al 1985, Takahashi et al 1986). Both factors are capable of synergising with IL-1 
to further increase bone resorption (Lorenzo et al 1988, Hurley et al 1989).
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Furthermore, Takahashi et al (1986) observed that TGFa and EGF both stimulated 
osteoclast-like cell formation in long-term bone marrow cultures by stimulating the 
proliferation of precursors. In contrast, FGF, IGF and PDGF in the same 
experiments, had no effect (Takahashi et al 1986). Collagenolytic enzyme 
production is also stimulated by EGF in rodent osteoblasts (Hamilton et al 1984, 
Shen et al 1988). EGF and TGFa both stimulate DNA synthesis in osteoblasts (Ng 
et al 1983, Hurley et al 1989) and reduce the synthesis of collagen (Ibbotson et al 
1986, Hurley et al 1989) and alkaline phosphatase (Ibbotson et al 1986).
FGFs exert mitogenic effects on bone cells (Canalis et al 1988, Canalis and Lian 
1988, Globus et al 1989) and both aFGF and bFGF are synthesised in vitro by 
fetal bovine bone cells which have characteristics of the osteoblast phenotype such 
as osteocalcin expression (Globus et al 1989). FGFs are present in the matrix and 
it is thought that FGF, released from the inactive complex of FGF bound to heparan 
sulphate containing proteoglycans, is able to promote the cell replication of 
osteoblasts (Globus et al 1989). Inhibition of the mature osteoblast phenotype, 
including down regulation of alkaline phosphatase and collagen synthesis (Canalis 
et al 1988) and a decrease in PTH-stimulated adenylate cyclase accompanies the 
stimulation of osteoblast proliferation by FGF. FGF stimulates bone resorption 
apparently by a similar mechanism to EGF (Tashjian and Levine 1978).
PDGF is also present in the matrix and increases bone DNA synthesis in fetal rat 
calvariae (Canalis 1987b). PDGF stimulates PG synthesis which leads to an 
increase in bone resorption in a manner similar to EGF, however this factor is 
mitogenic for mesenchymal cells and may therefore attract cells of the osteoblast 
lineage to the vicinity of the resorption lacunae thereby promoting the coupling 
effect.
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Colony stimulating factors fCSFsi
The CSFs represent a group of peptides which are involved in various stages of 
hematopoiesis and include granulocyte-macrophage-CSF (GM-CSF), 
granulocyte-CSF (G-CSF), macrophage-CSF-(M-CSF) and IL-3, also known as 
multi-CSF. For a review refer to Horowitz and Jilka (1991).
The most characterised function of IL-3 is to induce the proliferation and 
differentiation of early pluripotent stem cells however, IL-3 also stimulates the 
production of osteoclasts from purified murine stem cells in the presence of stripped 
metatarsal bones (Scheven et al 1986).
In long-term marrow culture systems, the effect of GM-CSF on formation of 
osteoclast-like cells has been variable, and may be dependent upon the maturity of 
the culture system used. MacDonald et al (1986b) reported that GM-CSF 
stimulated osteoclast-like cell production by baboon long-term marrow culture, 
whereas Lorenzo et al (1987) and Shinar et al (1990), using long-term mouse 
marrow culture failed to observe any effects of GM-CSF.
GM-CSF is produced by osteoblasts stimulated with lipopolysaccharide (LPS) or 
PTH (Horowitz et al 1989, Weir et al 1989) and has been reported to increase the 
proliferation of osteoblasts (Dedhar et al 1988, Evans et al 1989a).
M-CSF stimulates the proliferation and differentiation of more mature hematopoietic 
cells, monocytes and macrophages. There are also conflicting reports as to whether 
M-CSF induces osteoclast formation in long-term bone marrow cultures. In vivo 
however, in osteopetrotic mice, there is extensive evidence to show the importance 
of M-CSF in osteoclast biology since the deficiency of osteoclasts in this condition 
can be rectified following administration of M-CSF (Felix et al 1990). This would 
suggest that at least in the mouse, M-CSF is involved in osteoclastogenesis. In 
addition, MacDonald et al (1986b) observed that M-CSF increased the formation of 
osteoclast-like cells in long-term baboon marrow culture.
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Osteoblasts when stimulated with bacterial endotoxin, IL-1, PTH, and PTHrP 
produce M-CSF (Sato et al 1986, Elford et al 1987, Felix et al 1989, Horowitz et al 
1990) and therefore these cells may influence osteoclast maturation and activity. 
G-CSF induces the proliferation of granulocytic precursors. Its effects tend to 
divert the multipotential precursors away from the osteoclast lineage and towards 
granulocytes. The precursor for granulocytes does not give rise to osteoclasts 
(Hattersley et al 1991).
Under certain conditions, some osteoblast lines have been shown to produce 
G-CSF. Primary cultures of rat osteoblasts can produce G-CSF in the absence of 
IL-1 (Horowitz, unpublished observations). The majority of work however, 
shows that production of G-CSF is not a common feature of osteoblasts.
Interleukin 1 (TL-P
Two separate gene products of IL-1 exist these being IL-la and IL-ip. These 
represent two related proteins with a similar broad spectrum of activities which are 
reviewed by Dinarello (1988,1989).
The effects of IL-1 as a potent resorbing agent have long been recognised. Initial 
studies using conditioned media from stimulated lymphocytes (Horton et al 1972) 
and mononuclear cells (Mundy et al 1977) demonstrated that factors produced from 
the cells could stimulate bone resorption in fetal rat long bones. The first indication 
that the potent soluble resorbing factor was due to IL-1 activity was demonstrated 
by Gowen et al (1983) and Dewhirst et al (1985). The factor was identified by 
these groups to be approximately 17 kD and its NH2 -terminal sequence identical to 
IL-1 p. Subsequent to these studies, several groups have demonstrated the 
stimulation of bone resorption by IL-1 in neonatal mouse calvariae (Gowen and 
Mundy 1986) and fetal rat calvariae (Dewhirst et al 1990). Nishihara et al (1989) 
observed that the membrane bound form of IL-1 was also capable of inducing bone
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resorption. Further studies in vivo also demonstrated similar effects (Konig et al 
1988, Sabatini et al 1988, Sato et al 1989).
Although IL-1 clearly stimulates bone resorption, there appears to be conflicting 
evidence as to whether IL-1 exerts its resorptive effects via the generation of PGs. 
Some groups observed that IL-1 induced bone resorption via a PGE2-independent 
mechanism (Gowen and Mundy 1986, Dewhirst et al 1987, Amano et al 1988) 
whereas others demonstrated prostaglandin-dependent effects (Lorenzo et al 1988). 
Many groups have observed that IL-1-stimulated bone resorption requires partial 
dependence of PGs (Dewhirst et al 1987, Stashenko et al 1987a, Nishihara et al
1989). A possible reason for the discrepancy may lie in the fact that different bone 
resorption systems were utilized. Unlike calvariae, long bones contain 
chondrocytes which are capable of releasing PGs (Stashenko et al 1987a, Dewhirst 
et al 1987). This is unlikely to be the full explanation however, as IL-1-stimulates 
osteoblasts from several species to produce prostaglandins. These include human 
(Gowen 1988, Evans et al 1989b, Evans et al 1990b) rat calvarial (Tatakis et al 
1988) and MC3T3-E1 murine osteoblasts (Ikeda et al 1988). It is likely that 
prostaglandin-dependent and -independent effects are observed during the 
resorption of bone stimulated by agents such as IL-1 and TNF, and may be due to 
the concentrations of resorption-stimulating factors present. The fact that IL-1 
synergises with other agents including transforming growth factor a  (TGFa) 
(Lorenzo et al 1988, Hurley et al 1989), PTH (Dewhirst et al 1987), epidermal 
growth factor (EGF) (Lorenzo et al 1988), PTHrP (Sato et al 1989), tumour 
necrosis factor a and p (TNF) (Stashenko et al 1987a), interleukin 6 (IL-6) (Garrett 
et al 1990) and stimulators of cAMP (Dewhirst et al 1990) to stimulate bone 
resorption further supports this view, as prostaglandin involvement in the above is 
variable.
One of the possible ways by which IL-1 can stimulate bone resorption is via an
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increase in the formation and number of osteoclasts. This is evident in long-term 
bone marrow cultures that can be stimulated to form multinucleated cells with 
osteoclast-like characteristics (Takahashi et al 1989). Pfeilshifter et al (1989) 
demonstrated that the IL-1-induced formation of these cells in long-term human 
bone marrow culture occurred via a prostaglandin-independent mechanism. 
Kurihara et al (1991) observed that IL-ip was capable of inducing osteoclast 
formation from both early and late precursors within the culture. Presumably, IL-1 
increased the proliferation of the early precursors and subsequently induced their 
fusion. Others have reported that IL-1 is capable of maintaining the number of 
osteoclasts which would normally decline in neonatal mouse calvariae (Garrett and 
Mundy 1989). They postulated that IL-1 acted on the later stages of osteoclast 
formation since inhibitors of DNA synthesis did not alter the IL-1 effects.
IL-1, by reducing proteoglycan content, exerts other degradative effects on bone. 
The reduction of proteoglycans by IL-1 may be achieved by decreased proteoglycan 
synthesis or increased breakdown and was observed in murine patella chondrocytes 
(Van Den Berg et al 1988), human articular cartilage (Nietfeld et al 1990) and 
bovine nasal cartilage explants (Smith et al 1991). In addition, an intra articular 
injection of IL-1 into rabbit knee joints decreased proteoglycan content in vivo 
(Henderson et al 1991). Gowen et al (1984) and Rifas et al (1989) observed that 
IL-1 increased the secretion of collagenase and proteoglycanase in human articular 
chondrocytes but was unable to demonstrate this in human osteoblasts. Preliminary 
evidence by Bord et al (1991) may indicate that this is not the case as they 
demonstrated collagenase by immunofluorescence in human osteoblasts. 
Osteoblasts from other species such as rat have been shown to produce the latent 
form of collagenase upon stimulation with IL-1 (Shen et al 1988). Evans et al 
(1989b, 1990b) demonstrated that human osteoblasts can be induced by IL-1 to 
produce plasminogen activator which, via an enzyme cascade, is capable of
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cleaving latent collagenase to the active form. By the secretion of these enzymes, it 
is possible to envisage how the stimulation of osteoblasts by IL-1 can degrade the 
upper collagenous layer thereby exposing the underlying calcified matrix to the 
osteoclasts. However, it must be stressed that osteoblasts can also produce a 
number of inhibitors such as plasminogen activator inhibitor (PAI), tissue inhibitor 
of metalloproteinases (UMP) and collagenase inhibitor which are all capable of 
inactivating these matrix degradative enzymes and so highlights the complexity of 
the potential mechanisms.
Other reports of the effects of IL-1 on osteoblasts demonstrate that this cytokine 
opposes the basal or l,25(OH)2D3-stimulated differentiation of osteoblasts by 
reducing collagen type I production, alkaline phosphatase expression and 
osteocalcin synthesis (table 1.3). However, the length of incubation period 
(Canalis 1986) and presence of serum (Hanazawa et al 1986) are influential in these 
actions.
Another influence of IL-1 is the induction of cell proliferation of osteoblasts. This 
has been observed in fetal rat calvarial (Canalis 1986, Smith et al 1987), human 
(Gowen et al 1985, Gowen 1988, Evans et al 1989b, Evans et al 1990b) and 
MC3T3-E1 (Ikeda et al 1988) osteoblasts. These anti-differentiation, 
pro-proliferating effects may therefore serve to increase the immature osteoblast 
precursor pool in preparation for the formation phase and has lead to the 
proposition that IL-1 may exist as a coupling factor in the remodelling process. An 
in vivo study by Boyce et al (1989) supports this hypothesis as subcutaneous 
injection of IL-1 over mouse calvariae resulted in the increased number of 
osteoclasts and resorption pits in the short term. However long-term effects include 
periosteal cell proliferation, with the resorbed bone being subsequently replaced by 
new woven bone.
Some evidence would suggest that the effects of IL-1 on osteoclasts are not direct
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(Thomson et al 1986), rather, the presence of IL-1-stimulated osteoblasts are 
required. Thomson et al (1986) postulated that osteoblasts stimulate osteoclasts to 
resorb bone via the release of a soluble factor induced by IL-1 from the osteoblasts. 
This provides evidence that IL-1 actions on osteoclasts are not direct. IL-1 is 
capable of inducing the release of many cytokines and growth factors from 
osteoblasts (Gowen et al 1990, Merry et al 1990, Littlewood et al 1991b, Linkhart 
et al 1991b) and other cells present within the bone microenvironment. These 
factors may in turn exert actions on the bone cells and thereby create a potential 
complex network of synergistic and antagonistic interactions. Furthermore, many 
of these factors are able in turn to induce the production of IL-1 from cells within 
the bone microenvironment (Merry et al 1990, Kurihara et al 1990).
Receptors for IL-1 have been demonstrated on a number of different cell types 
including osteoblasts (Bird and Saklatvala 1986, Shen et al 1990), T-lymphocytes 
(O'Neill et al 1990), fibroblasts (O'Neill et al 1990, Dower et al 1986) and B-cell 
lines (Bensimon et al 1989). Dower et al (1986) observed that the receptor for IL-1 
on murine and human cells were identical and that both a and p forms of IL-1 bind 
to the same receptor. The majority of evidence indicates the presence of two 
receptors; a high affinity 55 kD and a low affinity 80 kD receptor (reviewed by 
Dinarello et al 1989).
Antagonists for the action of IL-1 function by competing for the 80 kD receptor 
(Hannum et al 1990, Carter et al 1990, Seckinger et al 1987a, 1987b, Mazzai et al 
1990) rather than by binding EL-1 to inactivate it. Natural inhibitors for IL-1 were 
first isolated from the urine of monocytic leukemia patients (Seckinger et al 1987a) 
and from human monocytes stimulated with IgG (Hannum et al 1990). The cDNA 
was subsequently obtained from U937 cells (Carter et al 1990) and monocytes 
(Eisenberg et al 1990) and the recombinant protein characterised and called 
interleukin-1 receptor antagonist protein (IRAP). Seckinger et al (1990) observed
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that IRAP was capable of blocking IL-1-stimulated bone resorption in both fetal rat 
long bones and in mouse calvariae. However, higher concentrations of IRAP were 
required to block the induction of bone resorption in mouse calvariae compared to 
the fetal rat long bones indicating a further difference between these two bone 
resorption systems. IRAP also antagonised IL-1-stimulated PGE2 production in 
synovial cells (Arend et al 1990) and collagenase production in chondrocytes 
induced with IL-1 (Arend et al 1990, Smith et al 1991). IRAP is also an effective 
IL-1 inhibitor in vivo, blocking the decreases in proteoglycan content induced by 
IL-1 in rabbit knee joints (Henderson et al 1991).
The overall effect of IL-1 on bone in vivo is likely to be dependent upon the 
relative concentrations that exist between IL-1 and the IL-1 inhibitors.
Tumour necrosis factor (TNF)
TNF shares many similar activities with IL-1 although it is substantially less potent 
in these respects. It also exists as two separate gene products, those being TNFa 
and TNFp and the proteins only share a 30% amino acid homology (reviewed by 
Beutler and Cerami 1987).
Both TNFa and TNFp have been demonstrated to induce bone resorption in fetal rat 
long bones (Bertolini et al 1986, Stashenko et al 1987a) and mouse calvariae 
(Gowen and Mundy 1986). Both TNFa and p were less potent than IL-1 in 
inducing bone resorption in a comparative study (Stashenko et al 1987a). This is 
also reflected in the ability to stimulate prostaglandin production by osteoblasts 
(Gowen 1988). TNF exhibits a synergism with IL-1 in inducing bone resorption 
(Stashenko et al 1987a) which may be an important influence in bone metabolism 
since they are both capable of inducing each others synthesis in a range of cell 
types. TNF also induces bone resorption in vivo (Garrett et al 1987, Konig et al 
1988).
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The mechanism of bone resorption induced by TNF appears to be similar to IL-1. 
Bertolini et al (1986) observed that TNF increased the number of osteoclasts and 
decreased the production of mineralized bone matrix. Both forms of TNF were 
active in inducing multinucleated osteoclast-like cell formation in the long-term 
human marrow culture (Pfeilschifter et al 1989). Preliminary in situ hybridisation 
studies indicate the presence of TNFa and TNFp in a population of osteoclast 
precursors (Qi et al 1991) although further studies are necessary to substantiate this 
evidence. Thomson et al (1987) observed that the effects of TNF on isolated 
osteoclasts were not direct and were probably mediated by the release of a soluble 
factor from osteoblasts. TNF is known to be capable of inducing the production of 
a range of growth factors from many different cell types, however, the identity of 
the soluble factor described by Thomson et al (1987) is still unresolved.
Another possible degradative effect of TNF on bone matrix may be via the decrease 
in proteoglycan content observed in porcine articular cartilage and bovine nasal 
septum (Saklatvala 1986). Furthermore, TNF decreases the synthesis of GAGs in 
rabbit chondrocytes (Enomoto et al 1990) and increases collagenase production by 
rat calvarial osteoblasts (Shen et al 1988).
The effects of TNF on osteoblasts are comparable to IL-1, although TNF is less 
potent in these respects (Gowen 1988). TNF appears to decrease the basal or 
l,25(OH)2D3-induced expression of mature phenotypic markers of the osteoblast 
(table 1.4) whilst promoting the proliferation of human (Gowen et al 1988, Gowen 
1988) and rat (Centrella et al 1988) osteoblasts although contrary results are 
reported (Nanes et al 1989).
Unlike IL-1, TNFa decreases the PTH-induced generation of cAMP in the human 
osteosarcoma cell line, SaOS-2, and in primary rat osteoblasts. This appeared to be 
a specific effect since it did not modify PGE2 -induced cAMP generation. 
Therefore, TNF may alter the effects of PTH on osteoblasts (Shapiro et al 1990).
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Receptors for TNF have recently been cloned (Smith et al 1990). Both TNFa and 
TNFp bind to these receptors of which two (55 kD and 75 kD) have been isolated. 
The purified 55 kD receptor was expressed as the recombinant protein and was 
demonstrated to bind TNF (Loetscher et al 1990). Thoma et al (1990) observed 
that for some TNF-induced activities, both receptors were necessary to elicit certain 
TNF responses such as TNF-induced cytotoxicity and enhancement of IL-2 
receptor expression in T cell lines. TNF binding proteins have been isolated from 
the serum of cancer patients (Schall et al 1990). Loetscher et al (1990) 
demonstrated that the TNF binding protein did not arise from a second gene that 
may encode a soluble inhibitor.
The TNF binding protein was partially sequenced and shown to be a soluble form 
of the 55 kD receptor (Schall et al 1990, Smith et al 1990). By binding to TNF it 
was able to inactivate the cytokine. Engelman et al (1990) isolated two proteins that 
specifically bound TNF in human urine. Both decreased the cytotoxic effect of 
TNF in vitro and bound TNFa more efficiently than TNFp. This group also 
demonstrated that these immunologically distinct proteins were structurally related 
to the TNF receptor. They may possibly represent soluble forms of the two 
receptors although amino acid analysis is required to unequivocally clarify this 
(Engelman et al 1990). Nophar et al (1990) also demonstrated the presence of a 
binding protein in urine which exhibited significant homology with the 80 kD 
receptor but was in fact a soluble form of the 55 kD receptor. In vivo studies 
demonstrated that TNF binding proteins are transiently increased following 
intravenous infusions of TNF and IFNy of cancer patients. This may represent a 
mechanism for reducing active TNF levels in disease.
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Leukemia inhibitory factor (LIF)
LIF was initially isolated and characterised by its ability to suppress the 
proliferation of myeloid leukemia cells Ml (Hilton et al 1988). With the recent 
biochemical and molecular characterisation of LIF, it became apparent that HILDA 
(human interleukin for DA cells) (Moreau et al 1988), DIA (differentiation 
inhibitory activity) (Smith et al 1988) and DIF (differentiation inducing factor) (Abe 
et al 1989) were all the same peptide. It is evident that the effects of LIF on many 
different cell types are pleiotropic, LIF can exert differentiation inhibitory 
properties, such as maintaining pluripotent embryonic stem cells in an immature, 
proliferative state (Williams et al 1988, Smith et al 1988). Conversely this factor 
can also stimulate the differentiation of other cells for example Ml cells towards the 
macrophage lineage (Hilton et al 1988, Metcalf 1989, Miyaura et al 1989a). 
Williams et al (1988) proposed that distinct intracellular signalling pathways exist in 
these two cell types resulting in opposing differentiation effects. LIF possibly 
regulates the proliferation and differentiation of hematopoietic precursors (Le et al
1990). Murray et al (1990), detected mRNA and protein for both LIF and IL-6 in 
mouse blastocysts and proposed that these factors exert an early hematopoietic role 
in mouse embryogenesis.
It is possible that LIF could direct pluripotent stem cells towards the osteoclast 
lineage and may therefore exert a permissive role on bone resorption. Abe et al 
(1988) observed that purified LIF from differentiated MC3T3-E1 osteoblast-like 
cells increased resorption and osteoclast number in mouse calvaria, probably via the 
action of prostaglandins. This study was confirmed by the work of Reid et al
(1990), however contradictory reports are also published. In a complex study Van 
Beek et al (1991) studied the effect of LIF on resorption in mouse metacarpals and 
radii of different ages. LIF decreased bone resorption both in metacarpals, where 
osteoclasts precursors are present, and in older metacarpals and radii containing
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mature osteoclasts. LIF appeared to be exerting its effects by blocking osteoclast 
formation as TRAP positive cells in the matrix were absent. LIF may well have 
been directing hematopoiesis along a different, but related lineage such as the 
macrophage lineage. Variable results have also been obtained in long-term mouse 
bone marrow cultures, with LIF either exerting no effect (Shinar et al 1990) or 
inducing osteoclast formation (Abe et al 1988). Differences may exist in the 
maturity of the marrow cells within the culture.
Osteoblasts, but not osteoclasts, possess receptors for LIF (Allan et al 1990, Rodan 
et al 1990) and also respond to LIF in a number of ways. Two groups 
independently observed that LIF increased the retinoic acid-induced alkaline 
phosphatase in osteoblast-like cells, UMR 201 (Allan et al 1990) and RCT-1 
(Rodan et al 1990). Evans et al (1992) observed that LIF exerted no effect on basal 
or l,25(OH)2D3-stimulated alkaline phosphatase levels. However, when 
l,25(OH)2D3 induction of alkaline phosphatase activity was low, LIF was able to 
potentiate the effects of l,25(OH)2D3 (Evans et al 1992). In contrasting studies, 
LIF was reported to reduce alkaline phosphatase activity in MC3T3-E1 cells 
(Hakeda et al 1991, Noda et al 1990). The differentiation state of the various 
osteoblast lines may have some influence on these results. LIF has also been 
reported to inhibit collagen synthesis (Rodan et al 1990, Noda et al 1990), 
proliferation (Noda et al 1990), and increase osteopontin mRNA (Noda et al 1990). 
LIF is produced by a number of osteoblast lines including MC3T3-E1 cells (Abe et 
al 1988), UMR series (Allan et al 1990) and human osteoblasts (Evans et al 1990c). 
Production of LIF by osteoblast-like cells may indicate a potential 
paracrine/autocrine function of the cytokine on bone cell metabolism.
Interleukin 6 (IL-61
IL-6 has been cloned from a human T cell line (Hirano et al 1986), human 
monocytes (Brakenhoff et al 1987), murine T cells and murine bone marrow (Chiu 
et al 1988, Van Snick et al 1988). The recombinant IL-6 protein from human and 
murine cells was expressed and found to possess a degree of homology; 65% at the 
nucleotide level and 41% at the amino acid level. Recombinant murine IL-6 was 
demonstrated to contain 211 amino acids (Chiu et al 1988, Van Snick et al 1988) 
whereas the recombinant human IL-6 consisted of 212 amino acids (Hirano et al
1986). IL-6 structure is unrelated to most other cytokines, however, Simpson et al
(1988) observed that the disulphide pattern was identical to granulocyte colony 
stimulating factor (G-CSF) and therefore IL-6 may have evolved from a common 
gene.
IL-6 exerts pleiotropic actions which have been characterised by many different 
laboratories and therefore this cytokine was originally known by a variety of names 
according to its function on a particular cell type. IL-6 is a potent plasmacytoma 
and hybridoma growth factor, therefore several groups called it plasmacytoma 
growth factor (PCTGF) or hybridoma growth factor (HGF) (Simpson et al 1988, 
Reis et al 1988, Van Damme et al 1987a, Van Damme et al 1987c). IL-6 was 
designated B cell stimulatory factor-2 (BCSF-2 or BSF-2) as it exhibited potent 
effects on B cells (see below). Others observed an antiviral action of IL-6 hence it 
was also known as LFN-J52 although this activity is controversial and most groups 
are unable to reproduce these findings.
IL-6 is produced during an inflammatory response and has many well characterised 
activities during inflammation including the stimulation of acute phase proteins 
(Andus et al 1987, Baumann et al 1987) and effects on B and T cells (reviews 
Kishimoto and Hirano 1988, Akira et al 1990a). IL-6 stimulates the final 
maturation of mitogen-stimulated B cells into immunoglobulin producing cells
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(Hirano et al 1986, Emilie et al 1988, Muraguchi et al 1988, Clark and Shu 1990). 
IL-6 exerts IL-l-like effects on mitogen stimulated- thymocytes and T lymphocyte 
subsets by inducing proliferation of these cells (Garman et al 1987, Helle et al 
1988a, Le et al 1988, Houssiau et al 1988b, Habetswallner et al 1988, Lotz et al 
1988, Hodgkin et al 1988, Ceuppens et al 1988, Tosato and Pike 1988, Okada et al 
1988, Takai et al 1988). There is controversy as to whether IL-2 involvement is 
essential or not; and it is likely that IL-2 dependent and independent pathways exist 
(Hodgkin et al 1988, Le et al 1988) depending on the different T cell subsets. 
Furthermore, a synergistic proliferation of T cells with IL-1 and IL-6 is also 
observed in some cases (Helle et al 1988a, Houssiau et al 1988b). In contrast to 
the late actions of IL-6 in the B cell response, it appears as though this cytokine acts 
at the early stages of T cell proliferation (Ceuppens et al 1988, Tosato and Pike 
1988) and this may be due to the levels of IL-6 receptor expressed by resting B and 
T cells (discussed in chapter 6).
IL-6 is involved in acute phase response by regulating the production of acute phase 
proteins from hepatocytes (Andus et al 1987, Baumann et al 1987). IL-6 has been 
demonstrated to increase the majority of acute phase proteins such as C reactive 
protein and haptoglobin whilst decreasing albumin production in human hepatoma 
cells (Morrone et al 1988). Many groups have studied the effect of IL-6 on acute 
phase protein release from a variety of hepatocytic lines including primary rat 
hepatocytes (Andus et al 1988, Gauldie et al 1987), human hepatoma cells 
(Morrone et al 1988, Ramadori et al 1988, Gauldie et al 1987, May et al 1988a), 
and adult human hepatocytes (Castell et al 1989). Although IL-1, TNF and LIF are 
able to induce a subset of acute phase proteins, IL-6 was able to modulate a much 
larger range, making it the most important mediator of the acute phase response 
(Castell et al 1989).
The mechanism by which IL-6 regulates acute phase protein synthesis has recently
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been elucidated (Poli and Cortese 1989). IL-6 has been shown to induce a nuclear 
protein, IL-6 DNA binding protein (IL-6DBP) in a human hepatoma cell line that 
binds to the promoter region of acute phase genes. This region is known as the 
IL-6 responsive element and binding of the nuclear protein induces transcription of 
the acute phase protein mRNA. Akira et al (1990b) also purified a nuclear protein, 
nuclear factor IL-6 (NF-IL6). The C terminal region of NF-IL6, which is essential 
for DNA binding, is highly homologous with a liver specific transcription factor, 
C/EBP (Akira et al 1990b). The significance of this has yet to be determined. 
Akira and co-workers also demonstrated that the expression of NF-IL6 could be 
induced by LPS, IL-1 and IL-6 and that NF-IL6 bound to gene regulatory regions 
for various acute phase proteins. Other workers have also established the presence 
of IL-6 responsive elements in the promoter region of certain acute phase genes 
(Poli and Cortese 1989, Oliviero and Cortese 1989, Ito et al 1989, Marinkovic and 
Baumann 1990,.Baumann et al 1990a). Yap et al (1991) observed that IL-1, TNF 
and IL-6 all interact to enhance or inhibit certain acute phase proteins in human 
hepatocytes. During an acute phase response, many of these factors will be 
increased and therefore their combination may be critical for the appearance of 
certain acute phase proteins.
During certain acute conditions IL-6 levels are elevated in the serum, such as 
systemic lupus erythematosus (SLE) (Swaak et al 1989, Israeli et al 1991, Stuart et 
al 1991), alcoholic hepatitis (Sheron et al 1991), renal transplant recipients (Van 
Oers et al 1988), surgical intervention (Nishimoto et al 1989, DiPadova et al 1991), 
severe bums (Nijsten et al 1987) and fever (Helle et al 1988b, Lesnikov et al 1991). 
In some of these studies, IL-6 levels in the serum have been reported to correlate 
with acute phase proteins, in particular CRP although evidence is highly subjective. 
Houssiau et al (1988a) demonstrated the presence of raised IL-6 levels in cerebro­
spinal fluid of patients with acute infections of the central nervous system such as
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meningitis and tuberculosis.
Rheumatoid arthritis is a chronic inflammatory condition characterised by massive 
cellular infiltration and proliferation of the synovial membrane to form a pannus that 
grows over and constitutes the erosion of cartilage and bone via release of 
destructive factors. Several groups have demonstrated raised IL-6 levels in 
synovial fluid, synovial cells and serum of patients with rheumatoid and other 
inflammatory arthritides when compared to osteoarthritic patients (Swaak et al 
1988, Hirano et al 1988, Houssiau et al 1988c, Nietfeld et al 1990). There are 
contrasting studies, such as those of Gueme et al (1989) who demonstrated that 
there was no difference between IL-6 production from rheumatoid and osteoarthritic 
synoviocytes.
Raised serum levels of EL-6 are observed in the disease psoriasis, and IL-6 
promotes the symptoms of this disease characterised by extensive epidermal 
proliferation and inflammation (Grossman et al 1989, Neuner et al 1991). Muller et 
al (1991) demonstrated that l,25(OH)2D3 or its analogue MC903 decreased the 
production of IL-6 in LPS-stimulated mononuclear cells and blocked IL-6-driven 
murine thymocyte proliferation. Morimoto et al (1986) has observed that 
l,25(OH)2D3 and MC903 are effective in the treatment of psoriasis and so Muller 
et al (1991) surmised that these agents may be acting by blocking the effects of 
IL-6. Arthritis is often associated with psoriasis and some groups are now 
investigating the role of IL-6 in pathogenesis of psoriatic arthropathy.
Many groups have observed increased IL-6 expression in various carcinomas 
(Hirano et al 1987, Erroi et al 1989, Tabibzadeh et al 1989), sarcoma cells (Miles et 
al 1990) and leukemic cells (Biondi et al 1989). It is possible that high levels of 
IL-6 from carcinomas may account for the raised acute phase proteins associated 
with malignancy, although more evidence is required.
Effects of IL-6 within the bone microenvironment have only recently been studied 
and as this constitutes a large portion of this thesis; the discussion in this respect is 
left to later chapters.



















Fig. 1.1 The remodelling sequence in normal human adult bone, 
LC - lining cell. POC - preosteoclast.
OC - osteoclast. OB - osteoblast.
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Human osteoblast-like cell culture
Human trabecular bone, obtained from femoral heads or above-knee amputations 
was dissected, in a sterile environment, into pieces of approximately 0.3 cm3. This 
was placed in a sterile container and washed extensively with phosphate buffered 
saline (PBS) to remove non-adherent bone marrow tissue and fatty deposits. Any 
soft connective tissue was then clearly visible and could be carefully removed after 
the washing procedure. The PBS was then replaced with Eagles Minimal essential 
medium (EMEM) supplemented with 10% (v/v) heat inactivated FCS, 100 U/ml 
penicillin, 100 ug/ml streptomycin and 2 mM L-glutamine (EMEM + 10% FCS). 
The bone pieces were incubated over night in 5% CO2 at 37°C in a humidified 
atmosphere to allow full separation of any remaining fat deposits. After this time, 
the medium was removed and the bone chips plated out at 6  - 8 explants per 9 cm 
tissue culture petri dish in 10 ml fresh EMEM + 10% FCS. The medium was 
changed once a week and cells migrated from the bone explants after two weeks of 
initiation of the culture. Cells became confluent after four to six weeks and at this 
stage, could then be passaged for experimental purposes.
Cell Passaging
The human osteoblast-like cells were passaged into 24, 48 or 96 well plates. The 
explants of bone were removed and could be added to fresh 9 cm tissue culture petri 
dishes for further culture. The medium was removed from the petri dish and the cell 
layer washed once with PBS. Trypsin-EDTA (2.5 ml) was added to the cell layer 
and the plate returned to the incubator at 37°C for 5 -15 minutes. The cell layer then 
became detached and EMEM + 10% FCS was added to neutralise the trypsin from 
proteolytically damaging the cells. The cells were centrifuged at 1000 rpm for
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7 minutes and the pellet was resuspended gently in 2 ml of EMEM + 10% FCS with 
a syringe and needle. The suspension was adjusted to 10 ml with EMEM + 10% 
FCS and cells counted on a haemocytometer. The cells were then plated out into the 
multi well plates at the appropriate cell density for the particular experiment
ROS 17/2.8 culture
ROS 17/2.8 cells (described on page 113) were maintained in HAMS F10 medium, 
10% (v/v) heat-inactivated FCS, 100 U/ml penicillin, 100 ug/ml streptomycin and 2 
mM L-glutamine in 9 cm tissue culture dishes (HAMS F10 + 10% FCS). They 
were split at a ratio of 1:4 once or twice a week. The culture medium was removed 
from a confluent 9 cm tissue culture petri dish of ROS 17/2.8 cells, the cell layer 
washed once in PBS and trypsin-EDTA was added as described for human 
osteoblast-like cell passaging. After the cells were centrifuged at 1000 rpm for 7 
minutes, the cell pellet was carefully resuspended in 4 ml of fresh HAMS F10 + 
10% FCS and 1 ml added to a 9 cm tissue culture petri dish containing fresh HAMS 
F10 + 10% FCS. If the cells were to be used for experimental purposes, the pellet 
was resuspended and treated the same way as described for the human 
osteoblast-like cells.
IL-6  Bioassav 
Principal
This bioassay utilizes the B9 murine hybridoma cell line which is an IL-6  dependant 
line and a sensitive variant of B 13.29 cells (Helle et al 1988a). B9 cells proliferate 
according to the amount of IL-6  added and are not responsive to any other cytokine 
except for a slight stimulation with murine IL-4. The proliferation of B9 cells can be 
stimulated by as little as 1 pg/ml of IL-6  (see fig. 2.1). The specificity of this assay 
is described on page 110 (Chapter 4). Intra and inter assay variation was routinely 
less than 1 0 %.
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Maintenance of the B9 cells
The B9 cells were maintained in RPMI supplemented with 5% (v/v) FCS, 100 U/ml 
penicillin, 100 ug/ml streptomycin, 2 mM L-glutamine 5xl0-5 M 2-mercaptoethanol 
and 0.1% (v/v) monocyte conditioned medium (RPMI + 5% FCS). They were 
passaged when the cell density reached 1 million/ml of medium. 1 ml of medium 
containing cells was removed and passaged into 29 mis of RPMI + 5% FCS in a 
75 cm3 flask.
Method for bioassav
B9 cells were washed twice in RPMI + 5% FCS lacking IL-6. The cells were then 
counted using a haemocytometer and adjusted to a concentration of 50,000 cells/ml. 
An aliquot of 2-mercaptoethanol was then added to a final concentration of 
5xl0-5 M and lOOul of the cell suspension was dispensed into 96 well flat bottomed 
plates.
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The conditioned media samples to be assayed were added to the wells. It was 
necessary to dilute the samples in order to obtain a reading on the linear part of the 
standard curve. lOOul of sample was then added to the 100 ul of B9 cells, thus 
resulting in a two fold dilution of the samples.
The standard curve was constructed using recombinant human IL-6  (rhIL-6 ) to give 
final concentrations of:- 100, 30, 10, 1, 0.1 and 0 pg/ml. Diluent medium which 
was used for the samples, was also used for the preparation of the standard curve. 
The plates were then incubated for 6 8  h after which 20 ul of 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT) solution (5mg/ml PBS) was added to 
each well for 4 h. The metabolically active B9 cells converted the MTT to formazan 
blue crystals. After 4 h, the reaction precipitate was solubilized in 50 ul of acidic 
(0.04M HC1) isopropanol after careful aspiration of the medium.
Once the precipitate was fully dissolved, the absorbance could be quantified on an 
ELISA platereader (Dynatech). The absorbances were measured at wavelengths of 
570nm (test) and 630nm (reference). A standard curve was plotted on logarithamic 
paper and the IL-6  content of the samples determined from the curve.
Preparation of monocvte conditioned medium
Blood was collected from normal volunteers in heparinised tubes. The mononuclear 
fraction was isolated by diluting the blood with PBS (10 ml blood: 14 ml PBS) and 
layering carefully over Ficoll-hypaque (12 ml diluted blood : 5 ml Ficoll). This 
was then centrifuged at 1450 rpm for 30 minutes and the mononuclear fraction 
aspirated from the interface between the plasma and the Ficoll with the erythrocytes 
and neutrophils having been pelleted. The mononuclear cells were washed with 
RPMI + 5% (v/v) FCS and centrifuged at 1000 rpm for 7 minutes. The cell pellet 
was suspended in the 10 ml of the same medium and plated into a 9 cm tissue culture
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petri dish. This was left overnight at 37°C and the following day the monocyte 
conditioned medium was removed and stored in aliquots at -20°C. This was used as 
a crude source of IL-6  and any other factors produced by these cells did not affect 
the B9 assay (Helle et al 1988b).
Preparation of probes
Preparation of competent bacteria
A 10 ml overnight culture of E. Coli (XL1 blue) bacteria was grown in LB medium 
(see Appendix 1) and the following day, 1 ml of this culture was transferred to 100 
ml of LB medium and cultured for 2-4 hours to a cell density of 5 x 10^ cells/ml 
(OD600= !)• Once the bacterial culture had reached the required optical density, they 
were chilled on ice for 10 minutes and centrifuged at 4000g for 5 minutes at 4°C. 
The supernatant was then discarded and 0.5 volumes of ice cold fresh, sterile 
50 mM CaCl2 , 10 mM Tris HC1 (pH 8 ) solution was added. This was placed on 
ice for 15 minutes and then centrifuged at 4000g for 5 minutes at 4°C. The 
supernatant was discarded and 0.066 volumes of the 50 mM CaCl2 , 10 mM Tris 
HC1 (pH 8 ) solution was added to the cell pellet on ice. Aliquots (0.2 ml) were then 
dispensed into pre-chilled eppendorf tubes and stored at -70°C.
Transformation of bacteria
Competent XL 1 blue E. coli bacteria were removed from -70°C storage and thawed 
slowly on ice. The equivalent of 10 ng of the appropriate cDNA (cDNA enclosed 
within the vector DNA) was added to 50 ul of bacteria for 30 minutes on ice. The 
bacteria were then 'heat shocked' by first immersing them in a 42°C water bath for 2 
minutes and subsequently transferring them onto ice for a further 2 minutes. The 
bacteria were allowed to recover by addition of 0.5 ml LB medium at 37°C for 30 
minutes. The bacteria were then plated out on L-ampicillin (amp) plates (see 
Appendix 1) (25 mM stock used at a 1: 500 dilution). This was performed using a
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sterile glass spreader under aseptic conditions. Once the bacteria were added, the 
plates were left inverted in the incubator overnight at 37°C. A control plate 
consisting of competent bacteria without DNA, was also prepared at the same time. 
The following day no colonies should be detected on the control amp plate since the 
bacteria do not contain resistance to ampicillin. A few colonies from the positive 
plate were then picked and grown up in 10 ml LB medium (containing amp) for 4 
hours at 37°C. A small quantity of DNA could then be prepared to verify that the 
bacteria contained the cDNA/vector (see below).
Small scale plasmid preparation
For the small scale preparation of plasmid DNA, 1.5 mis of the bacteria were poured 
into an eppendorf tube and centrifuged (15,000 rpm) at room temperature for two 
minutes. The cell pellet could be enlarged by adding a further 1.5 mis of the 
bacterial culture and re-centrifugation. The remaining bacteria were kept at 4°C for 
subsequent large scale plasmid preparation. The cell pellets were sequentially 
resuspended in various solutions to isolate the plasmid DNA (see Appendix 1). The 
contents of the tubes were centrifuged at 15,000 rpm for 5 minutes, the supernatant 
was transferred to a clean tube and 2 x (v/v) absolute ethanol was added. This was 
allowed to stand for 30 minutes on ice to permit the DNA to precipitate. The pellet 
of precipitated DNA was washed in 100 ul of 70% ethanol and dried under vacuum. 
The DNA was then dissolved in 50 ul of 1 x TE (see Appendix 1) and quantified on 
the spectrophotometer (see Appendix 1).
The equivalent of 1 ug of DNA was digested with appropriate enzymes to excise the 
cDNA from the vector DNA. Enough enzyme was required to cut 1 ug of DNA per 
hour at 37°C (generally a slight excess of enzyme was used). 20 ug/ml of RNase A 
(RNA exonuclease) was also added to the digestion mixture. This treatment 
removed RNA from the preparation which would obscure the DNA bands on an
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ethidium bromide-stained agarose gel when viewed over an ultra violet (UV) 
transilluminator. The digestion was allowed to proceed for 1.5 h at 37°C and 1 ul of 
DNA 'loading dye' (see Appendix 1) was subsequently added. The samples were 
electrophoresed on a 1% (w/v) agarose gel together with molecular weight markers 
and some undigested vector + insert DNA (see Appendix 1). The gel was then 
viewed over a UV transilluminator and the size of excised DNA assessed with the 
aid of X DNA cut with Hind in and Eco RI used as the molecular weight markers. 
If the expected size of DNA was obtained, the remaining bacteria culture could then 
be used for large scale preparation of plasmid DNA.
Large scale plasmid preparation
About 5 mis of the bacteria were added to 250-500 mis LB medium containing amp 
(25 mM stock used at a 1: 500 dilution). This was cultured overnight in a shaking 
incubator at 37°C. The whole bacterial culture was subsequently centrifuged at 9000 
rpm for 10 minutes. A 'Qiagen kit' was then used to purify the vector (containing 
insert) DNA.
The DNA was precipitated with 0.8 volumes of isopropanol and the pellet was 
dissolved in 50 ul of 1 x TE and quantified (see Appendix 1). 1 ug of plasmid DNA 
was digested as described previously in order to ascertain the presence of the 
cDNA/vector DNA. There was no necessity to perform an RNase digestion as the 
Quiagen kit contained an RNase digestion stage. The DNA was electrophoresed on 
a 1% (w/v) agarose gel as described previously and the remaining DNA was stored 
at -20°C.
Purification of the DNA
The equivalent of 5 ug of vector + insert DNA was digested with the two appropriate 
enzymes for excising the insert DNA from the vector DNA. If enzymes required
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different buffers, the lower salt buffer enzyme was used first for 1.5 h at 37°C. The 
salt concentration was then altered for the second enzyme and the restriction digest 
continued for a further 1.5 h at 37°C (unless the enzyme required an alternative 
temperature).
One tenth of the digest was removed and checked on an agarose gel, as described 
previously, to assess whether the digestion had been completed. If this was 
satisfactory, the remaining DNA was run out on a 1% (w/v) agarose gel and the 
appropriate ethidium bromide-stained DNA band was excised from the gel over a 
UV transilluminator. A kit was used to purify the DNA (Gene Clean kit) using glass 
milk silica particles which bind to the DNA. The DNA was subsequently eluted 
twice at 50°C with 10 ul of 1 x TE. An aliquot (2 ul) of the purified insert cDNA 
was removed and assessed on another gel for recovery of the DNA. The remaining 
purified DNA was stored at -20°C until use for hybridisation.
Statistics
All statistical differences were determined using the Student’s t test. P < 0.001***, 
p < 0.01**, p< 0.05*.
Where the term ’representative experiment (n=x) is written under the figure legends, 
this means that ’x’ experiments were performed and a representative experiment was 
chosen. Each treatment was performed in triplicate. The errors represent the variation 
between the triplicate wells.
In Chapter 5, the original magnification is shown on the bottom right hand side of 
the photographs. Where the same magnification was used for all the photographs 
within the figure, the magnification is only shown once.
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APPENDIX 1
Preparation of competent bacteria
Using a sterile loop; the bacteria were transferred from a frozen vial stored in 
liquid nitrogen at -70°C to a 10 ml culture of LB medium containing ampicillin 
(25 mM stock used at a 1: 500 dilution).
LB medium 
bacto-tryptone lOg 
bacto-yeast extract 5g 
NaCl 10 g
The reagents were dissolved in 800 ml deionised water, the pH adjusted to 7.5 
with NaOH and the volume made to 1 litre. This was then autoclaved 
immediately.
Preparation of L ampicillin plates
These were prepared if the vector contained an ampicillin resistance region.
LB medium was made up as above and 1.5% (w/v) agar was added. This was 
heated thoroughly until all the agar dissolved and the solution was cooled to 
about 50°C before addition of ampicillin (50 ug/ ml). The plates were poured 
under aseptic conditions and allowed to set. They were then transferred to a 
37°C incubator and inverted with the lids off in order to dry off the 
condensation.
Small scale preparation of plasmid DNA 
Isolation of the vector + insert DNA
100 ul of solution 1 (50 mM glucose, 25 mM Tris, 10 mM EDTA pH 8 and 
freshly added lysozyme 2 mg/ml) was added to the bacterial pellet. Following 
this, 200 ul of solution 2 (0.2 M NaOH, 1% SDS) and 150 ul of cold solution 3 
was added (5 M potassium acetate, pH 4.8 with glacial acetic acid). Contents
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were gently mixed in between each addition and the tubes were placed on ice for 
5 minutes followed by centrifugation (15,000 rpm) for 5 minutes in a microfuge. 
The clear supernatant was carefully removed and the DNA precipitated by 
addition of 2 x the volume of absolute ethanol.
10 x TE pH 7.4 
100 mM Tris pH 7.4 
10 mM EDTA pH 8
These reagents were dissolved in distilled water (For pH 8 TE; Tris is made to 
pH 8).
Quantification of DNA
An aliquot of DNA (usually 2.5 or 5 u l ) was diluted in water to a total volume 
of 250 ul.
The absorbance was read in a silica cuvette at 260 nm and 280 nm and the ratio 
of absorbance at 260 nm : 280 nm was determined. A pure DNA preparation 
should have a ratio of 1.8 at 260 nm : 280 nm.
Concentration of DNA was calculated by:-
A26O x 50 x dilution = ug/ml DNA 
(50 ug/ml of pure DNA has an OD of 1)
IPX DNA 'loading dve'
0.25% bromophenol blue 
0.25% xylene cyanol 
25% ficol
Reagents were dissolved in distilled water.
The solution contained ficol, a heavy sugar which helped to sink the DNA to the 
bottom of the wells in the gel. 1 ul of loading dye was added to 9 ul of DNA 
sample (which was usually diluted in distilled water).
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Agarose gel
For a 1% agarose gel, lg of agarose was dissolved in 100 ml of 1 x tris acetate 
by boiling. 0.05% v/v ethidium bromide was added on partial cooling, the 
liquid poured into a gel mould containing a comb to form wells and allowed to 
set. The gel was placed in a tank containing 1 x tris acetate running buffer, the 
comb was removed and samples containing the dye were loaded. The samples 
were electrophoresed until the dye markers had migrated over half the length of 
the gel. In order to obtain a good resolution, the samples were often 
electrophoresed until the dye had migrated to the end of the gel. As DNA 
possesses a negative charge; the samples migrated towards the anode.
10 x tris acetate 
0.4 M Tris
0.05 M sodium acetate 
0.01 MEDTA
The reagents were dissolved in distilled water and the pH was adjusted to pH 
8.1 with glacial acetic acid.
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CHAPTER 3
THE EFFECTS OF EXOGENOUS IL-6  ON HUMAN AND RAT 
OSTEOBLAST-LIKE CELLS.
ABSTRACT
Interleukin 6  (IL-6 ) exerts well established effects on cells of the immune system as 
well as on a variety of other cell types. Many of its activities overlap with the well 
characterised cytokine IL-1 which is a potent agent in the control of bone turnover. 
Elevated levels of IL-1 and IL-6  in synovial fluid and serum have been implicated in the 
pathogenesis of inflammatory conditions such as rheumatoid arthritis. Several groups 
have studied the effects of EL-6  on bone resorption by osteoclasts, however, little work 
with respect to the actions of IL-6  on osteoblasts has been reported. The effects of 
recombinant human IL-6  (rhIL-6 ) on human osteoblast-like cells derived from explants 
of trabecular bone were investigated and compared with those exerted on ROS 17/2.8 
cells. rhIL-6  used over the concentration range of 0.05 - 5 ng/ml had no observable 
effects on the cell proliferation, alkaline phosphatase activity or release of 
prostaglandins by either osteoblast-like cell model system. In addition, the synthesis of 
osteocalcin, IL-1 and TNF were not regulated by rhEL-6  in human osteoblast-like cells. 
Thus, from the parameters investigated in this study, IL-6  does not appear to be 
involved in the regulation of osteoblast activity. In addition, rhIL-6  does not exhibit 
similarities with IL-1 on the above osteoblast functions, nor does it modulate several 
IL-1-stimulated activities.
INTRODUCTION
IL-6  although distinct in structure from IL-1, exhibits strikingly similar activities such 
as stimulation of the synthesis of the acute phase proteins from human hepatocytes 
(Gauldie et al 1987, Castell et al 1989), induction of fever (Helle et al 1988a) and 
enhanced thymocyte proliferation (Lotz et al 1988). In addition, both cytokines 
stimulate the production of ACTH from rat anterior pituitary cells (Besedovsky et al
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1986, Naitoh et al 1988) and are involved in hematopoiesis (Ikebuchi et al 1987). Both 
IL-1 and IL-6  are able to synergise with IL-3 to increase hematopoietic stem cell 
formation (Koike et al 1988, Hoang et al 1988, Wong et al 1988), although IL-1 was 
reported to be less effective than IL-6  (Koike et al 1988, Ogawa and Clark 1988). IL-1 
has previously been shown to exert complex effects on bone metabolism. IL-1 is a 
potent bone resorptive agent (Gowen et al 1983, Dewhirst et al 1987, Stashenko et al 
1987a, Sabatini et al 1988, Sato et al 1989) and induces osteoclast-like cell formation in 
long-term bone marrow culture (Pfeilschifter et al 1989, Kurihara et al 1991). IL-1 
appears to exert variable effects on bone formation and matrix synthesis according to 
the culture conditions. Stashenko et al (1987b) observed that IL-1 inhibits matrix 
synthesis, whereas Canalis (1986) demonstrated that under certain conditions, the 
production of collagen type I in fetal rat calvarial osteoblast-like cells could be induced 
by IL-1. IL-1 also stimulates osteoblast proliferation (Gowen et al 1985, Ikeda et al 
1988, Gowen 1988, Evans et al 1989b, Evans et al 1990b, Rickard et al 1990) which 
may lead to subsequent bone formation (Boyce et al 1989) related to the successful 
coupling with previous bone resorption. In contrast, the activities of IL-6  are not so 
well established with respect to the bone remodelling cycle. The potential involvement 
of IL-6  in bone metabolism is supported by a number of lines of evidence. IL-6  is 
present in the synovial fluid in patients with inflammatory arthropathies such as 
rheumatoid arthritis in contrast to patients suffering from osteoarthritis (Hirano et al 
1988, Gueme et al 1989). IL-6  is likely to be involved in the disease multiple myeloma 
(Kawano et al 1988, Asaoku et al 1988, Bataille et al 1991) which, like rheumatoid 
arthritis, is associated with extensive bone resorption (Mundy et al 1974). There are 
also reports of a bone resorbing effect of this cytokine in murine and rat bone models 
(Lowik et al 1989, Black et al 1990, Suda et al 1990). In contrast, others have been 
unable to show any stimulatory effects of IL-6  on bone resorbing cells (Al-Humidan et 
al 1991, Barton et al 1990).
There are relatively few reports of the effect of IL-6  on osteoblast activity however, and 
since IL-1 and IL-6  share certain similar activities discussed earlier in this introduction,
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a comparison of the effects of these cytokines were studied on human osteoblast-like 
cells. IL-1 has previously been demonstrated to exert a number of effects on 
osteoblast-like cells including the stimulation of prostaglandin production, cell 
proliferation (Gowen 1988, Evans et al 1989b, Evans et al 1990b) and the induction of 
other cytokines such as TNF (Gowen et al 1990). Therefore, the effects of IL-6  on cell 
proliferation, production of prostaglandin E2 and TNF in the presence and absence of 
IL-1 was examined. In addition, the effects of IL-6  on the production of IL-1 were 
also studied. Alkaline phosphatase and osteocalcin expression are markers for the 
maturing osteoblast phenotype and so the ability of IL-6  to modulate the activity of 




The murine fibrosarcoma WEHI 164 clone 13 cell line (Espevik and Nissen-Mayer 
1986) is lysed in the presence of TNFa and TNFp. As a consequence an inverse 
relationship exists between cell number and TNF concentration. This therefore 
represents a cytotoxic bioassay.
Maintenance of WEHI cells
The WEHI 164 clone 13 cells were cultured in RPMI1640 containing 10% (v/v) FCS, 
100 U/ml penicillin, 100 ug/ml streptomycin and 2mM L-glutamine (RPMI 1640 
+ 10% FCS). Cells were passaged at, or before, confluency. This cell line is not 
cell contact inhibited, and so cell viability and attachment is reduced on prolonged 
culture. For the purpose of cell passaging, the cells were trypsinised for 3-5 mins. 
Detached cells were removed and centrifuged (7 minutes, 1000 rpm, 22°C) and 
resuspended in 10 ml of medium. New cell cultures were established in culture flasks 
using a 1:10 split ratio. Cells were adherent 4 h post-passage.
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Method
Following trypsinisation and centrifugation, the cells were resuspended in 10 ml 
RPMI 1640 + 10% FCS and the cell number determined. Cells were then passaged 
into flat-bottomed 96-well plates at a density of 2x104 cells per well in a total media 
volume of 100 ul. Cells were allowed to adhere to the tissue culture well following a
3-4 h incubation period at 37°C.
1 0 0  ul aliquots of sample, such as bone cell conditioned medium, (giving a 2 -fold 
dilution of the samples) and 100 ul of rhTNFa standards made at 2x the final 
concentration were then added. A TNFa standard curve was constructed in triplicate 
over the concentration range of 0, 0.001, 0.01, 0.1, 1.0, 10, 100, 1000 U/ml. The 
WEHI 164 clone 13 cells were incubated with the samples at 37°C for a total period of 
24 h. After 20 h, 10 ul of MTT solution (5 mg/ml in PBS) was added to each well and 
incubated for the final 4 h. Viable cells metabolized the tetrazolium salt to a blue/purple 
coloured formazan metabolic product. The medium was then aspirated and 50 ul 
isopropanol containing 0.04 M HC1 was added which solubilised the formazan blue 
crystals and bleached any residual medium which would interfere with the absorbance. 
The absorbance was read on an ELISA plate reader using reference and test 
wavelengths of 630 nm and 570 nm respectively. The % cytotoxicity was calculated 
using the formula:-
1- (OD sample) x 1 0 0%
(OD zero standard)
A standard curve of % cytotoxicity against TNF U/ml was plotted. The % cytotoxicity 
for each sample was then calculated and the TNF concentration was determined using 




The DION4M murine T cell line (Hopkins and Humphreys 1989) proliferates in 
response to IL-1 and, to a lesser extent, with IL-2 and murine IL-4. The assay is 
therefore performed in the presence of an excess concentration of IL-2 to saturate the 
effects of any IL-2 that may be present in the test samples.
Maintenance of cells
Cells were maintained in RPMI 1640 containing 10% (v/v) FCS, 100 U/ml penicillin, 
100 ug/ml streptomycin, 2 mM L-glutamine, rhIL-la (2-4 U/ml), rhIL-2 (10-30 U/ml), 
concanavalin A (5 ug/ml) and 2-mercaptoethanol (5xl0-5 M). Under optimal growing 
conditions, the cells formed large clumps usually visible to the naked eye. For general 
maintenance the cells were split 1 :1 0  twice weekly by transferring 2  ml of the cell 
suspension into a new flask containing 18 ml of medium with the added growth 
factors.
Method
Cells were pelleted by centrifugation (1000 rpm, 7 minutes, 22°C) and resuspended in 
RPMI 1640 containing 10% (v/v) FCS and re-centrifuged to remove residual traces of 
growth factors. Since the assay is performed in the presence of concanavalin A and 
saturating concentrations of IL-2, the pellet was then resuspended in RPMI 1640 
containing 10% (v/v) FCS, 20-40 U/ml of IL-2 and 6-10 ug/ml of concanavalin A. A 
100 ul aliquot of cells was plated into a 96-well round-bottomed plate at a density of 
lxlO4 cells per well and lOOul of conditioned medium was added. This is equivalent to 
a 2-fold dilution of the sample and of the medium containing the cells and factors. A 
standard curve was constructed using rhIL-la as the standard in triplicate. A 100 ul 
aliquot of rhIL-la was added to the appropriate wells to give a final concentration range 
of 0, 0.001, 0.003, 0.01, 0.03, 0.1, 1.0, and 10 U/ml. The cells were incubated for 
72 h at 37°C and pulsed with 1 uCi/well of 6 -[^H]-thymidine for the final 4 h. A 
Skatron cell harvester was used to collect the radioactivity incorporated into the cells. 
This radioactivity was retained on paper discs (Titertek) which were allowed to dry and
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placed in scintillation vials containing 0.5 ml of Optiscint scintillation liquid (LKB). 
Incorporated radioactivity was assessed by liquid scintillation counting using a 
(5-counter. A standard curve plot of 6 -[3H]-thymidine incorporation (cpm) against IL-1 




To assess the effect of various agents on the proliferation of the human osteoblast-like 
cells and ROS 17/2.8 cells, 10,000 cells/well were passaged into a 48-well plate for a 
24 h period, prior to a 24,48 or 72 h incubation in the appropriate medium containing 
3% or 10% (v/v) FCS, or under serum-free conditions, together with the test agents. 
The cells were incubated with luCi 6 -[3H]thymidine for the final 6  h of the experiment. 
The experiment was terminated by the removal of the medium and the cell layer was 
washed twice with PBS. Trypsin-EDTA (100 ul) solution was added to each well and 
incubated until the cell layer was detached. Medium (200 ul) containing 10% (v/v) 
FCS was added to each well and the contents were transferred to LP4 tubes on ice. 
Each well was rinsed again with 200 ul of the same medium and the washings 
transferred to the corresponding LP4 tubes. The DNA was precipitated by addition of 
50 ul of 60% (w/v) trichloroacetic acid (TCA) and the contents of the tubes were 
vortexed and placed at 4°C for 20 h.
The samples were centrifuged at 2000 rpm for 10 mins at 4°C and the supernatant 
containing the unincorporated 6 -[3H] thymidine was discarded. The precipitate was 
dissolved in 1 ml warm dH2 0  and vortexed. Once dissolved, the tubes were placed on 
ice and the DNA was reprecipitated with 100 ul of 60% (w/v) TCA. The tubes were 
placed at 4°C for 3-5 h and then centrifuged as before. The supernatant was discarded 
and the precipitate was vortexed and dissolved in 0.5 ml warm CIH2O. In some cases 
where the final precipitate would not dissolve in (IH2O, a small amount of NaOH (3 M) 
was added to aid this process.
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The contents of each LP4 tube were then transferred to scintillation vials and 4 ml of 
(aqueous) scintillation fluid (LKB Optiphase ’Hisafe'3) was added to each vial. 
Incorporated 6 -[3H] thymidine was determined by counting for 60 seconds on a 
6 -counter.
Alkaline phosphatase assay and protein estimation 
Alkaline phosphatase
Alkaline phosphatase is the generic name given to a group of phosphatases which 
display maximum activity in the range pH 9.0-10.5. They are hydrolases and an 
alternative name is orthophosphoric monoester phosphohydrolase. The reaction that 
these enzymes catalyse can be represented:-
ROP + H20  => ROH + POH 
Phosphoester Alcohol + Orthophosphate
In the assay described above, 4-nitrophenylphosphate is the substrate and p-nitrophenol 
is the reaction product.
Method
Human bone cells or ROS 17/2.8 cells were plated out in the appropriate medium in 
24-well plates at a cell density of 40,000 cells/well and allowed to attach to the tissue 
culture substratum for 24 h. The medium was replaced with new EMEM or 
HAMS-F10 containing 10% (v/v) FCS or serum-free, together with the test agents, for 
a 24,48 or 72 h incubation period. After this time the medium was removed and either 
stored for bioassays or discarded. The plates were placed on ice and 200 ul of 0.1% 
(v/v) Tween in ddH2 0  added to each well. The cell layers were scraped thoroughly 
and the contents of each well transferred to an LP3 tube. For the determination of 
alkaline phosphatase activity, 50 ul of each sample or p-nitrophenol standard (see 
Appendix 2) was added to an LP3 tube in duplicate. A 100 ul aliquot of the remaining
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sample was transferred to another LP3 tube and stored at -20°C for protein estimation - 
see Protein Estimation. To 100 ml of assay buffer (see Appendix 2) 46.4mg
4-nitrophenylphosphate was added immediately prior to use. To each sample and 
standard, 500 ul of this solution was added and incubated at 37°C for 30-60 minutes 
until optimal colour development was obtained. The reaction was stopped by adding 
1 ml of 0.2 M NaOH to each tube.
The absorbance was measured at 410 nm using a spectrophotometer or by transferring 
a 300 ul aliquot into a 96-well plate and using an ELISA platereader (Dynatech). For 
the standard curve, the absorbance was plotted against p-nitrophenol concentration. 
Hence the amount of p-nitrophenol generated in the samples could then be determined 
by extrapolation.
Protein Estimation
This method is based on the Folin phenol reagent of Folin and Ciocalteu, the active 
constituent of which is phosphomolybdic-tungstic mixed acid. The mixed acids in the 
preparation are the final chromagen and involve the following chemical species: 
3H20.P20 5.13WO3.5 M0O3.10H2O 
and 3H2O.P20 5. 14W03.4Mo03. 10H2O
Proteins affect the reduction of the mixed acid by loss of 1,2, or 3 oxygen atoms from 
tungstate and/or molybdate, thereby producing one or more of several possible reduced 
species which have a characteristic blue colour (Xmax 745-750 nm, Xmjn 405 nm). 
Copper is thought to chelate with the peptide structure and facilitate electron transfer to 
the mixed acid chromagen, particularly in the vicinity of amino acid functional groups, 
thereby increasing the sensitivity to protein.
Method
A 100 ul aliquot of the scraped cell layer in 0.1% (v/v) Tween as described for alkaline 
phosphatase was used to determine the amount of cellular protein present in the well. 
The 100 ul aliquot was placed in an LP3 tube and a standard curve constructed using
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BSA at various dilutions (see Appendix 2). 500 ul of alkaline copper reagent (see 
Appendix 2) was added and the contents of the tubes vortexed and left to stand for 10 
minutes. After this time, 50 ul of freshly diluted Folin's Reagent (1:2 in dcLF^O) was 
added to each tube and the contents were mixed immediately and left to stand for 30 
minutes. A 300 ul aliquot of sample/standard was transferred to a 96-multiwell plate 
and the absorbance determined using an ELISA plate-reader at a wavelengh of 750 nm. 
A graph of absorbance against protein concentration was then plotted and the amount of 
protein in the samples determined.




Osteocalcin concentration was determined using a competitive RIA. Unlabelled 
osteocalcin released into the culture media and radiolabelled 125I-osteocalcin compete in 
binding to the primary osteocalcin antibody. The secondary antibody then binds to the 
osteocalcin/primary antibody complex to form an immunoprecipitate which is collected 
at the end of the assay.
When more osteocalcin is released by the cells into the supernatent, less 
125i_osteocalcin is able to bind to the primary antibody and so the associated 
radioactivity in the precipitate is decreased. In contrast, if less osteocalcin is released 
into the culture supernatent, more 125I-osteocalcin is able to bind to the primary 
antibody and so the radioactive counts increase.
Method
Conditioned medium, either saved from the alkaline phosphatase assay or prepared 
freshly by plating out human bone cells as for the alkaline phosphatase assay, was 
dispensed into LP4 tubes in 50 ul aliquots in triplicate. A standard curve of 100, 50,
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33, 20, 10, 5, 3.3, 2, and 1 ng/ml was constructed using bovine osteocalcin standard 
(Biogenesis) diluted in assay buffer (see Appendix 2).
Tubes were also prepared to assess total counts (TC) (3 LP4 tubes x 50ul 125j_ 
osteocalcin), non specific binding (NSB) (3 LP4 tubes x 50ul non-immune rabbit 
serum diluted to 2.5% (v/v) in assay buffer) and maximum binding (MB) (3 LP4 
. tubes). Bovine osteocalcin (Biogenesis) was radioiodinated using the Chloramine-T 
method (prepared by Dr. D.B. Evans).
Assay buffer, then primary antibody followed by l25I-osteocalcin were added to the 
tubes (see Appendix 2). After all of the additions, the contents of the tubes were 
vortexed and incubated for 24 h at 4°C. After 24 h, 50 ul (0.5 U) of the secondary 
antibody (Goat anti-rabbit IgG, Calbiochem) was added to all tubes except total counts. 
The contents of the tubes were vortexed and incubated overnight at 4°C again. After 
this time, the tubes were centrifuged at 3000 rpm for 25 minutes at 10°C and the 
supernatant carefully removed by aspiration. The radioactivity of the 
immunoprecipitate was determined in a y-counter and the osteocalcin in ng/ml 
calculated from the standard curve by on-line computer.
Prostaglandin assay (PGEol 
Principle
Radiolabelled and unlabelled PGE2 compete for the binding site on a specific PGE2 
antibody. Following incubation, the unbound radiolabelled PGE2 is then removed by 
treatment with Dextran-coated charcoal. The antibody-radiolabelled PGE2 complex 
remaining in the supernatent is then counted on a p-counter.
Method
Human bone cells or ROS 17/2.8 cells were plated out as described for the cell 
proliferation experiments and allowed to adhere for 24 h prior to the addition of the test 
agents in the appropriate medium in the presence and absence of FCS. The bone 
cell-conditioned medium was removed after 24,48 or 72 h and stored for PGE2 assay.
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An aliquot of appropriate medium (not incubated with bone cells) was saved for 
constructing the PGE2 standard curve.
Aliquots of the conditioned medium (100 ul) were transferred into LP4 tubes on ice and 
assayed in duplicate. The standard curve (100 ul aliquots assayed in triplicate) was 
made by diluting stock PGE2 standard (see Appendix 2) to 5, 2.5,1.25,0.625, 0.313, 
0.156, 0.078,0.039, 0.020 and 0.010 ng/ml in non-conditioned medium. Tubes were 
also prepared to assess total counts, non-specific binding and maximum binding (0  
standard) and placed on ice. Assay buffer (see Appendix 2), 100 ul 
[5,6,8,11,12,14,15 (n) 3h-PGE2] (160 Ci/mmol) (diluted 1:15,000 in assay buffer) 
and finally 100 ul antibody (one vial of anti-PGE2 (Steranti Research) was dissolved in 
100 ml assay buffer) were added to the tubes. The contents of the tubes were vortexed 
and placed at 4°C overnight. The following day, a charcoal/dextran mixture (300 mg 
Norit A charcoal + 62.5 mg Dextran T70 in 100 ml working buffer) was prepared and 
mixed on ice for 30 minutes prior to use. A 200 ul aliquot of this mixture was 
dispensed into all the LP4 tubes except for the total counts. The contents of the tubes 
were subsequently vortexed and left for 5 minutes. Following this, the tubes were 
centrifuged at 4°C for 15 minutes at 3000 rpm. A 200 ul aliquot of the supernatent was 
transferred into 4 ml of Optiphase aqueous scintillant, vortexed and counted on a liquid 
scintillation p counter.
Calculation:- Sample count per minute - NSB xlOO = % Binding
Total counts
A graph of % binding against PGE2 concentration was plotted and from the % binding 




Wherever possible, the studies of the effects of IL-6  on osteoblasts were undertaken in 
serum-free culture in order to exclude the possibility of interactions with many other 
cytokines and growth factors contained within FCS. This presented difficulties when 
studying the production of TNF and IL-1 by human trabecular bone cells, since 
bioassayable levels of TNF and IL-1 were not readily detectable under serum-free 
conditions even when a known positive stimulator was present. Therefore these 
experiments had to be conducted in media containing 10% (v/v) FCS. Indomethacin is 
a non-steroidal anti-inflammatory drug known to inhibit cyclooxygenase activity 
(Flower 1974) and hence prostaglandin synthesis (Vane 1971). This drug was added 
to abolish prostaglandin synthesis since prostaglandins are known to modify certain 
actions of cytokines on cell proliferation (Gowen et al 1985) and cytokine production 
(Kunkel and Chensue 1985).
After a 6  h culture period, in 10% (v/v) FCS-containing EMEM with indomethacin 
(1.4 uM), unstimulated human osteoblast-like cells produced a small amount of 
bioactive TNF (fig. 3.1). Over a series of 10 experiments in medium containing 10% 
(v/v) FCS, the basal levels of TNF ranged from <0.001 - 0.302 U/ml TNF. rhIL-la 
(10~13 - 10" 11 M) consistently stimulated TNF release in human bone cells, although 
the levels of induction varied from one patient to another over the range of 0.62 - 5.7 
U/ml. rhIL-6  over the concentration range 0.05 to 5 ng/ml did not affect basal or 
rhIL-la-induced release of TNF (fig. 3.1). ROS 17/2.8 cells did not produce 
detectable quantities of TNF in 10% (v/v) FCS-containing HAMS F10 and 1.4 uM 
indomethacin (data not shown).
IL-1 production
Unstimulated levels of IL-1 in the conditioned medium of human osteoblast-like cells 
were very low (<0.001 U/ml). In the presence of indomethacin (1.4 uM), and 10% 
(v/v) FCS-containing EMEM, human osteoblast-like cells released 0.03 U/ml IL-1
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when stimulated with rhTNFa (10-7 M) for 24 h and this was therefore used as a 
positive stimulatory control. Basal levels were unaffected by rhIL-6  over the dose 
range of 0.05 - 5 ng/ml (fig. 3.2). Non-conditioned media containing the test agents 
were added at least once directly to the TNF and IL-1 bioassays in order to confirm that 
the effects measured were due to agents released into the medium by the osteoblast-like 
cells and were not due to the interference with the test agents themselves (data not 
shown).
PGE? production
A 5-7 fold increase in basal PGE2  levels was observed with 10-12 M rhIL-la 
(Fig. 3.3) after a 24 h culture period under serum-free conditions. After 48 and 72 h 
of serum-free culture, the stimulatory effect of rhIL-la was still evident (fig. 3.3). 
rhIL-6  over the concentration range 0.05 - 5 ng/ml alone exerted no modulatory effect 
on basal PGE2 production at any time point studied or following stimulation with 
10-12 M rhIL-la (fig. 3.3).
rhIL-6  (0.05 - 5 ng/ml) did not modulate the basal or rhIL-la-stimulated (1 0 -12 M) 
PGE2 production in ROS 17/2.8 cells after incubation for 72 h in serum-free conditions 
(fig. 3.4). It was of interest to note that the basal and rhIL-la-stimulated PGE2  
production from these osteosarcoma cells was approximately 100-fold lower than levels 
produced by human osteoblast-like cells. The basal production of PGE2 by 
ROS 17/2.8 cells after a 72 h serum-free culture was 0.05 ng/well compared with 
4ng/well in human osteoblast-like cells. rhIL-la-stimulated PGE2 levels under the 
same cultural conditions varied from 0.09 ng/well in the ROS 17/2.8 cells to 
2 2  ng/well in the human trabecular bone cells.
Cell proliferation
rhIL- 6  (0.05 - 5 ng/ml) in the presence of indomethacin (1.4 uM), did not modulate the 
cell proliferation of the human osteoblast-like cells in serum-free medium when 
incubated for 24, 48 or 72 h (Fig. 3.5). IL-1 has been previously demonstrated to
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stimulate the cell proliferation of the human osteoblast-like cells, thus rhIL-la was used 
as a positive stimulatory control (Gowen 1988, Evans et al 1989b, Evans et al 1990b). 
In contrast to these published observations, IL-1 did not stimulate cell proliferation in 
serum-free culture in the present studies.
The effect of indomethacin (1.4 uM) on the basal cell proliferation in the presence and 
absence of IL-6  (0.05 - 5 ng/ml) was studied in human trabecular bone cells 
(Table 3.1). Indomethacin did not influence cell proliferation under these conditions in 
either serum-free or 3% (v/v) FCS-containing medium (Table 3.1). IL-6  had no effect 
on cell proliferation under any of the conditions used. However, addition of serum 
(3% v/v) did cause an increase in the basal proliferation of the human osteoblast-like 
cells.
rhIL-6  (0.05 - 5 ng/ml) was also ineffective when studying the proliferation of 
ROS 17/2.8 cells under serum-free conditions in the presence of indomethacin 
(1.4 uM) after 24, 48 and 72 h incubation (Fig 3.6). In contrast, rhIL-la (10" 11 M) 
stimulated the proliferation of the ROS 17/2.8 cells after a 48 and 72 h incubation. 
This response was unaltered by the simultaneous addition of rhIL-6  (Fig. 3.6).
Alkaline phosphatase expression
l,25(OH)2D3 stimulates the expression of alkaline phosphatase in human trabecular 
bone cells (Beresford et al 1986, Evans et al 1990a) and ROS 17/2.8 cells (Majeska and 
Rodan 1982). The action of rhIL-6  was examined to determine whether it exhibited 
any regulatory action on basal and l,25(OH)2D3-stimulated alkaline phosphatase 
production in human bone cells cultured in the presence and absence of serum. rhIL-6  
(0.05 - 5 ng/ml) exerted no effects on both the unstimulated and l,25(OH)2D3- 
stimulated (10-8M) levels of alkaline phosphatase in the presence (fig. 3.7) or absence 
(fig. 3.8) of serum after a 72 h culture period.
ROS 17/2.8 cells expressed high basal alkaline phosphatase levels which were only 
slightly, but consistently, stimulated with l,25(OH)2D3 (10-8M). rhIL-6
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(0.05 - 5 ng/ml) did not modulate the basal or l,25(OH)2D3 (10-8M)-stimulated 
alkaline phosphatase expression after a 72 h incubation in serum-free culture (fig. 3.9).
Osteocalcin expression
The production of osteocalcin by osteoblasts is stimulated by l,25(OH)2D3 (Beresford 
et al 1984b, Evans et al 1990a). rhIL-6  (0.05 - 5 ng/ml) did not affect the basal or 
l,25(OH)2D3-stimulated production of this bone matrix protein after a 72 h serum-free 
culture period (fig. 3.10).
DISCUSSION
These studies were devised to determine whether the actions of IL-6  were similar to that 
of IL-1 on osteoblast-like cells and whether IL-6  modulated any of the IL-1 responses. 
There are definite differences between the actions of IL-1 and IL-6  observed on bone 
cell function in contrast to the similarities observed in the immune system. Using two 
osteoblast-like cell models IL-6 , unlike IL-1, did not affect the basal expression of any 
of the parameters studied. Furthermore, IL-6  (0.05 - 5 ng/ml) did not appear to alter 
the phenotype of the osteoblast-like cells with respect to alkaline phosphatase and 
osteocalcin levels. In addition, IL-6  did not modulate any of the effects of IL-1 on the 
cell proliferation, cytokine and prostaglandin E2 production by either osteoblast-like 
model system.
Other groups have not studied the effects of IL-6  on cytokine production in 
osteoblast-like cells. However, Kurihara et al (1990) demonstrated that IL-6  increased 
the formation of osteoclasts in long-term human bone marrow culture by inducing the 
expression of IL-1. By the use of a specific ELISA, they were able to demonstrate an 
increased production of IL-1 following addition of IL-6 , although the IL-6 -responsive 
cells within the marrow culture were not determined. IL-6  is reported to induce IL-1 
secretion in fibroblasts, marrow stromal cells and glial cell lines (Kishimoto and Hirano 
1988). It is possible that some cells within the bone microenvironment are capable of
being induced by EL-6  to release IL-1, although studies presented in this chapter would 
indicate that osteoblasts are not the primary target for IL-6 .
IL- 6  did not modulate either the basal or EL-la-stimulated PGE2 production in human 
osteoblast-like cells or ROS 17/2.8 cells. Bunning et al (1990) also demonstrated that 
IL-6  did not regulate PGE2 expression in human articular chondrocytes. Contrasting 
studies from Fang and Hahn (1991) using UMR 106-01 rat osteoblast-like cells, 
demonstrated that IL-6  was capable of stimulating PGE2 production. Their results 
were somewhat unusual however, as indomethacin did not inhibit prostaglandin 
production.
Proliferation of human trabecular bone cells was not stimulated by IL-6  or IL-1. The 
lack of effect of EL-6  could not be determined conclusively, as the positive control was 
also ineffective. There is some controversy as to whether IL-1 stimulates (Gowen et al 
1985, Gowen 1988, Evans et al 1989b, Evans et al 1990b Canalis 1986) or inhibits the 
proliferation of osteoblast-like cells (Stashenko et al 1987b). The major arguement 
posed by Stashenko et al (1987b) was that the cultures in which cell proliferation was 
observed were heterogeneous, and therefore non-osteoblastic cells such as fibroblasts 
may have been proliferating in preference to the osteoblastic populations. This has 
been clarified in part by a new technique assessing cell proliferation on an individual 
cell basis (Rickard et al 1990). In these studies the osteoblast-like cells were induced to 
proliferate with IL-1 in the presence of [3H]-thymidine. The cells were then 
subsequently induced to differentiate with l,25(OH)2D3, to a more mature phenotype 
as assessed by alkaline phosphatase expression. By use of this dual autoradiography- 
histochemical localisation method, cells which had been induced to replicate in response 
to IL-1 and then to subsequently differentiate into osteoblasts were specifically 
identified (Rickard et al 1990). It is likely that the lack of effects of IL-1 in the present 
study may have been due to either culture conditions (serum-free culture) or differences 
in donor responsiveness. Previously, the studies describing a stimulatory effect of 
IL-1 on human osteoblast-like cells were conducted in the presence of serum (Gowen et 
al 1985, Gowen 1988, Evans et al 1989b, Evans et al 1990b, Rickard et al 1990).
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Under such conditions it is likely that important interactions between IL-1 and serum 
factors may have contributed to the proliferative action described for IL-1. However, 
an indication that IL-6  does not exert any proliferative action on human osteoblast-like 
cells is clearly demonstrated in the final chapter of this thesis.
In contrast to the human cells, IL-1 induced the cell proliferation of ROS 17/2.8 cells, 
which are highly proliferative osteosarcoma cells, and which were probably not 
adversely affected in the short term by serum-free culture. IL-6  however, did not 
modulate either the basal or IL-1-stimulated proliferation of the ROS 17/2.8 cells. In 
contrast, IL-6  increased the cell proliferation of UMR-106-01 cells (Fang and Hahn 
1991). This occurred via a prostaglandin-dependent mechanism, associated with the 
endogenous stimulation of PGE2 production by IL-6 . The maximal effects observed 
with IL-6  occurred during the logarithmic growth phase of these UMR 106-01 cells. In 
the present studies, both the human and rat osteoblast-like cells were seeded at 
subconfluent levels as these were shown to be the most effective conditions for the 
induction of cell proliferation by IL-1 (Gowen 1988). IL- 6  does influence the 
proliferation of other cell types however. This cytokine increases the proliferation of 
murine hybridoma cells (Helle et al 1988a, Helle et al 1988b), thymocytes (Helle et al 
1988b) and AIDS-Kaposi sarcoma-derived cells (Miles et al 1990). Grossman et al
(1989) demonstrated that IL-6  stimulates the proliferation of keratinocytes which may 
contribute to the clinical conditions associated with psoriasis. Others have 
demonstrated the inhibition of cell proliferation by IL-6  in mammary carcinoma cell 
lines (Tamm et al 1989, Tamm et al 1991).
The production of alkaline phosphatase and osteocalcin following stimulation by 
l,25(OH)2D3 in human osteoblasts is strongly inhibited by IL-1 and TNF (Gowen 
1984, Gowen 1988, Evans et al 1989b, Evans et al 1990b). At least in the human 
osteoblastic cell system, these cytokines may possibly be exerting a de-differentiating 
effect on osteoblasts associated with concomittant cell proliferation. IL-6 , however, 
had no effect on either basal or l,25(OH)2D3-induced synthesis of alkaline phosphatase 
activity or osteocalcin by human trabecular bone cells. Basal levels of alkaline
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phosphatase were much higher in ROS 17/2.8 cells compared to human osteoblast-like 
cells as this was one of the selection markers used when isolating and cloning the ROS 
cell series. l,25(OH)2D3 responses, although present, were not as marked in 
ROS 17/2.8 cells. This could have reflected the density and maturity of the rat 
osteosarcoma cultures (Majeska and Rodan 1982). Majeska and Rodan (1982) 
demonstrated that in mature ROS 17/2.8 cultures where alkaline phosphatase activity 
was high, l,25(OH)2D3 exhibited a biphasic effect, with a concentration of 10-8 M 
l,25(OH)2D3 stimulating the enzyme activity in agreement with the results presented in 
this chapter. However, in the present studies IL-6  did not modulate either the basal or 
l,25(OH)2D3-stimulated alkaline phosphatase levels. Also in accordance with the 
studies presented in this chapter, IL-6  exerted no effect on the alkaline phosphatase 
activity of UMR 106-01 cells (Fang and Hahn 1991). However, there are other 
contrasting studies. Ishimi et al (1990) observed that IL-6  slightly suppressed the 
alkaline phosphatase activity in MC3T3-E1 cells, whereas Hughes and Howells (1992) 
observed that IL-6  at very high concentrations was able to induce alkaline phosphatase 
in rat calvarial osteoblasts.
The studies presented in this chapter examining the effects of IL-6  on human 
osteoblast-like cells and ROS 17/2.8 cells, would suggest that the osteoblast does not 
appear to represent the primary target cell within the bone microenvironment Although 
the effects of IL-6  on collagen synthesis and other matrix proteins have not been 
studied in this chapter, Linkhart et al (1991) recently demonstrated that IL-6  did not 
modulate collagen synthesis in normal human osteoblasts. Other studies would suggest 
that IL-6  may slightly depress collagen synthesis in various osteoblast systems (Ishimi 
et al 1990, Fang and Hahn 1991). It is possible that IL-6  does exert effects on human 
osteoblasts, but on a different range of features not measured in this study.
There is evidence to suggest that an osteoclast precursor is responsive to IL-6  however, 
the effect of IL- 6  on bone resorption still remains controversial. Barton and Mayer
(1990) demonstrated that IL-6  exerted no effect on bone resorption in neonatal mice 
calvariae. In these series of experiments, the mothers were allowed to deliver their litter
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before sacrificing the 1 day old pups and labelling the calvariae for 48 h with 45Ca. 
The effects of the interactions of IL-6  with other agents on bone resorption were not 
investigated in these studies. Al-Humidan et al (1991) also showed that IL-6  alone did 
not affect resorption in 45Ca-prelabelled neonatal mouse calvariae. Here newborn mice 
were injected subcutaneously with 45Ca and sacrificed 4 days later before dissection of 
calvaria. However, this group demonstrated that IL-6  exerted an inhibitory effect on 
PTH- and l,25(OH)2D3-stimulated bone resorption but not that induced by IL-1. 
Addition of an anti-IL-6  antibody blocked the inhibitory effect of IL-6  on resorption 
stimulated by PTH and l,25(OH)2D3. This is in contrast to work by Black et al (1990) 
who demonstrated that IL-6  did not affect bone resorption stimulated by l,25(OH)2D3 
and PTH although it enhanced resorption stimulated by TNF and IL-1. They observed 
that an anti-IL-6  antibody could inhibit bone resorption stimulated by IL-1 and TNF. 
The reason for the discrepancy is unknown since the same bone resorption assay model 
was utilised, but could be a result of using slightly different culture conditions and 
different preparations of IL-6  and anti-IL-6  antibody. Ishimi et al (1990) also 
demonstrated that EL-6  increased bone resorption in fetal mouse calvariae from 16 day 
45Ca injected pregnant mice killed 1 day later. IL-1 and IL-6  at suboptimal doses 
synergistically induced bone resorption and osteoclast number on the trabecular bone 
surface. Several other groups have studied the effects of IL-6  on bone resorption using 
other experimental systems. Lx>wik et al (1989) observed that in systems which contain 
very early osteoclast progenitors such as 17 day old fetal mouse metacarpals, IL-6  
stimulates bone resorption. However in 17 day old fetal mouse radii already containing 
mature osteoclasts, they found that IL-6  did not exert any effect on bone resorption. 
This suggests that IL-6  may be involved in the recruitment of osteoclast precursors 
rather than the activation of mature osteoclasts. Evidence for this is further 
substantiated by the observation that IL-6  increases the formation of multinucleated 
osteoclast-like cells in long-term human bone marrow culture as defined by reactivity to 
an antibody 23C6, that recognises osteoclasts (Kurihara et al 1990). Furthermore, EL-6  
did not modulate the l,25(OH)2D3-stimulated multinucleated cell formation but did
85
increase the percentage of 23C6 positive cells within these cultures. A specific 
anti-IL-1 antibody also blocked IL-6 -induced multinucleated cell formation and the 
number of 23C6 positive cells. It would therefore appear as though IL-6  is exerting 
quite complex effects and is almost certainly acting in concert with other factors within 
the bone microenvironment. The above evidence would indicate that IL-6  may be 
exerting its effects on an immature osteoclast precursor rather than on mature 
osteoclasts, although this does not explain all of these observations. The different 
strains of mice, culture conditions and slight variations in experimental design are quite 
likely to contribute to these variations.
Relatively little work has been performed to study the function of IL-6  on bone 
remodelling in vivo. However, Black et al (1991a) have demonstrated a 
hypercalcaemic effect of IL-6  in vivo. This was shown by transfecting IL-6  cDNA into 
Chinese hamster ovarian cells which were then injected into tumour bearing nude mice. 
After 15 days, the serum ionized calcium levels were outside the normal range and by 
19 days serum calcium levels were significantly elevated above control values. In 
further studies, Black et al (1991b) observed that antibodies to IL-6  reversed the 
induction of hypercalcaemia in nude mice bearing tumours producing DL-6 and TNF. It 
is possible that the hypercalcaemia observed in these nude mice was due to an increase 
in bone resorption although this was not described histologically and so the evidence is 
therefore circumstantial.
Another well characterised activity of IL-6  is its involvement in hematopoiesis. 
Therefore hematopoietic stem cells are another potential target for IL-6  within the bone 
microenvironment. Different systems such as 5-fluorouracil treated mouse spleen cells 
(Ikebuchi et al 1987, Koike et al 1988, Wong et al 1988, Suda et al 1988), mouse bone 
marrow cells (Suda et al 1988) and human marrow cells (Hoang et al 1988, Ogawa and 
Clark 1988, Leary et al 1988) have been used to study the effect of IL-6  on 
hematopoiesis. Using myeloid leukemia Ml cells, several groups have observed that 
IL-6  directed the differentiation of Ml cells down the macrophage lineage (Chen et al 
1988, Miyaura et al 1988, Miyaura et al 1989a, Metcalf 1989). These macrophages
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were shown to possess several macrophage characteristics such as phagocytic activity, 
adherence to the culture vessel and surface markers (Miyaura et al 1989a). Murray et al 
(1990) demonstrated presence of LIF and IL-6  mRNA and protein but not GM-CSF or 
IL-3 in mouse blastocysts at 3.5 days of gestation and surmised that IL-6 , together with 
LIF, may be involved in early hematopoiesis. Suematsu et al (1989) fused the IL-6  
gene with an IgG heavy chain enhancer and obtained transgenic mice with elevated 
serum levels of IL-6  and IgG. In addition, Suematsu and co workers (1989) observed 
that there was an increase in megakaryocytes in the bone marrow which indicates a 
hematopoietic role for IL-6 . That IL-6  is involved in hematopoiesis is well established 
and the majority of evidence demonstrates that this cytokine favours the differentiation 
of lineages, such as monocytes and macrophages, which may ultimately lead to 
osteoclast generation (Ikebuchi et al 1987, Hoang et al 1988,Wong et al 1988). In 
support of this theory, IL-6  has been reported to increase the number of osteoclast-like 
cells in long-term human marrow culture (Kurihara et al 1991). IL-6  appeared to 
induce the differentiation of a committed (unipotential) precursor and increase the 
proliferation of early GM-CFU bipotential precursors which can subsequently 
differentiate into osteoclasts or macrophages (Kurihara et al 1991).
Therefore, IL-6  rather than acting on the bone forming cells, may play a role in bone 
resorption and hematopoiesis and hence could be important for potential growth and 
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Fig. 3.1 The effect of.IL.-.6 on basal and rhIL-,1 -stimulated »m ls of
TNF activity in human osteohlast-like cells.
Human trabecular bone cells were incubated in the presence of agents under 
test for 6 h in 10% (v/v) FCS-containing EMEM and indomethacin (1.4 uM). 
The bone cell conditioned medium was removed and assayed for TNF activity 
(see methods). Mean ± S.E.M. Representative experiment (n=10).








C 0.05 0.5 5 IL' 6 ng/ml
7 TNF alpha (-log M)
Fig. 3.2 The effect of IL-6 on basal levels of IL-1 activity in human 
osteoblast-like cells.
Human trabecular bone cells were incubated with the agents under test for 24 h 
in the presence of 10% (v/v) FCS containing EMEM and 1.4 uM indomethacin. 
The bone cell conditioned medium was removed and assayed for IL-1 
bioactivity (see methods). Mean ± S.E.M. Representative experiment (n=3). 
Significant difference from unstimulated levels ** p<0.01.
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Fig. 3.3 The effect of IL-6 on basal and rhiL-1 ^ -stimulated levels of
prostaglandin E actiyitv in human asteQ.biast-!iKe cells,
Human trabecular bone cells were incubated with the agents under test for 24, 
48 and 72 h in the presence of 0.1%(w/v) BSA-containing EMEM. The bone 
cell conditioned medium was removed and assayed for PGE2 activity (see 
methods). Mean±S.E.M. Representative experiment (n=3). Significant 
difference from unstimulated levels 
* p<0.05, ** p<0.01.
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Fig. 3.4 The effect of IL-6  on basal and rhIL-^stimulated__
levels of PGE activity in ROS 17/2.8 cells.
Rat osteosarcoma ROS 17/2.8 cells were cultured with the agents 
under test for 72 h in the presence of 0.1% (w/v) BSA-containing 
HAMS F10. The conditioned medium was removed and assayed for 
PGE2 activity (see methods). Mean ± S.E.M. Representative 
experiment (n=3). Significant difference from unstimulated levels
**p<0 .0 1 , ***p<0 .0 0 1 .
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Y/A  Control (0.1% BSA 1.4uM indomethacin in EMEM) 
IL-6 0.05,0.5 and 5 ng/ml respectively
■  IL-1 11 (-log M)
Fig. 3.5 The effect of IL-6  on basal levels of human osteoblast-like 
cell proliferation.
Human trabecular bone cells were cultured in the presence of the agents under 
test for 24, 48 and 72 h in the presence of 0.1% (w/v) BSA-containing 
EMEM and 1.4 uM indomethacin. The cell layer was assessed for 








24 hours 48 hours 72 hours
\ / / \  Control (0.1% BSA, 1.4 uM indomethacin in HAMS F10) 
IL-6  0.05, 0.5 and 5 ng/ml respectively
H  IL-1 11 (-log M)
IL -111 (-log M) + IL-6 0.05, 0.5 and 5 ng/ml respectively
Fig. 3.6 Th? effect pf IL-6 on basal 2nd rhjL-lc* stimulated l<?v?l$ pf 
proliferation in ROS 17/2.8 cells.
ROS 17/2.8 cells were incubated with the agents under test for 24, 48 and 72 
h in the presence of 0.1% (w/v) BSA-containing HAMS F10 and indomethacin 
(1.4 uM). The cell layer was assessed for proliferation (see methods). Mean 
± S.E.M. Representative experiment (n=3). Significant difference from 
unstimulated levels *p<0.05.
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Fig. 3.7 The.effect vf i l-S  on ^asa! and }i2 $ (Q H ^ $ timu!ated.fey£ls of 
alkaline phosphatase activity in human osteoblast-like cells.
Human trabecular bone cells were incubated with the agents under test for 
72 h in the presence of 10% FCS-containing EMEM. The cell layer was assessed for 
alkaline phosphatase activity by measurement of p-nitro phenol release (see methods). 
Mean ± S.E.M. Representative experiment (n=3). Significant difference from 
unstimulated levels *p<0.05, ** p<0.01.
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Fig. 3.8 The effect of IL-6  on basal and 1.25(OHVX>3-stimulated 
kids of alkaline phosphatase activity in human 
osteoblast-like cells,
Human osteoblast-like cells were incubated with the agents under test for 72 h 
in the presence of 0.1% (w/v) BSA-containing EMEM. The cell layer was 
then assessed for alkaline phosphatase enzyme activity by release of p-nitro 
phenol (see methods). Mean ± S.E.M. Representative experiment (n=3). 
Significant difference from unstimulated levels *p<0.05, **p<0.01.
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Fig. 3.9 The effect of IL-6 on basal and 1.25
levels of alkaline phosphatase activity in
Stimulated 
$ 17/2,8 cells,
ROS 17/2.8 cells were cultured with the agents under test for 72 h in the 
presence of 0.1% (w/v) BSA-containing HAMS F10. The cell layer was assessed 
for alkaline phosphatase activity by measuring p-nitro phenol release 
(see methods). Mean ± S.E.M. Representative experiment (n=3). Significant 
difference from unstimulated levels *p<0.05, ** p<0.01.
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Fig. 3.10 The effect of IL-6 on basal and USCQH^ -gtiniuiated lewis of 
osteocalcin production in human osteoblast-like cells,
Human trabecular bone cells were incubated in the presence of the agents under test 
for 72 h in 0.1% (w/v) BSA- containing EMEM. The osteoblast conditioned medium 
was assayed for osteocalcin production (see methods). Mean ± S.E.M. Representative 




IL-6 0.05 ng/ml 
IL-6 0.5 ng/ml 
IL-6 5 ng/ml
Control + Indomethacin (1.4 uM)
IL-6 0.05 ng/ml + Indomethacin (1.4 uM) 
IL-6 0.5 ng/ml + Indomethacin (1.4 uM) 
IL-6 5 ng/ml + Indomethacin (1.4 uM)
EMEM + 0.1 % BSA EMEM + 3% FCS
4245 ±524 7581 ±852
4695 ±589 8227 ±1048
4553 ±712 8927 ±1123
4177 ±450 8512 ±967
4035 ±573 9033 ±901
3824 ±632 9145 ±955
4233 ±648 8506 ±779
4343 ±595 8801 ±1116
Table 3.1 The effect of indomethacin (1.4 uM) on proliferation in the 
presence of IL-6  and under basal conditions in human 
osteoblast-like cells.
Human trabecular bone cells were incubated with the agents under test for
72 h in 0.1% (w/v) BSA or 3% (v/v) FCS- containing EMEM. The cell layer was then
assayed for proliferation (see methods). Mean ± S.E.M. Each column
represents 6  pooled experiments using the same 6  bone donors for both conditions.
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APPENDIX 2
Alkaline phosphatase standard curve
Stock solution : p-nitrophenol 10 umoles/ml in dd water.
Stock (ul) 0.1% (v/v) Tween diluent Standard (umoles/ml)
50 2 0 0 2
40 182 1 .8
40 2 1 0 1 .6
40 246 1.4
40 293 1 .2
50 450 1 .0
50 575 0 .8
50 783 0 .6
25 600 0.4
25 1225 0 .2
1:1 dilution of 0 .2 0 .1
1:1 dilution of 0.1 0.05
Alkaline phosphatase assay 
Assay buffer
10.52 g diethanolamine and 400 mg magnesium chloride 6 -hydrate were dissolved in 
distilled H2O to make a total volume of 1 litre and the pH was subsequently adjusted to 
pH 10-10.5 using 0.1M HC1. This stock buffer was stored at 4°C.
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Protein standard curve
Stock solution: Bovine serum albumin (BSA): 500 ug/ml in ddH2 0 .
Stock (ul) 0.1% (v/v) Tween diluent (ul) Standard (ug protein)












This was prepared as a fresh solution and contained
1 ml of copper stock solution: (1% (w/v) tri-sodium citrate dihydrate in 0.5% (w/v) 
copper sulphate in dd H2O;
20 ml alkaline stock solution (10% (w/v) anhydrous Na2<X>3 in 2% (w/v) NaOH in dd 
H20)




0.01M Tris pH 7.4 6.055g 
0.14M NaCl 40.908g
0.025M EDTA 46.525g 
0.1% Tween 5g
0.25% BSA 12.5g
5 litres of 0.01M Tris pH7.4 was made up, then remaining chemicals were added. 
Preparation of primary osteocalcin antibody
Primary antibody was diluted to approx 1 : 1100 in assay buffer (dilution should be 
determined after each iodination: A range of dilutions was used and binding of tracer 
compared at each dilution-1:1 ratio of tracer: antibody was required).
Addition of reagents to the tubes for osteocalcin assay
vol (ul) vol assay buffer vol 1' antibody vo lI25j
(ul) (ul) osteocalcin (ul)
Total counts - - - 50
Non spec. bind. 50 150 - 50
Max. bind. - 150 50 50
Sample 50 100 50 50
Standard 50 100 50 50
Prostaglandin assay 
Preparation of stock PGE?
1 mg of PGE2  was dissolved in 1 ml of ethanol and further diluted in working buffer to 
1 ug/ml and stored as 100 ul aliquots at -20°C. The standard was subsequendy diluted 
in medium 1 :10  to obtain 100  ng/ml.
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Assay buffer
lg of gelatin was added to 2 0 0  ml of water and heated gently to dissolve. 100  ml stock 
buffer and 1 ml of chloroform were added to preserve the assay buffer. The pH was 
adjusted to pH 7.4 with HC1 and the final volume was adjusted to 1 litre. Buffers were 
stored at 4°C.
Stock buffer 
Trizmabase 12.1 g 
NaCl 81.6 g
Reagents were dissolved in 800 ml dd water, the pH adjusted to 7.4 with HC1 and the 
volume adjusted to 1 litre.
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MODULATION OF THE EXPRESSION OF IL-6 IN OSTEOBLAST-LIKE CELLS. 
ABSTRACT
The release of IL-6 from human trabecular bone cells and rat osteosarcoma cell line 
ROS 17/2.8 treated with a variety of stimuli has been assessed using the murine B9 
hybridoma bioassay. In serum-free medium, unstimulated human osteoblast-like cells 
constitutively produced IL-6 in the range of 200 - 2050 pg/ml over a 24 h period. 
Recombinant human interleukin la  (rhIL-la) (10"13 M - 10“H M), recombinant 
human tumour necrosis factor a (rhTNFa) (10~9 M - 10"7 M) and lipopolysaccharide 
(LPS) (5 - 500 ng/ml) all stimulated the release of IL-6 from human bone cells. In 
these studies maximal levels of 17,000 pg/ml of IL-6 were observed using the highest 
concentration of IL-la. In contrast, l,25(OH)2D3 (10“12 M - 10'8 M) and PTH 
(lO'H M - 10"9 M) did not stimulate IL-6 release. The bioactivity of the IL-6 released 
by the primary bone cells was completely neutralised using a specific sheep anti-human 
IL-6 antibody. In parallel studies, ROS 17/2.8 rat osteosarcoma cells released 
approximately 50 pg/ml of IL-6 under basal conditions which was increased to a 
maximum of 900 pg/ml by treatment with PTH (10-9 M) following a 24 h incubation 
period. The cytokines rhIL-la (10"13 M - 10'11 M), rhTNFa (10"9 M - 10'7 M) were 
less effective than PTH, whilst l,25(OH)2D3 had no effect.
It was of interest to note the differences in levels of production of IL-6 and the cytokine 
and hormonal responsive profile between the two osteoblast-like cell models used, with 
the ROS 17/2.8 cells exhibiting a lower basal production compared to the human cells. 
Modulation of expression of IL-6 mRNA in human osteoblast cells was examined 
using a human cDNA probe. IL-6 mRNA was constitutively expressed by human 
osteoblast-like cells and was increased by rhIL-la (10"11 M) and rhTNFa (10-7 M) 
within 2 h of treatment and this effect was sustained over a 24 h period. l,25(OH)2D3 
(10'8 M), IL-6 (2000 pg/ml) and PTH (10"9 M) exerted no effects at any time point
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examined whilst dexamethasone (10-6 M) suppressed both the basal and rhIL-la- and 
rhTNFa- induced IL-6 mRNA expression.
These results support the hypothesis that IL-6 is produced locally in human bone by 
osteoblasts under the direction of other cytokines. This could have implications in bone 
remodelling, hematopoiesis and systemic responses to local injury.
INTRODUCTION
As well as exerting a variety of actions, IL-6, like IL-1 is produced by a large range of 
cell types, these include endothelial cells (Norioka et al 1988, Howells et al 1991), 
monocytes (Aarden et al 1987, Tosato and Pike 1988, Bauer et al 1988), fibroblasts 
(Content et al 1985, Haegeman et al 1986, VanDamme et al 1987b, Gauldie et al 1987, 
Kohase et al 1987a, Kohase et al 1987b, Walther et al 1988), T cells and blastoid B 
cells (Hirano et al 1986), thyroid epithelial cells (Zhang et al 1991), synoviocytes 
(Gueme et al 1989), macrophages (Horn et al 1988, Waage et al 1990, Evans et al 
1991), human osteosarcoma cells (VanDamme et al 1987a), myeloid leukemia cells 
(Miyaura et al 1989a) and thymocytes (Helle et al 1988a). In addition; the IL-6 gene is 
transcribed in a number of organs including spleen, liver and kidney, and IL-6 
expression is closely associated with IL-1 expression (Tovey et al 1988). Many of 
these groups demonstrated that IL-6 mRNA and/or protein were induced by IL-1 and 
TNF (Van Damme et al 1987a,1987c, Gueme et al 1989). Although IL-6 is distinct in 
structure from IL-1, IL-6 exhibits strikingly similar biological activities (discussed in 
Chapter 3). This together with the fact that IL-1 further induces IL-6 from many cell 
types may indicate that IL-1 could be exerting some of its effects via a secondary 
cytokine such as IL-6.
The osteoblast is thought of by many as the central cell in bone remodelling since it not 
only lays down the matrix but also may control osteoclast activity via the release of 
soluble mediators (see Chapter 1). Previous work has demonstrated that IL-6 is 
produced by murine osteoblast-like cells (Lowik et al 1989, Feyen et al 1989, Li et al 
1991), synovial cells (Gueme et al 1989) and chondrocytes (Gueme et al 1990,
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Bunning et al 1990), an indication that IL-6 may be involved in connective tissue 
responses.
The aim of the work presented in this chapter was to study the regulation of IL-6 






Gloves were worn for all procedures. All of the solutions were sterile and RNase free 
by treatment with 0.1% (v/v) Diethyl pyrocarbonate (DEPC).
Confluent cultures of human osteoblast-like cells, grown in 9 cm petri dishes, were 
used for mRNA experiments. A separate plate was required for each treatment or 
control and time point.
The confluent osteoblast cell layer was passaged by trypsinisation, centrifuged 
(1000 rpm 7minutes) and the cell pellet was suspended in EMEM + 10% (v/v) FCS 
and plated into fresh 9 cm petri dishes at a density of 1 x 106 cells/plate. The cells were 
allowed to adhere for 24 h prior to addition of the test agents or vehicle in EMEM + 
10% (v/v) FCS. If the agents were to be tested under serum-free conditions however, 
the cells were serum depleted for a further 24 h before addition of the test agents.
The test agents or vehicle alone were added for each time point (generally 2, 6 and 
24 h).
At each time point, an aliquot of conditioned medium was removed from the cultures 
and stored at -20°C for IL-6 bioassay. The remaining medium was discarded and the 
cell layer was dissolved in 0.5 ml solution D (see Appendix 3). The cell layer was 
scraped thoroughly using a sterile cell-lifter and the contents were transferred to a 
microfuge tube.
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RNA was isolated by phenol/chloroform extraction and further purified by two 
sequential chloroform washes (see Appendix 3). Following storage of the isopropanol 
precipitated RNA for at least 3 hours at -20°C, the RNA pellet was redissolved in 
150 ul solution D and re-precipitated with an equal volume of isopropanol and stored at 
-20°C overnight.
The RNA pellet was washed twice with 70% (v/v) ethanol and once with absolute 
ethanol, dried down under vacuum and redissolved in 50 ul DEPC treated water. 
Quantification of RNA
An aliquot of RNA (usually 5 or 10 u l) was diluted in water to a total volume of 
250 ul.
The absorbance was read in a silica cuvette at 260 nm and 280 nm and the ratio of 
absorbance at 260 nm : 280 nm was determined. A pure RNA preparation should have 
a ratio of 2 at 260 nm : 280 nm. Contamination by phenol or proteins would lower this 
ratio.
Concentration of RNA was calculated by:-
A26O x 40 x dilution = ug/ml RNA 
(40 ug/ml of pure RNA has an OD of 1)
Northern blot analysis of RNA
Northern hybridisation is used to assess the size and amount of a specific mRNA 
species. RNA is separated by electrophoresis according to its size on a denaturing 
agarose gel and is subsequently transferred onto a nylon membrane. The particular 
mRNA species is then localised by hybridisation with a specific radiolabelled cDNA 
probe followed by autoradiography.
After RNA quantification, the equivalent of 10 ug of RNA was reprecipitated in 3 M 
sodium acetate (0.1 x sample volume) and absolute alcohol (2 x sample volume) 
overnight at -20°C. Two extra samples were prepared for the purpose of assessing the 
ribosomal RNA bands on the Northern gel by using ethidium bromide staining.
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(Ethidium bromide was not used to stain the whole gel as it hampered the blotting 
procedure).
The RNA was centrifuged (13,000 rpm for 10 minutes) and the pellet was washed 
twice in 70% (v/v) ethanol and once in absolute ethanol, dried under vacuum and each 
sample resuspended in 10 ul of 'loading solution' (see Appendix 3). Samples were 
denatured at 65°C for 10 minutes, placed on ice and 2 ul RNA loading dye (5 mg 
bromophenol blue + 0.5 g Ficoll 400 in 2.5 ml DEPC water) added and the samples 
were loaded immediately into a formaldehyde gel (see Appendix 3).
After sufficient migration of the samples by electrophoresis, the gel was removed and 
two lanes were carefully cut off for detection of the ribosomal RNA bands (see 
Appendix 3). The remainder of the gel was set up for Northern blotting (see Appendix 
3).
On the following day the blot was carefully disassembled and the transferred RNA on 
the Hybond N+ filter placed RNA side down on a filter paper soaked in RNase free 
50mM NaOH for 5 minutes in order to fix the RNA to the filter. The remaining gel 
was stained with ethidium bromide in order to ensure that all RNA had been transferred 
onto the Hybond N+ filter.
The Hybond filter was then washed in 2X SSC (DEPC treated) (see Appendix 3) and 
wrapped in cling film and stored at 4°C ready for hybridisation.
Dot blotting
This procedure results in a sequential two fold titration of the mRNA thus allowing 
quantitation between mRNA samples treated with different agents by using a 
densitometer.
Equal amounts of RNA from each sample were dissolved in DEPC treated water to a 
final volume of 50 ul. An equal volume of formamide (ultra pure, de-ionised) was then 
added to each sample tube and the RNA denatured at 65°C for 10 minutes. The sample 
tubes were placed on ice and 3 M sodium acetate was added to give a final 
concentration of 0.25 M. Solution A (see Appendix 3) was added to the samples to
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adjust the final volume to 200 ul. The samples were then diluted sequentially 1:1 with 
solution A on ice ready for loading into the prepared dot blot apparatus.
The dot blot manifold was pre-soaked in DEPC treated water for 30 minutes before 
loading. The Hybond N+ filter membrane, which was used to bind the RNA, was 
placed on Whatman filter paper soaked in DEPC treated water followed by soaking in 
the solution 20 X SSC (DEPC treated) (see Appendix 3).
The dot blot apparatus was assembled containing the Hybond N+ membrane and the 
samples were loaded (lowest dilution first) by drawing the sample RNA slowly through 
the manifold under pressure generated by a water pump. Each sample well was 
subsequently washed using 100 ul of solution A.
The apparatus was carefully disassembled and the Hybond N+ filter placed with the 
RNA side facing down, as for the Northern blot, on paper soaked in DEPC treated 
50 mM NaOH for 5 minutes. The Hybond N+ filter was washed in 2 X SSC, 
wrapped in cling film and stored at 4°C ready for subsequent hybridisation.
Hybridisation of filters
Filters were first pre-hybridised with a pre-treatment solution (see Appendix 3) in order 
to block non-specific binding of the probe to the Hybond N+ membrane by placing the 
filter in pretreatment solution in a shaking water bath at 50°C for at least 3 hours. 
Labelling of the cDNA probe
Random sequence hexanucleotides are used to prime DNA synthesis on denatured 
template DNA. These hexanucleotides bind to complementary sites along the full 
length of the denatured probe. The Klenow fragment (exonuclease fragment removed) 
of the DNA polymerase I enzyme is used for the incorporation of unlabelled and 
(or32P) dCIP in complement to the denatured DNA template.
Denatured cDNA probes (25 ng) were labelled with (or32P) dCTP using a multiprime 
labelling kit (Amersham) which utilises the random hexanucleotide method. The 
cDNA probe was denatured at 100°C for 5 minutes and chilled on ice. Random
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hexanucleotides, primer (containing unlabelled nucleotides), radiolabelled (a_32P) 
dCIP and Klenow enzyme were sequentially added to the denatured cDNA probe.
The labelling procedure was allowed to continue for at least 5 hours at room 
temperature and the polymerase reaction was stopped using 2 ul of 0.5 M EDTA. 
Distilled water was added to give a final volume of 200 ul and the incorporation of the 
32P into the probe was determined (see Appendix 3). Probes were usually labelled to 
an excess of 108 cpm/ug. If the specific activity was satisfactory, the probe was 
denatured again at 100°C for 5 minutes and cooled on ice. The labelled probe was then 
transferred to the prehybridisation mixture and left for hybridisation to the filter 
overnight at 50°C.
On the following day, the filter was washed once in 2 X SSC (room temperature for 
30 minutes) followed by a washing step using 2 X SSC containing 0.5% SDS (two 
hours at 65°C). The filter was then monitored using a geiger counter and, if required, 
an optional 0.1 X SSC wash was performed to increase the stringency and subsequent 
specificity. Following this, the filter was wrapped carefully in cling film and set up for 
autoradiography. The light-proof autoradiography cassette (+ intensifying screen) 
containing sensitive film was stored at -70°C until developing (usually 24 h later). The 
mRNA could be quantitated by recording densitometer readings off the exposed film 
over a light box and relating the levels to the house-keeping mRNA (p actin).
RESULTS
Release of IL-6 bioactivitv bv human osteoblasts
Human osteoblast-like cells constitutively released IL-6 when cultured in serum-free 
and 10% (v/v) FCS-supplemented medium. Concentrations of IL-6 ranged from 200 
to 2050 pg/ml and 1950 to 19000 pg/ml in serum-free and 10% (v/v) FCS containing 
cell conditioned media respectively. After 6 h in serum-free culture, rhBL-la (10-13 - 
10'11 M) caused a dose dependent release of IL-6. LPS and rhTNFa (10-7 M) exerted 
a slight stimulation of IL-6 synthesis whereas PTH and l,25(OH)2D3 had no detectable 
effects (fig. 4.1). The stimulatory effect of rhIL-la (10-13 M - 10*11 M), rhTNFa
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(10'8 - 10'7 M) and LPS (50 - 500 ng/ml) was further enhanced after 24 h in serum- 
free culture. rhIL-la was the most potent stimulator at both time points studied with as 
low as 10'13 M rhIL-la enhancing IL-6 release (fig. 4.2). TNF is generally 100 - 1000 
times less potent than IL-1 in its actions on bone in vitro (Gowen 1988) and this was 
reflected by the observation that a concentration of 10-8 M rhTNFa was most effective 
in stimulating IL-6 release in these studies. LPS, a stimulator of cytokine release was 
used in these studies as a comparison. LPS induced IL-6 production by 24 h, but was 
less effective than rhIL-la. The osteotropic hormones PTH and l,25(OH)2D3 did not 
affect IL-6 production in human osteoblast-like cells. Parallel studies using human 
osteoblasts cultured in the presence of 10% fetal calf serum, resulted in the same pattern 
of expression although levels of IL-6 protein were generally 5 to 50 fold higher in such 
conditions. After a 6 h incubation, there was little effect of any of the agents on basal 
IL-6 production (data not shown). However after 24 h culture; rhIL-la (10-12 - 
10-11 M) stimulated very high levels of IL-6 production. LPS (50 - 500 ng/ml) and 
rhTNFa (10-7 M) were considerably less potent in this respect (fig.4.3).
A quantitative variation in IL-6 production between different patients was observed 
although similar patterns of stimulation were evident. This appeared to be unrelated to 
the disease, sex or age of the donor.
A sheep anti IL-6 antibody was used to confirm that the activity in the conditioned 
medium was due to IL-6 only. (The B9 murine hybridoma assay was sensitive only to 
IL-6). A 1:1000 dilution of the anti-IL-6 antibody neutralised all IL-6 activity in both 
the human bone cell conditioned medium and in the standard curve (table 4.1).
Release of IL-6 bioactivitv bv ROS 17/2.8 cells
Release of IL-6 by ROS 17/2.8 rat osteosarcoma cells was compared with human 
osteoblast-like cells. The overall production of IL-6 by ROS 17/2.8 cells was much 
lower than that observed with human bone cells, by at least 10 fold after a 24 h 
incubation. In 4 experiments the basal range in the amount of IL-6 produced was 17 to
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71 pg/ml under serum-free conditions and 247 to 1100 pg/ml using 10% (v/v) FCS- 
containing HAMS F10.
Under serum-free conditions, after a 6 h incubation, rhIL-la (10~12 M), LPS (5 ng/ml) 
and PTH (10-9 M) showed a slight enhancement of IL-6 release (fig. 4.4). After 24 h 
serum-free culture, rhIL-la (10-12 M) and rhTNFa (10-8 M) exerted only a slight 
stimulatory effect whereas LPS (5 - 500 ng/ml) enhanced IL-6 release in a 
dose-dependent manner. l,25(OH)2D3 had no effect on IL-6 release although PTH 
had a strong stimulatory effect at (10-1  ^M - 10'9 M) in a dose-dependent manner 
(fig. 4.5). ROS 17/2.8 cells cultured in 10% FCS containing medium showed 
enhanced production of IL-6 as compared to serum-free culture. PTH (10-11 - 10-9 M) 
had a stimulatory effect on IL-6 production in 10% (v/v) FCS-containing HAMS F10 
by 6 h and rhTNFa (10'9 - 10’7 M) and LPS (50 - 500 ng/ml) also induced IL-6 
release (fig. 4.6). After a 24 h incubation, PTH (10-9 M) was the only agent tested 
that significantly induced IL-6 release which may infer that factors within the FCS were 
contributing to the higher basal level of IL-6 expression observed at this time point in 
ROS 17/2.8 cells (fig. 4.7).
Expression of IL-6 mRNA bv human osteoblasts
Using a cDNA probe for IL-6, constitutive expression of an IL-6 mRNA transcript of 
1.3 kb was detected in human osteoblast-like cells from all patients tested (n=12). An 
example from cells obtained from one representative patient is shown in Fig. 4.8.
Under serum-free conditions, rhIL-la (10*11 M) increased IL-6 mRNA levels after 2 h 
and 6 h with an increase of 17.5 and 38.5 times the constitutive levels (measured by 
densitometer as described in the methods) at 2 h and 6 h respectively (fig.4.9). This 
stimulatory effect was sustained over 24 h. The IL-6 protein release was also measured 
in these cultures and a short lag phase following increased mRNA expression was 
observed as expected (fig 4.9).
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In 10% (v/v) FCS-containing medium, the stimulation of IL-6 mRNA by rhIL-la 
(10-11 M) was maximal within 4 h (fig. 4.10) which would suggest that other factors 
within the FCS were contributing to the effects of rhIL-la.
A marked induction of IL-6 mRNA by rhTNFa (10-7 M) was observed under serum- 
free conditions after 2 h (fig. 4.9 and 4.11). It was interesting to note that rhTNFa 
exhibited a more marked stimulation of IL-6 mRNA levels after 2 h than rhIL-la (fig. 
4.9). However after 6 h, rhIL-la appeared to be more potent than rhTNFa. This may 
indicate that the mechanism of induction of IL-6 mRNA by these two cytokines differs. 
After 24 h, the enhancement of IL-6 mRNA levels by rhTNFa was still evident. In 
medium containing 10% (v/v) FCS, the stimulation of IL-6 mRNA by rhTNFa was 
maximal after 2 h of culture (Fig. 4.12). It would appear from these studies that 
rhTNFa produced a more rapid accumulation of IL-6 mRNA in comparison to the 
effects observed with IL -la (figs 4.12 and 4.10). Northern blot analysis of the 
induction of IL-6 mRNA by rhTNFa under 10% (v/v) FCS-containing EMEM showed 
similar effects at 4 h and 8 h although a shorter time point was not included (fig. 4.13). 
This confirmed that the hybridising species does not alter upon stimulation with various 
agents.
In contrast to these findings, l,25(OH)2D3 (10-8 M) (fig. 4.14) and EL-6 (2000 pg/ml) 
(fig. 4.15) did not exert any significant effects on IL-6 mRNA levels under serum-free 
conditions. The effects of l,25(OH)2D3 on IL-6 mRNA stimulation in 10% (v/v) 
FCS-containing EMEM were not studied. PTH (10-9 M) also had no modulatory effect 
under serum-free conditions (fig.4.16) or in the presence of 10% (v/v) FCS (fig. 
4.17).
Dexamethasone (10-6 M) inhibited basal, rhIL-la- (10-11 M) and rhTNFa- (10-7 M) 
stimulated levels of IL-6 mRNA expression and reduced the IL-6 bioactivity measured 
in serum-free culture (fig. 4.18 and fig. 4.19).
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DISCUSSION
Human osteoblast-like cells synthesized and released IL-6 protein both under 
serum-free conditions and in the presence of serum. This release could be enhanced 
by incubation with rhIL-la, rhTNFa and LPS but not by the hormones PTH or 
l,25(OH)2D3. In agreement with the stimulatory effect of IL-1 on IL-6 production in 
other cell types (Van Damme et al 1987a, 1987c, Helle et al 1988), rhIL-la was also 
found to be the most potent stimulator of IL-6 synthesis by the human bone cells. TNF 
is known to share many of the activities of IL-1 on bone as well as a variety of other 
tissues (Gowen 1988). It is far less potent than IL-1 in bone cell systems and therefore 
it is not surprising that the stimulation of IL-6 production in response to TNF was 
much lower.
ROS 17/2.8 cells have been used as a model system for studying osteoblasts in vitro 
due to their response to PTH with an increase in cAMP and their high levels of alkaline 
phosphatase and osteocalcin (Majeska et al 1978). IL-6 release in ROS 17/2.8 cells 
differed from the primary human cells, ROS 17/2.8 cells being more responsive to 
PTH rather than the cytokines IL-1 and TNF.
There is clearly a qualitative and quantitative difference between human and rodent 
osteoblasts in terms of the modulation of IL-6 production. From these studies, IL-6 
release from human bone cells was not modulated significantly by osteotropic 
hormones PTH and l,25(OH)2D3, whilst the cytokines rhIL-la and rhTNFa appeared 
to be potent stimulators of IL-6. The differences observed may reflect the possibility 
that ROS 17/2.8 cells were not primary cells, although other groups have studied the 
production of IL-6 by non transformed mouse calvarial osteoblasts and have also 
reported responses to PTH (Lowik et al 1989, Feyen et al 1989). It is possible that 
osteoblast cell maturation may contribute to these observations. Indeed, it has been 
shown that an 'immature' osteoblast-like cell within rat long bones has the capacity to 
bind PTH, although more mature, terminally differentiated osteoblasts did not (Rouleau 
et al 1990). This may indicate that the PTH response could reflect the maturity of the 
cells in culture. Individual human osteoblast-like cultures, although heterogeneous,
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have previously been monitored for an increase in adenylate cyclase activity in response 
to PTH (MacDonald et al 1986). In the studies presented in this chapter, it was 
therefore assumed that the lack of response to PTH was not likely to be related to 
unresponsiveness of the human osteoblast-like cells to PTH but may be related to the 
number of receptors for PTH or the number of responsive cells in the osteoblast 
cultures.
The rest of the chapter involved the study of IL-6  mRNA expression in order to 
investigate whether it parallelled IL-6  protein production and whether the osteotropic 
agents were acting at the transcriptional level.
In this chapter, IL-6  mRNA levels were unaffected by PTH, IL-6  and l,25(OH)2D3 
whilst rhTNFa and rhIL-la induced IL-6  mRNA in human trabecular bone cells. 
Induction was maximal after 6  hours of serum-free culture and was maintained over 24 
hours. The studies of Linkhart et al (1991b), who observed that IL-ip, unlike PTH, 
was capable of stimulating IL-6  mRNA levels in normal human osteoblast-like cells 
support the data presented in this thesis.
Whether IL-6  mRNA accumulation is a result of increased rate of transcription or 
stabilization of the IL-6  mRNA species remains to be determined. Elias and Lentz 
(1990) observed that in human lung fibroblasts, IL-1 and TNF both increased 
transcription and stabilization of EL-6  mRNA. Further work using actinomycin D, an 
RNA synthesis inhibitor, is necessary to investigate whether this is the case for the IL-1 
and TNF induction of IL-6  mRNA in human osteoblasts.
Other groups, using murine and rat osteoblast systems (Suda et al 1990, Ishimi et al 
1990) have also demonstrated that IL-1 and TNF stimulated IL-6  protein and mRNA 
levels. The observation that the induction of IL-6  mRNA in the presence of 10% (v/v) 
FCS was faster than in serum-free medium would indicate that FCS contains factors 
which were acting either in synergy or enhancing the effects of TNF and IL-1. A 
possible candidate is TGFp which is present within FCS and induces the production of 
IL- 6  protein from human osteoblast-like cells (K. Merry and A.J. Littlewood 
unpublished observations). Other workers have demonstrated a similar rate of
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induction of IL-6  mRNA with TNF and IL-1 as described here, in fibroblasts and 
monocytes (Walther et al 1988, May et al 1988). The mechanism of induction of IL-6  
mRNA by IL-1 and TNF however appear to be different; IL-1 induction of the IL-6  
mRNA was sustained and could be largely blocked by cycloheximide (a protein 
synthesis inhibitor) whereas the increase in IL-6  mRNA by TNF was more transient 
and was not blocked by cycloheximide (Walther et al 1988). This group postulated that 
IL-1 induced a newly synthesized protein that was involved in the transcription of IL-6  
mRNA. It was interesting to note in this chapter that TNF consistently induced IL-6  
mRNA expression more rapidly than IL-1 in human osteoblast-like cells. These 
observations may indicate a difference between the induction of IL-6  mRNA by TNF 
and IL-1. The hypothesis that IL-1 and TNF may regulate IL-6  gene expression via 
different mechanisms could be elucidated by work on the transcriptional control 
elements within the IL-6  gene. Comparison of the human and mouse IL-6  genes has 
revealed highly homologous regions 350 base pairs upstream of the transcription start 
site (Tanabe et al 1988). Several potential transcriptional control elements such as 
glucocorticoid responsive elements (GRE), c-fos serum responsive element (SRE), 
cyclic AMP responsive element (CRE) and AP-1 and NF-kB binding sites have been 
located within the IL-6  promotor regions of both species (Ray et al 1989). The 
presence of the SRE may indicate why serum enhanced the induction of IL-6  mRNA at 
a faster rate than under serum-free conditions in human osteoblast-like cells. Ray et al 
(1989) also revealed that a 23 base pair multi-responsive element (MRE) within the 
c-fos SRE may be involved in the induction of IL-6  by TNF, IL-1, serum, forskolin 
and phorbol ester. Furthermore, Ray and Co-workers (1989) discovered that certain 
mutations of this 23 base pair MRE, containing an AP-1-like motif, caused a lack of 
responsiveness to forskolin and phorbol ester. This was in contrast to IL-1, TNF and 
serum which were still able to react with the MRE. It was therefore postulated by these 
workers that different sequences within the MRE are important for IL-1, TNF and 
serum responsiveness. Further studies using other gene mutations/deletion
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experiments may show a difference between the effects of IL-1 and TNF induction of 
IL-6 .
Studies involving 5' deletion mutants of the IL-6  gene indicated that an IL-1 responsive 
element existed which mapped within the IL-6  promoter region containing the c-fos 
SRE (Isshiki et al 1990), confirming the work of Ray et al (1989). A nuclear factor 
(NF-IL-6 ) was identified that recognised a unique palindromic 14 base pair sequence 
which corresponded to the region homologous to the c-fos SRE (Isshiki et al 1990) 
which could also be stimulated by EL-1. It would be interesting to study whether TNF 
and other inflammatory cytokines reacted with this same 14 base pair region. Ray et al 
(1989) and Isshiki et al (1990) independently observed that NF-kB was not necessary 
for the IL-1 responsiveness in the IL-6  promoter. This contrasted with the work of 
another group who demonstrated that NF-kB may also be responsible for IL-6  
induction by IL-1 and TNF (Shimizu et al 1990). Shimizu and Co-workers (1990) also 
showed that TNF induction of the IL-6  gene was more transient than IL-1 induction 
although they recognized the same 10 base pair sequence (homologous to NF-kB) in 
accordance with data obtained by Walther et al (1988).
From the above lines of evidence, it is therefore possible that EL-1 and TNF may bind 
preferentially to different combinations of the various responsive elements within the 
IL-6  promotor. Alternatively, TNF and EL-1 may recognise common IL-6  promotor 
elements despite subsequent differences in mechanism of action of these cytokines as a 
consequence of the induction of different nuclear factors.
In the studies presented in this chapter, dexamethasone inhibited the production of IL-6  
by human osteoblast-like cells both at the transcriptional level and at the protein level. 
Glucocorticoids have been reported to inhibit the production of IL-6  by many other cell 
types including rat anterior pituitary cells (Carmeliet et al 1991), human monocytes, 
endothelial cells and fibroblasts (Waage et al 1990). It is likely that dexamethasone is 
acting on the glucocorticoid responsive element located in the 5' upstream sequence of 
the IL-6  gene. Almawi et al (1991), demonstrated that dexamethasone inhibited T cell 
proliferation by blocking the expression of various cytokines including IL-6 . Alamwi
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and co-workers postulated that dexamethasone interaction with a glucocorticoid 
responsive region within a cytokine gene may either mask part of the sequence 
necessary for transcription or initiate transcription of novel regulatory proteins which 
could subsequently block gene transcription. The inhibitory effects of dexamethasone 
observed in the study presented in this chapter may indicate a functional role of 
naturally circulating glucocorticoids in suppressing IL-6  release from IL-6  producing 
cells. IL-6  is produced by rat anterior pituitary cells and is induced by IL-1 (Spangelo 
et al 1991) and inhibited by dexamethasone (Carmeliet et al 1991). In addition, IL-6  is 
reported to increase the secretion of adrenocorticotrophic hormone (ACTH) within 30 
minutes in rats (Naitoh et al 1988) and ACTH in turn can increase glucocorticoid levels 
which subsequently decrease cytokine levels. Therefore a potential complex negative 
feedback loop may exist in this system. Other groups have observed significant 
correlations between cortisol levels and the inflammatory activity in rheumatoid arthritis 
(Neeck et al 1990). This stresses that raised cytokine levels during inflammatory 
conditions may be capable of inducing the production of immunosuppressive 
glucocorticoids. One mechanism of action of therapeutically administered 
glucocorticoids could be to reduce local and circulating levels of inflammatory 
cytokines such as IL-6 .
From the studies presented within this chapter, it is evident that the production of IL-6  
in osteoblasts can be modulated by certain bone active agents in vitroy although the 
physiological consequences of this observation still remain to be clarified.
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Table 4.1
Neutralisation of the standard curve and human bone cell conditioned medium with a
specific sheep anti human IL-6  antibody.
Standard Curve 
pe/ml
A E 570-630 
absence of antibody presence of antibody
1 :1 0 0 0  dilution
100 0.349 0.140
30 0.321 0 .1 2 0
10 0.286 0 .1 1 1
1 0 .2 2 2 0.096
0 .1 0.159 0.092
0 0.118 0.097
Conditioned medium 0.326 0.156
0.333 0.125
0.313 0.114
Known quantities of IL-6  were preincubated with antibody or non immune sheep 
serum for an hour before addition to the B9 cells (See Chapter 7 Methods). Triplicate 
samples of conditioned medium from unstimulated human osteoblast-like cells were 
diluted 1:1000 and preincubated as above. This experiment is representative of eight 
carried out on different conditioned media.
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Figs. 4.1 and 4.2. IL-6 production in human osteoblast-like cells
after 6 h (4,1) and 24 h (4,2) in $grpm-free culture,
The trabecular bone cells were incubated with the osteotropic agents shown 
for 6  h (Fig. 4.1) and 24 h (Fig. 4.2) and the bone cell conditioned medium 
was assayed for IL-6  activity using the B9 cells (see general methods section). 
C= 0.1% (w/v) BSA and 1.4 uM indomethacin in EMEM. Representative 
experiment (n = 4). Significant difference from control *p < 0.05, **p < 0.01,
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Fig. 4.3. IL-6 production in human osteoblast-like ceils after ?4 h in 
1Q% (y/y) FCS-CQntaining EMEM,
The human trabecular bone cells were incubated with the osteotropic agents 
shown for 24 h and the bone cell conditioned medium was removed and 
assayed for IL-6  activity using the B9 cells (see general methods section).
C = 10% FCS and 1.4 uM indomethacin. Representative experiment (n = 4). 
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Figs. 4.4 and 4.5 IL-6 production in RQS 17/2,8 cells after 6 h.(Fjg, 4,4) 
and 24  h (Fig, 4 ,5 ) jn serum-free culture.
The rat osteosarcoma cells were incubated with the osteotropic agents 
shown and the cell conditioned medium was removed at 6  h (Fig. 4.4) and 
24 h (Fig. 4.5) for IL-6  bioassay using the B9 cells (see general methods 
section). C = 0.1% (w/v) BSA and 1.4 uM indomethacin in HAMS F10. 
Representative experiment (n = 4). Significant difference from control 
*p < 0.05, **p < 0.01, ***p < 0.001.
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Fig. 4.6
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Figs. 4.6 and 4.7 IL-6  production in ROS 17/2.8 cells after 6 h (Fig. 4.6) 
and 24 h (Fig. 4.7) in 10% (v/v) FCS-containig EMEM
The rat osteosarcoma cells were incubated with the osteotropic agents 
shown and the cell conditioned medium was removed at 6  h (Fig. 4.6) and 
24 h (Fig. 4.7) for IL-6  bioassay using the B9 cells (see general methods 
section). C = 0.1% (w/v) BSA and 1.4 uM indomethacin in HAMS F10. 
Representative experiment (n = 4). Significant difference from control 
*p < 0.05, **p < 0.01, ***p < 0.001.
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Fig.4.8. Constitutive expression of IL-6  mRNA in human osteoblast-like 
cells hv Northern blot.
10 ug of RNA from trabecular bone cells was loaded for each of the 2 lanes. 
The resultant filter was probed for IL-6  mRNA. Ribosomal RNA bands 
were used as size markers and the IL-6  mRNA transcript was 1.3 kb. This 
is a representative example of the twelve patients studied.
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Fig.4.9. rhTNF.X and rhIL-lx induced stimulation of IL-6 mRNA and
protein in human osteoblast-like cells under serum-free conditions,
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RNA from unstimulated human osteoblast-like cells, and those treated with 
rhTNFix or rhIL-l<x for 2 ,6 , and 24 h were loaded using doubling serial 
dilutions starting with a highest concentration of 3 ug. Blots were probed 
with IL -6  cDNA, stripped and reprobed withftactin to ensure equal loading. 
IL-6  protein content in the conditioned medium, taken at the same time as 
the cells were used for RNA extraction, was assayed using the B9 bioassay.
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Fig 4.10 Modulation of IL-6 mRNA bv rhIL-lrin trabecular bone cells
in the presence of EMEM +10% (v/v) FCS.
Human osteoblast-like cells were stimulated with rhIL-1 at a concentration of 
10“11M for 4 ,8 , 24 and 48 h. Total RNA was extracted and doubling dilutions 
starting at 5 ug of RNA were used and the filter probed for IL-6  and^actin.
Modulation of IL-6 mRNA levels bv rhTNF*in trabecular bone cells in






•  *  + M
Human osteoblast-like cells were treated with rhTNF£*(10_7M) and total RNA was 
extracted at various time points. Sequential two-fold dilutions were made starting 
with 4 ug of RNA as the highest concentration. After probing with IL-6 , the filter 
was stripped and reprobed withBactin.
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Fig 4.13 Stimulation QfJL:6.mRNA in human trabecular bone cells by rhTNF*
in EMEM containing 10% (v/v) FCS hv Northern blot analysis.
C T T T C 
0  4  8  2 4  2 4
— 1 1 k 1
Human osteoblast-like cells were treated with rhTNF<x(10~ M) for 4, 8  and 24 h and 
total RNA was extracted. 9 ug of RNA was loaded in each lane. After probing with 
IL-6 , the filter was stripped and reprobed with G actin. C = unstimulated cells and 
T = rhTNF(x.
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la c k  Qf IMKllllatiQn Qf IL-6 mRNA in human QgtgQfrla§t-likg- CCHg frY L 25(Q H U I
(fig. 4.14) and IL-6 (fig. 4.15) in serum-free containing EMEftL.
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Human osteoblast-like cells were treated with l,25(OHy>3 (10‘8 M) or IL-6  
(2000 pg/ml) for 2, 6  and 24 h and total RNA was extracted. Doubling dilutions 
starting at 6  ug of RNA were used and the filter probed for IL-6  and ftactin.
C = unstimulated cells (vehicle) and T = treatment.
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Lack of modulation of IL-6 mRNA bv PTH in human trabecular hone cells in
serum-free (fig. 4.16) and 10% (v/v) FCS (fig. 4.17) containing EMEM.
4 .1 6
4-17
1 1  LL
Human osteoblast-like cells were treated with PTH (lO '^I) for 2, 6  and 24 h and total 
RNA was extracted. Doubling dilutions starting with 3 ug of RNA were used. After 
probing with IL-6 , the filter was stripped and reprobed withftactin. C = unstimulated 
cells (vehicle) and T = treatment.
129
Effect of rhIL-tx(fig. 4.18) and rhTNF<x(fig, 4.19) alone and in combination with 
dexamethasone on IL-6  mRNA and protein levels in human trabecular bone cells
under serum-free conditions.
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The osteoblasts were treated with rhIL-l«(10 M), rhTNEX(10 M) alone and in 
combination with dexamethasone (10*6 M) for various time points and the total RNA 
was extracted. Doubling dilutions starting with 4ug of RNA were used.
The filter was probed for IL-6  mRNA followed by Gactin. At the time of RNA 
extraction, the conditioned medium was retained for IL-6  bioassay using B9 cells 
(figures under theft actin strip). C = unstimulated cells (vehicles),
D = dexamethasone and T = treatment (rhIL-l<*and rhTNFo<).
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APPENDIX 3
Denaturing solution - Soln. D
4M guanidinium thiocyanate (disrupts cells and inhibits RNase activity)
25mM sodium citrate, pH 7 
0.5% sarcosyl
0.1M 2-mercaptoethanol (2-ME) (inhibits RNases)
To minimize handling of guanidinium thiocyanate, a stock solution was prepared 
as follows:-
Guanidinium thiocyanate 250g
distilled deionized water 293ml
0.75M sodium citrate pH 7 17.6ml
10% sarcosyl 26.4ml
The above reagents were dissolved in the manufacturer's bottle at 65° C and the 
solution stored in the fridge.
For use, Soln. D was prepared by adding 72 ul of p-ME to 10ml Soln. D.
Tris saturation of phenol
Stocks of 0.1 M Tris and 1 M Tris both DEPC treated and adjusted to pH 8 were 
prepared. To minimise handling of phenol, the bottle was thawed at room 
temperature and then melted at 6 8 °C. Hydroxyquinoline was added (to prevent 
oxidation of phenol) to a final volume of 0 .1% (w/v) and the solution transferred 
to a large conical flask with a side arm. An equal volume of 1 M Tris was added 
and the mixture was shaken and left to separate into two layers for 1 h or longer. 
The aqueous top layer was decanted and discarded using the side arm and an 
equal volume of 0.1 M Tris added to the flask and the process repeated with the 
weaker Tris solution until the phenolic layer reached a pH of greater than 7.8.
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The phenol was then transferred back into the manufacturers bottle and stored in 
the fridge under 0.1 M Tris.
Extraction of RNA
1 ml of Soln. D was added to the cell layer which was subsequently scraped 
using a cell lifter, and the contents transferred to an eppendorf tube. 50 ul of
2 M sodium acetate pH 4 (helps to precipitate low molecular weight mRNA 
species), 500 ul of tris saturated phenol (see above) and 100 ul of chloroform - 
isoamyl alcohol (49:1) (the two solvents result in a better separation than one; 
also isoamyl alcohol improves the interface between the layers as well as 
decreasing foaming) were sequentially added with mixing by inversion in 
between each addition. The solution of RNA/phenol/chloroform was then 
shaken vigorously for 10 seconds and cooled on ice for 15 minutes. The 
samples were centrifuged at 13,000 rpm in a microfuge for 10 minutes. The 
aqueous top layer containing RNA was transferred into a fresh eppendorf tube 
and an equal volume of chloroform - isoamyl alcohol added. This was shaken 
vigorously and re-centrifuged for 5minutes. A second chloroform extraction 
was performed in the same manner and the aqueous layer was transferred to a 
fresh eppendorf tube. The RNA was precipitated by addition of an equal volume 
of isopropanol and storage at -20°C for at least 3 h.
Loading solution
This helps to keep RNA samples denatured.
60 ul of lOx MOPS (see below)
300 ul formamide 
100  ul formaldehyde 
140 ul DEPC water
1 3 2
Preparation of a formaldehyde gel
The gel was made up by first assessing the size of the hybridising species 
expected. Low % agarose separate out heavy molecular weight species to a 
better resolution. For a 1% (w/v) agarose gel, 30 mis 10 x MOPS buffer, 3 g 
agarose and 227 ml DEPC treated water were heated up until the agarose was 
fully dissolved. The solution was transferred to a fume cupboard and 40 ml of 
formaldehyde (to help keep RNA samples denatured) was added and the solution 
cooled slightly before pouring into a gel mould containing a comb to form wells 
in a levelled gel tank in the fume cupboard. After the gel had set, the tank was 
filled with lx MOPS buffer before removing the comb. The samples in loading 
buffer were added and electrophoresed.
IPX MOPS OfN-Morpholino^propanesulfonic acid)
200 mM MOPS 
50 mM sodium acetate
10 mM EDTA (ethylenediaminetetraacetic acid)
The reagents were dissolved in distilled water and the solution was adjusted to 
pH 7 withNaOH.
Ethidium bromide staining of a formaldehyde gel
The lanes for ethidium bromide staining were cut off and placed in 100 ml 
distilled water containing 10 ul ethidium bromide (10 mg/ml) for 30 minutes. 
The gel was subsequently destained in fresh water for at least 1 h and then 
placed on a UV transilluminator. Length of the two ribosomal bands from the 
origin (well) was noted.
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Setting up a Northern blot
Tissue paper + towels 
Whatman filter paper 
Hybond N+ membrane 
Formaldehyde gel 
Whatman filter paper 
20 x SSC
Cling film was placed around the edges of the gel to ensure transfer of SSC 
through the gel before the Hybond N+ membrane was carefully layed down. 
No air bubbles should be present between the membrane and gel, and lanes were 
carefully marked with pencil. A large weight was placed on top of the towels 
and the blot was left overnight.
20x SSC
350.6 g sodium chloride 
176.4 g sodium citrate 
distilled, deionized water 1.8 litres
Salts were dissolved in the water and the pH adjusted to pH 7 with HC1 before 
making the solution up to 2  litres.
Solution A
50 % formaldehyde (deionized, ultra pure)
0.25 M sodium acetate pH 5.2 ( pH with glacial acetic acid)
These were made up in DEPC treated water.
13 4
Prehvbridisation solution - 50 mis 
10 mis 50% dextran sulphate 
10 mis 50 x Denharts (see below)
16.5 mis formamide 
10 mis 10 x SSC (see below)
1.25 mis 20% SDS (lauryl sulphate)
200 ul 0.5MEDTA
0.5 ml denatured (100°C for 5 minutes) 10 mg/ml salmon sperm DNA (see 
below)
Denharts solution
2g of BSA was dissolved in 80 ml of distilled, deionized (dd) water and the pH 
adjusted to pH 3 with 2 M HC1. The solution was placed in a boiling water bath 
for 15 minutes, cooled on ice for 10 minutes, adjusted to pH 7.5 with 2 M 
NaOH on ice and made up to 100 ml with ddwater. Meanwhile 100 ml of 2% 
(w/v) polyvinylpyrrolidone (PVP), 2% (w/v) Ficol 400 was prepared, 
autoclaved and cooled. The two 100 ml solutions were then mixed and frozen in 
aliquots.
Salmon sperm DNA (ss DNA1
1 g of ss DNA was added to 100 ml ddwater, dissolved by warming and then 
sonicated and stored in eppendorf tubes in the freezer. Upon thawing, the DNA 
was syringed to make the solution less viscous, denatured at 100°C for 5 
minutes and added to the prehybridisation mixture.
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IPX  SSC
175.3 g sodium chloride (molecular biology grade)
8 8 .2  g sodium citrate (molecular biology grade)
The salts were dissolved in 1.8 litres of DEPC treated water and the pH adjusted 
with HC1 to pH 7. The volume was made up to 2 litres and then filtered through 
a 0.45 u millipore filter into a sterile bottle.
Incorporation of radiolabelled nucleotides
This was performed by spotting two lots of 1 ul of each probe onto Whatman 
DE81 ion exchange paper and washing one of the pieces of Whatman paper in 
NaHPC>4 (3 x for 5 minutes), water (1 x for 2 minutes) and absolute ethanol 
(1 x for 1 minute). The washed paper was allowed to dry and the Whatman 
discs were placed in vials containing optiphase 'hisafe' scintillant and counting 
on the Beta counter. Incorporation of nucleotides was then calculated by 
dividing the washed filter counts by the unwashed filter counts.
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CHAPTER 5
LOCALISATION OF IL - 6  PROTEIN AND mRNA B Y
IMMUNOCYTOCHEMICAL STAINING AND IN SITU HYBRIDISATION. 
ABSTRACT
It has been demonstrated in the previous chapter that bioactive IL-6  protein and 
mRNA for IL-6  is produced by human osteoblast-like cells in vitro. In order to 
obtain information about the expression and role of IL-6  in situ, immunolocalisation 
and in situ hybridisation techniques were studied using cryostat cut tissue sections 
of bone and tumour.
Immunolocalisation techniques in tissue sections were confounded by high non­
specific binding and several attempts were made to reduce this. Cells cultured on 
multispot slides provided more satisfactory results. IL-6  was localised in 
osteoblast-like cells treated with monensin. Furthermore co-localisation of IL-6  
with a marker of osteoblast phenotype, alkaline phosphatase, was demonstrated in 
these osteoblasts. IL-6  protein was present in nearly all the cells whereas alkaline 
phosphatase was only present in a proportion of the cells. IL-6  was also localised 
in osteoclasts derived from an osteoclastoma and was present in all the osteoclasts 
although intensity of staining was variable. By pre-incubating IL-6  with the anti- 
IL-6  antibody before addition to the multispot slides it could be demonstrated that 
the IL-6  antibody was specific for IL-6 .
Several different tissue sections were used in the in situ hybridisation study which 
comprised of osteophytic osteoarthritc bone, giant cell tumor, and fetal tissue.
RNA probes were used for in situ hybridisation. The IL-6  cDNA insert was 
present within a vector containing only one bacterial promoter and so it was 
necessary to subclone the insert into a vector containing two promoters in order to 
obtain both sense and anti-sense RNA probes.
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DL-6  mRNA was localised in many cells within the osteophytic sections including 
osteoblasts, osteoclasts, osteocytes, marrow cells and chondrocytes. Similar areas 
of tissue were stained for tartrate resistant acid phosphatase (marker of osteoclast 
phenotype). By using this stain as well as a Wright's stain, the osteoclasts were 
easily identified in the sections containing RNA probes.
This method has the potential to provide valuable information about cells and their 
function within the remodelling cycle. The expression of IL-6  by osteoclasts raises 
interesting questions about the functions of this cell in bone remodelling in that it 
may not play a purely resorptive role. It is possible that these multinucleated cells 
also have a communicative function in the remodelling cycle.
INTRODUCTION
Immunohistochemistry is a useful tool to study cytokine expression, but at any one 
time insufficient protein may be available for positive detection. In addition, if the 
protein is detected, it may have arrived there by some other route such as 
endocytosis, entrapment or special transport systems rather than by de novo 
synthesis. Only in situ hybridisation of mRNA unequivocally identifies the protein 
producing cells in vivo. The localisation of a particular mRNA within a cell could 
indicate which cells are transcriptionally active although this does not mean that the 
cell will translate the mRNA into the final mature protein (McDonald and Tuan 
1989). Therefore it is preferable to study both immunolocalisation and in situ 
hybridisation techniques in parallel.
Using immunofluorescence, Andersson and Matsuda (1989) successfully localised 
IL-6  protein in peripheral blood mononuclear cells. This procedure utilized a 
murine specific anti IL-6  antibody bound to an FITC-coupled goat anti mouse 
immunoglobulin. Tabibzadeh et al (1989) also demonstrated specific IL-6  
immunoreactivity in human tumors using an avidin-biotin-peroxidase detection
138
system. Furthermore preadsorbtion of IL-6  antiserum with IL-6  antigen blocked 
specific staining in the sections Tabibzadeh et al (1989).
Several groups have employed the technique of in situ hybridisation to localize 
specific mRNA sequences within various tissues. There seems to be a number of 
contentious points when studying this technique, the first of these being the choice 
of probe. Single stranded RNA probes have several advantages over double 
stranded DNA probes. Using anti-sense RNA probes, there is a large increase in 
sensitivity due to the absence of self-reassociation which is a problem associated 
with double stranded cDNA probes. RNA-RNA duplexes, formed when the RNA 
probe hybridises with the particular mRNA, have a higher stability than RNA- 
DNA hybrids. RNA probes characteristically exhibit less non-specific binding than 
DNA probes. The generation of sense and anti-sense RNA probes results in the 
production of transcripts of similar concentration and fragment length. 
Furthermore, by adjusting the volume of the sense and anti-sense probes, equal 
amounts of 35S radioactive counts are obtained for both conditions. The sense 
strand should be identical to the mRNA produced in the cell and no binding should 
occur; therefore an appropriate negative control is obtained. Another advantage of 
using RNA probes is evident during the washing procedure where RNase A is used 
to digest unbound and non specifically bound RNA probes. (The probe-target 
hybrids are resistant to this digestion.) The major disadvantage of RNA probes is 
the sensitivity to digestion due to naturally occuring RNases prior to hybridisation. 
This makes handling and treatment of the tissue and probes more difficult (Ogilvie 
et al 1990).
In situ hybridisation at first utilized radioactive probes ( Bratic and Hoase 1978, 
Angerer and Angerer 1981, Lawrence and Singer 1986, Croen et al 1987, 
Sandberg and Vuorio 1987, Lieure et al 1989, Bosseloir et al 1989, Kato et al 
1990a, Noji et al 1990, Ogilvie et al 1990, Furuta et al 1990). 35S was found to be
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the most appropriate isotope which provided a good balance between activity and 
resolution as opposed to 3H and 32P. The disadvantages of radioactively labelled 
probes are that they are time consuming, expensive and not easily quantitated. 
Non-radioactive probes can provide a quicker, quantitative method although they 
are not as sensitive. Biotinylated probes are the best studied non-radioactive 
method (Bums et al 1985, Lawrence and Singer 1986, McDonald and Tuan 1989, 
Pringle et al 1989, Furuta et al 1990, Morris et al 1990). These could be detected in 
a number of ways such as avidin-biotin, avidin-fluorescein or by antibodies to 
biotin (Bums et al 1985). Alkaline phosphatase or peroxidase conjugated to 
streptavidin-biotin was then used to amplify the signal. Bums et al (1985) used a 
further amplification which results in the deposition of silver and was found to be a 
good sensitive method in their hands. The major problem with biotinylated probes 
is the lack of sensitivity and high non-specific binding (Morris et al 1990, Ogilvie et 
al 1990). More recently digoxigenin, a derivative of cardiac glycoside digoxin has 
been utilized to tag probes. It does not appear to have the same specificity problem 
as biotin (Morris et al 1990, Furuta et al 1990), and appears to be almost as 
sensitive as 35S labelled probes (Furuta et al 1990). The study presented in this 
study utilises 35S labelled RNA probes as they are sensitive and appropriate sense 
controls are generated.
The next question addressing this technique is the use of an appropriate fixative to 
preserve intracellular mRNA and tissue morphology. Several groups have 
compared different fixatives (Pringle et al 1989, McDonald and Tuan 1989). The 
majority of workers successfully used cross-linking agents such as 
paraformaldehyde, glutaraldehyde and formalin (Angerer and Angerer 1981, 
Bosseloir et al 1989, Cox et al 1984, Pringle et al 1989, Kato et al 1990a, Furuta et 
al 1990).
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Access of the probe to mRNA within the cells is a further consideration for 
successful hybridisation. Many groups employ demineralization and proteinase K 
treatments to break down large structures such as hydroxyapatite (Bratic and Hoase 
1978, Angerer and Angerer 1981, Cox et al 1984, Croen et al 1987, Sandberg and 
Vuorio 1987, Pringle et al 1989, McDonald and Tuan 1989, Furuta et al 1990). 
Concentrations of proteinase K have been found to be critical for various tissues 
(Angerer and Angerer 1981, Pringle et al 1989) whereas other groups have 
demonstrated that this treatment is unnecessary (Ogilvie et al 1990). The use of 
triton-X-100 to permeabilize the sections has also been used by some workers 
(Bosseloir et al 1989, Morris et al 1990).
Size of probe also has some bearing on the effectiveness of this procedure; optimal 
size of RNA probes for in situ hybridisation is generally 50-250 bases (Ogilvie et 
al 1990). As the IL-6  RNA probe is approximately 300 base pairs, access of this 
probe was considered to be satisfactory for this technique.
Many groups also included a protein acetylation stage to reduce electrostatic binding 
of the probe to any remaining proteins (Angerer and Angerer 1981, Cox et al 1984, 
Croen et al 1987, Sandberg and Vuorio 1987, Kato et al 1990, Noji et al 1990). 
The content of the hybridisation mix also varies in different studies although the 
consensus favours 50% deionized formamide (Bratic and Hoase 1978, Cox et al 
1984, Coghlan et al 1985, Bums et al 1985, Lawrence and Singer 1986, Croen et 
al 1987, Sandberg and Vuorio 1987, Bosseloir et al 1989, Pringle et al 1989, 
Furuta et al 1990, Kato et al 1990). Other important components include Denhardts 
solution which blocks hydrogen bonding of the probe to basic proteins, dextran 
sulphate which increases the hybridisation signal, tRNA and salmon sperm DNA to 
block non specific binding, and DTT when using 35s labelled probes to prevent 
their oxidation.
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Washing procedures also vary enormously although an RNase digestion stage is 
usually incorporated when RNA probes are used (Kato et al 1990, Noji et al 1990) 
to reduce non specific binding further.
In situ hybridisation has been used to successfully localise IL-6  mRNA in human 
tonsils (Bosselior et al 1989), mononuclear cells (Kato et al 1990) and rheumatoid 
synovium (Ogilvie et al 1990).
The study presented in this chapter investigates the localisation of IL-6  mRNA in 
various tissues by in situ hybridisation. Osteoarthritic osteophytic bone was used 
for this technique, especially at the initial stages, as it was a very cellular tissue 
containing all stages of bone remodelling. Once the conditions were optimised for 
the IL- 6  RNA probe, other tissues were investigated: namely osteoclastoma 
tumours and fetal bone.
METHODS
Immunolocalisation - Staining
Human osteoblast-like cells were trypsinised, resuspended in EMEM + 10% (v/v) 
FCS and 3000-5000 cells in a 30 ul volume were plated out on 10 spot slides and 
left to adhere for 24 h. Following this, 30 ul of l,25(OH)2D3 was added in EMEM 
+ 10% (v/v) FCS (to stimulate alkaline phosphatase) for 24 h. Stimulatory agents 
for IL-6  (based on bioassay results) were subsequently added in the presence of 
1 uM monensin, which blocked secretion of proteins from cells, for 6  h. The cells 
were fixed by addition of 4% paraformaldehyde, 1% CaCl2 in water pH 7 for 15 
minutes at room temperature and were left to dry and stored at -70°C wrapped in 
aluminium foil.
Osteoclasts were obtained from giant cell tumours. The tumour was roughly 
chopped up in EMEM and wetted sections placed on 10 spot slides. Some of the
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osteoclasts tended to settle on the glass slides and they were subsequently fixed in 
acetone for 10 minutes then left to air dry before freezing.
Sections of bone, tumour and osteophytes were placed on 4 spot slides and fixed in 
acetone as for the osteoclasts.
Alkaline phosphatase staining
10 mg of Napthol AS MX phosphate was dissolved in 0.5 ml ethylene glycol 
monoethyl ether EGMEE. 20 mg of fast blue BB dye was added and the solution 
was mixed. This was then added to 50 ml of 0.1 M Tris pH 9 - 9.2 and the 
solution stirred and filtered onto the slides for staining. The colour was left to 
develop in the dark for up to 30 minutes.
The slides could then be co-localised for a particular cytokine such as IL-6 . In this 
case, l,25(OH)2D3 (10*8 M) was incubated with the human osteoblast-like cells for 
24 h in order to induce their differentiation. IL-1 (10-11 M) and monensin (1 uM) 
were subsequently added for a further 6  h to stimulate IL-6  expression and the cells 
were fixed and stored as described previously.








IL-6  in cell
This method is used to amplify a signal. It is especially useful when only small 
quantities of protein are present. The primary antibody is sandwiched between the 
antigen and a biotinylated polyclonal antibody raised against the primary antibody
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species. The biotin moiety subsequently binds to streptavidin conjugated to alkaline 
phosphatase and using a fast red salt and Napthol phosphate, a red product can be 
detected.
The slides, containing cells or sections, were placed in tris buffered saline (TBS) 
(0.05 M Tris/HCl, pH 7.6,0.15M NaCl) for 5 minutes. Phosphate buffers should 
not be used as phosphate inhibits the alkaline phosphatase reaction. Excess liquid 
was drained off the slides and using a tissue the edges were carefully wiped 
between the spots. The sections or cells were incubated for 20 minutes with normal 
serum from the secondary polyclonal antibody species (eg swine) diluted 1:5 in 
TBS. During all incubation stages, the slides were placed in a humidified box. The 
excess serum was then tapped off and primary antibody optimally diluted in TBS 
was incubated with the cells for 20 - 30 minutes. As a negative control, half of the 
cells or sections were incubated with normal serum from the primary antibody 
species diluted to the same extent as the antibody (eg sheep serum). In between 
each stage, the slides were gently washed in TBS using a pipette, taking great care 
to keep all the different treatments separate, and subsequently immersed in a TBS 
bath for 5 minutes. Biotinylated antibody, followed by streptavidin/alkaline 
phosphatase, optimally diluted in TBS were sequentially added to the wiped slides 
for 30 minutes. After the final wash, the slides were incubated for 10 - 15 minutes 
with alkaline phosphatase substrate solution (see Appendix 4).
The slides were subsequently washed with distilled water and counterstained with 
haematoxylin for 20 seconds. The counterstain was washed off with water and the 
slides were dried and mounting fluid (90% glycerol, 10% PBS) was added. A 
glass coverslip was carefully layered over the slide and the edge sealed with clear 




Tissue sections were cut using a cryostat and mounted on TESPA coated (See 
Appendix 4) 4 spot slides. All equipment and solutions were RNase free by 
handling with gloves and treatment with DEPC (see Chapter 4 methods). Sections 
were fixed in DEPC treated paraformaldehyde (4% in PBS) for 5 minutes followed 
by extensive washing in DEPC treated PBS, air drying and storage at -20°C in 
aluminium foil.
Cryostat sections were cut by Dr. R.A.Dodds (see acknowledgements).
Generating the RNA probes
*
Principal
The DNA insert is present in the polylinker site of the transcription vector (eg IL-6  
in blue script). The promoters for T3 and T7 RNA polymerases are located on 
either side of the polylinker (area where there are multiple enzyme restriction sites). 
T3 and T7 RNA polymerases specifically transcribe DNA sequences downstream 
of the T3 or T7 promoters respectively. Cloned DNA inserts within the polylinker 
region are transcribed from either promoter. T3 and T7 RNA polymerase use the 
cloned DNA as a template and synthesize complementary RNA in the presence of 
Mg2+ and ribonucleoside triphosphates. Spermidine stimulates enzyme activity. 
Highly specific labelled transcripts are obtained when radiolabelled ribonucleoside 
triphosphates (eg 3 5SCTP) are present in the reaction. The vector must be 
linearised with a suitable restriction enzyme before initiation of the transcription 
reaction in order to obtain transcripts of a defined length. Using intact plasmid 
DNA as a template for transcription will result in heterogeneous transcripts of 
multiple lengths. The DNA template may be removed by digestion with DNase 1, 
RNase-free, after the reaction. Ribonuclease inhibitor may be added to the 
transcription reactions to ensure the preservation of the full-length single-stranded 
RNA molecules.
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Generation of RNA probes
The vector containing the insert of interest eg IL-6  was linearised using the two 
enzymes which cut at the junction between vector/insert. The two enzymes were 
reacted separately so that two different linear species were obtained (see Appendix 
4). These were then purified using a 'gene clean kit' containing glass milk.
The RNA probes were made from the cDNA using an SP6  T7 T3 kit (Boeringer). 
About 500 ng of DNA cut with each enzyme was transferred to two eppendorf 
tubes containing 3 ul of ATP, GTP, UTP mix; 2 ul 10 X buffer; 1 ul RNase 
inhibitor, 2.5 ul ^5§ c t p  and 1 ul of the appropriate polymerase (either T7 or T3 
for inserts contained within the blue script vector - see Appendix 4). The volume 
was adjusted to 20 ul with DEPC treated water and the tube placed at 37°C for 30 
minutes. Transcripts were generated by the enzyme binding to the directional 
bacterial promoter and incorporating the complementary nucleotides for the insert 
cDNA sequence. When the enzyme reached the end of the sequence, the reaction 
was terminated and started again thereby generating a series of transcripts. 
Following this, 2 ul of DNase 1 (RNase free) was added for 15 minutes at 37°C. 
The reaction was stopped with 2 ul of 0.5M EDTA (DEPC treated). Therefore the 
tubes contained RNA probes generated from cDNA templates. One enzyme 
produced a sequence complementary to the coding strand (anti-sense) and the other 
enzyme produced a sequence complementary to the non-coding strand (sense).
The volume was made up to 50 ul with DEPC treated water and incorporation of 
radiolabelled nucleotides assessed (see Appendix 3)
Spun columns were prepared using the outer part of a 1 ml syringe. A small plug 
of glass wool was pushed into the bottom of the syringe and Sephadex G25 
(suspended in ddwater and pre-expanded in a 90°C water bath for 1 h followed by 
suspension in DEPC treated water) was carefully layered into the syringe avoiding
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air bubbles. This creates a molecular sieve whereby the unincorporated 
trinucleosides were retained in holes in the Sephadex G25. The relatively large 
transcripts filter through the Sephadex G25 and are therefore separated out. Once 
the column was filled, it was placed in a 15 ml centrifuge tube and spun at 2000 
rpm for 4 minutes. The water was then tipped out and an eppendorf tube (without 
lid) (RNase free) placed into the bottom of the 15 ml tube. The column was then 
carefully set up so that the tip protruded into the eppendorf tube. The appropriate 
probe was then added to the top of the column carefully. This was then spun at 
2000 for 4 minutes. During this time the probe was collected in the eppendorf tube 
which was then capped and frozen ready for use.
Prehvbridisation
All solutions were DEPC treated. The slides were dipped into a series of solutions 
at room temperature in DEPC pre-soaked coplin jars. These were: PBS (0.1 M pH 
7.2) for 3 minutes, 0.1 M Glycine/PBS for 2 x 3 minutes, and PBS for 3 minutes. 
This rehydrated the cells and sections on the slides.
For the sections only, the slides were demineralized with citric acid buffer (100 ml 
of 1M citric acid (tri sodium salt) was adjusted to pH 4.5 with 1 M citric acid (free 
acid). This was then diluted 1:4 with ddwater) at room temperature for 1 h in order 
to break down large moieties such as hydroxy apatite and thereby reduce 
non specific binding and allowing access of the RNA probe to the mRNA species. 
This was followed by proteinase K treatment (1 ug/ml diluted in 0.1 M Tris (pH 8 ) 
50 mM EDTA (pH 8 )) at 37°C for 5 minutes (cells) or 20 minutes (sections). 
Proteinase K degrades proteins in order for the probe to gain access to the mRNA 
within the cells. The slides were then re fixed in 4% paraformaldehyde/PBS room 
temperature for 5 minutes in order to retain the cellular localisation of the mRNA 
before washing in PBS twice (3 minutes).
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The remaining proteins were acetylated with acetic anhydride (0.5 ml/200 ml of 
0.1 M triethanolamine). The anhydride is only active for 1 minute and so the 
solution was prepared just before addition to slides. This was left for 10 minutes 
before addition of 50% deionized formamide/2 X SSC for a further 10 minutes. 
(This pre- equilibrates the sections in organic phase).
Hybridisation
The formamide/SSC was carefully drained off and 10 - 15 ul of hybridisation 
buffer (see Appendix 4) was carefully delivered to each section.
This mixture helps to block non specific binding of the probe to the cells. tRNA 
interchelates with looped sequences within the DNA which would otherwise attract 
the probe. The function of the other components is discussed in the introduction of 
this chapter. The slides were placed in a humidified (DEPC treated 2 X SSC) box 
in a 42°C waterbath for at least 3 h (tissue paper was taped to the inside of the lid to 
prevent drops of liquid splashing onto the slides).
Without creating air bubbles; 5 - 10 ul of each RNA probe was added (diluted in 
more hybridisation buffer) to each section so that the specific activity of the RNA 
probe was 300,000 cpm per section. The slides were then covered carefully with 
parafilm strips to prevent evaporation and care was taken to ensure that the different 
RNA probe conditions remained separate.
The slides were incubated in a humidified box overnight at 42°C.
Washing
The parafilm was carefully removed from the slides at room temperature in a coplin 
jar containing 4 X SSC and left for 30 minutes. Four 15 minute washes in 4 X 
SSC were performed in a shaking water bath set at 37°C. The slides were washed 
in a solution of 0.5 M NaCl/10 mM Tris-HCl pH 8/  1 mM EDTA for 10 minutes at 
37°C and were subjected to RNase digestion in the previous solution containing 20
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ug RNase A/ ml for 30 minutes at 37°C. The slides were washed in 2 X SSC for 
30 minutes at 37°C followed by a higher stringency wash of 0.1 X SSC for 30 
minutes at 37°C. The cells were progressively dehydrated in 70% ethanol/0.3 M 
ammonium acetate for 5 minutes, 95% ethanol/0.3 M ammonium acetate for 5 
minutes and twice in 100% ethanol/0.3 M ammonium acetate for 5 minutes. The 
sections were air dried, placed in a box containing dessicant packets and stored 
at -20°C ready for autoradiography.
Autoradiography
LM1 emulsion was used to expose the radioactivity. At this stage, all work was 
performed in a dark room. The emulsion was pre-warmed in a coplin jar in a 45°C 
water bath (as the solid emulsion melted, air bubbles were removed using a 
needle). The slides were allowed to warm to room temperature before removing 
from the box. The sections were dipped into the emulsion and left for 5 seconds 
before smoothly drawing the slide out and allowing the excess emulsion to drain 
off. The slides were placed on an inverted metal tray on ice for 10 minutes (this 
helps to gel the emulsion so that it does not run off the slide whilst air drying). 
Following this, the slides were stood up in a rack and allowed to air dry. The dry 
slides were transferred to a box containing dessicant. The box was carefully 
wrapped in aluminium foil and by two black light proof bags and taped up. The 
box was placed at 4°C until development 2 weeks later.
Development
In the dark room, the slides were removed and placed in developer (Ilford phenisol 
high contrast developer) (diluted 1:4 in water) for 10 minutes. The slides were 
transferred to a 'stop' solution of 0.5 M acetic acid followed by 30% (w/v) sodium 
thiosulphate fixer for 10 minutes. Following this, the slides were removed from 
the dark room and extensively washed in several fresh changes of water before
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staining with hematoxylin. The slides were air dried and coverslips placed over the 
sections using DPX mountant.
Subcloning IL-6  into Bluescript vector
IL- 6  was present in a vector containing only one bacterial promoter. In order to 
obtain both a sense and anti-sense transcript, it was necessary to subclone IL-6  into 
another vector containing two bacterial promoters. Blue script vector was chosen 
as it contains T3 and T7 promoters and part of the p-galactosidase gene. This 
vector when transformed into XL-1 blue bacteria, forms blue or white colonies 
depending upon whether or not the insert has been ligated to the vector. The insert 
interupts the gene upon insertion into the polylinker region and the bacteria can not 
convert the substrate into a blue colour, therefore this is a simple selection 
procedure to isolate and amplify the insert.
IL-6  was isolated from the original vector by double digestion with Xba 1 and 
Sal 1. Several attempts to ligate the overhanging cohesive ends to blue script 
vector cut with the same enzymes failed. 100 ug of purified IL-6  insert cut with 
the above enzymes was subjected to a T4 DNA polymerase reaction in order to fill 
in the overhanging ends thereby creating blunt ends. This involved incubation of 
the DNA with enzyme and buffer which included nucleotides, for 30 minutes at 
37°C (see Appendix 4). This was then phenol/chloroform extracted once and 
washed with chloroform before precipitation. In the meantime; bluescript vector 
(containing a polylinker region with many restriction enzyme sites) was digested 
with Sma 1 which results in blunt ends, and purified. A proportion of the vector 
and insert were then electrophoresed on a 1% (w/v) agarose gel along with a 
molecular weight marker. IL-6  insert is 300 bp whereas bluescript is 3000 bp long. 
Therefore 10 ng IL-6  contains more blunt ends than the equivalent amount of 
vector. This is important when setting up ligation reactions as an excess of vector is
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required to account for the differences in size. From the gel, approximate amounts 
of DNA were estimated. It was considered that IL-6  amounted to about 10 ng of 
DNA whereas bluescript was approximately 100 ng. Therefore ligation mixes 
including stringent controls were as follows:
A) 3 ul IL-6 , 1 ul vector, 1 ul ligase buffer, 1 ul T4 ligase enzyme and 4 ul water.
B) 6  ul IL-6 , 1 ul vector, 1 ul ligase buffer, 1 ul T4 ligase enzyme and 1 ul water.
C) 1 ul vector, 1 ul ligase buffer, 1 ul T4 ligase enzyme and 7 ul water.
D) 1 ul vector, 9 ul water
E) 1 ul uncut vector, 9 ul water.
C - E were controls. C was the ligation control - theoretically, the ligase should 
have re-circularised the vector without disrupting the P-galactosidase and therefore 
many blue colonies should be apparent after transformation and plating out. This 
shows that the ligase enzyme is functional. D and E are to prove that the XL-1 blue 
bacteria are competent. The competent bacteria should take in the closed circular 
bluescript with at least 100  fold more efficiency than the unligated vector.
These ligations are blunt-ended and therefore the reaction is allowed to proceed over 
night at 16°C.
Half of the ligation mix for each reaction was removed and transformed into 
competent XL-1 blue bacteria (see general methods). The bacteria were spread onto 
ampicillin (50 ug/ml) containing agar plates which had previously been spread with 
substrate for the p-galactosidase reaction. This involved addition of 0.8 mg/ml of 
X-gal and 0.8 mg/ml isopropylthio-p-D-galactosidase (IPTG) to the plates after 
which the substrate was allowed to soak into the agar for about an hour prior to the 
addition of the bacteria. Once the bacteria were spread, the plates were inverted and 
placed in a 37°C incubator over night.
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On the following day, there were more white colonies on A) and B) when 
compared to C) (30% compared to 10%). 10 colonies were picked and grown up 
in 5 mis L-broth + ampicillin over night (see Chapter 2). 1.5 mis was then 
removed from each preparation and spun down in an eppendorf tube. The resulting 
pellets were then subjected to small scale plasmid preparation (see Chapter 2). 
After quantification of the DNA (see Appendix 1), 2.5 ug was digested with a 
restriction enzyme with only one cutting site in the vector-insert sequence. This 
was electrophoresed on a 1% (w/v) agarose gel along with molecular weight 
markers. The insert, present within the vector, should be approximately 3.3 kb 
long (fig. 5.1a). Only one of the ten preparations did not contain the insert. This 
was checked by Southern blotting the gel onto Hybond N+ under denaturing 
conditions (0.4 M NaOH) for 1 h. The Hybond N+ was subsequently probed for 
IL-6  (see Chapter 4 for method). The filter was set up for autoradiography for 30 
minutes (see fig. 5.1b). The probe annealed to all the preparations except the one 
which did not contain the insert. One of the preparations was chosen and grown up 
in 250 mis L-Broth + ampicillin overnight (from the remaining 3.5 mis). A large 
scale plasmid preparation was performed and the 300 bp insert checked by double 
digestion with Eco R1 and Xba 1. By restriction enzyme digests, the orientation of 
the insert and therefore which restriction enzyme resulted in the sense and anti­
sense transcripts was ascertained. RNA probes could then be generated for IL-6 .
RESULTS
Immunolocalisation
By doing a series of titration experiments, optimum LL-6 staining of cells was 
obtained with sheep anti-human IL-6  antibody at 1:100 dilution, biotinylated swine 
anti-sheep antibody at 1 :2 0 0  dilution and streptavidin conjugated to alkaline 
phosphatase at 1:200 dilution (data not shown). Presence of IL-6  protein was
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observed in both human osteoblasts and human osteoclasts (fig. 5.2a,b). 
Non-immune sheep serum at a dilution of 1:100 was used as a negative control 
(figs. 5.2c,d, and fig. 5.3b).
In a separate experiment, IL-6  was co-localised with a marker of the osteoblast 
phenotype, alkaline phosphatase. Alkaline phosphatase was present in a proportion 
(approx. 40%) of the cells which may indicate that osteoblasts at different 
maturation stages are present. Intracellular IL-6  staining was observed, using the 
sheep anti-human IL-6  antibody (1:100), in over 90% of the cells (fig. 5.3a).
In order to ascertain that the IL-6  staining was specific, the anti IL-6  antibody 
(1:100) was preadsorbed with varying concentrations of rhIL-6  prior to addition to 
the cells (fig. 5.4). Preadsorption of the anti IL-6  antibody with rhIL-6  at a 
concentration of 1 0 ,0 0 0  pg/ml resulted in partial inhibition of antibody interaction 
with endogenous IL-6  production by the human osteoblasts and osteoclasts (fig. 
5.4c,d). A concentration of 500,000 pg/ml of IL-6  totally inhibited antibody 
binding to the osteoblasts and osteoclasts (fig. 5.4e,f).
The anti-IL-6  antibody was used for the immunolocalisation of IL-6  in various 
cryostat cut sections of tissue, including human fetal bone, osteoclastoma and 
osteophyte. Non specific binding was very high and various attempts were made to 
reduce this, such as pre-incubation with avidin and biotin, variation of secondary 
antibody species and increasing levamisole content in the substrate solution. Some 





Osteophytes are characteristic bony outgrowths that develop in osteoarthritic joints 
in the human (Hamerman 1989). This rapidly developing bone is an excellent tissue 
for in situ hybridisation study as it is highly cellular, contains all the stages of the 
remodelling cycle and exhibits both endochondral and intramembranous bone 
formation (see Chapter 1).
Endochondral bone formation
Fig. 5.5a. shows a histology of an osteophyte and demonstrates the process of 
endochondral bone formation. Osteophytes are composed of cancellous trabeculae 
covered by cartilage and fibrocartilage. The matrix around the hypertrophic 
chondrocytes calcifies in the preliminary stages of endochondral bone formation. 
Invasion by vascular connective tissue results in the mass of calcified cartilage. 
Osteoclastic resorption of this cartilage is followed by the deposition of woven bone 
on these eroded surfaces. In this way trabeculae of woven bone replace and 
eminate from the initial cartilage. In a similar process of remodelling, osteoclasts 
resorb this woven bone which is ultimately replaced with parallel fibred lamellar 
bone. During acute bone remodelling the marrow stroma is highly cellular 
(hematopoietic tissue) and is rich in mononuclear cells and migrating osteoclasts. 
Fig. 5.5b shows a higher magnification of a similar area of endochondral 
ossification. Anti-sense binding of the IL-6  RNA probe to the tissue was 
particularly intense in the osteoblasts although varying degrees of hybridisation 
were evident within these cells (Fig. 5.5b). Furthermore; IL-6  mRNA was only 
present in a population of chondrocytes, with the more hypertrophic chondrocytes 
lacking IL-6  mRNA expression. Marrow cells were also positive for IL-6  mRNA
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expression. The binding was specific as the sense transcript exhibited no binding 
(fig. 5.5c).
Intramembranous ossification
The histology in fig. 5.6a demonstrates the deposition of woven bone by a fine 
layer of osteoblasts that have differentiated from the surrounding connective tissue. 
Similar to that observed in endochondral bone formation, the newly formed more 
rounded osteoblasts, actually laying down osteoid, expressed higher levels of IL-6  
mRNA than the more mature osteoblasts (lining cells) apposed to the bone surface 
(fig. 5.6b). A similar situation is evident at the tip of the developing osteophyte, 
whereby both types of bone formation are observed within the same section. Fig. 
5.7a illustrates a very early stage of endochondral bone formation; woven bone is 
formed by osteoblasts apposed to the cartilage. Concurrently, large osteoblasts 
differentiate from the surrounding connective tissue and either form woven bone 
directly (intramembranous) or congregate and appose distinct areas of the newly 
formed cartilage. High IL-6  mRNA expression was observed in the rounded newly 
formed osteoblasts (fig. 5.7b); this was absent in the corresponding negative 
control (fig. 5.7c).
Maturation of the osteophyte
Fig. 5.8a is a histology of another section of developing osteophyte depicting 
mature lamellar bone and a spicule of newly formed bone lined by osteoblasts, 
surrounded by connective tissue and a small pocket of marrow. Osteoblasts, 
osteocytes, marrow cells and a population of the chondrocytes all hybridised 
positively with the IL-6  anti-sense probe (fig. 5.8b). In addition some larger cells, 
possibly osteoclasts within the marrow, also expressed IL-6  mRNA. Hybridisation 
was specific as the sense probe exhibited no binding (fig. 5.8c).
155
IL-6  mRNA expression bv osteoclasts
Fig. 5.9a shows the presence of osteoclasts stained for TRAP activity in an area of 
endochondral bone formation. Fig. 5.9b shows osteoclasts in a similar area which 
are expressing very high levels of IL- 6  mRNA. Figs. 5.10a and 5.10b 
demonstrate IL-6  anti-sense hybridisation to other osteoclasts within different 
osteophytes.
Human osteoclastoma
Osteoclastoma is a rare form of tumour, often not malignant and usually found in 
the shaft of long bones. This tumour is characterised by high numbers of giant 
cells, although it is the stromal cells that form the neoplastic element (Goldring et al 
1987). These giant cells have been shown to possess several characteristics of 
osteoclasts such as their ability to resorb bone slices in vitro (Horton et al., 1985, 
James et al., 1991) and retraction of cytoplasmic processes upon addition of 
calcitonin (Horton et al, 1985). Some unknown element appears to promote 
differentiation of osteoclast formation, as the percentage of osteoclasts within the 
tumour compared to that in bone is extremely high. Within the tumour, areas of 
active bone formation can be observed. IL- 6  mRNA expression in the 
osteoclastoma was very intense and specific to the anti-sense probe (fig. 5.11a) as 
the sense RNA probe exhibited no binding (fig. 5.11b). The anti-sense probe 
hybridised to all the cells within tumour including the stromal cells and osteoclasts 
(Fig. 5.1 la ). Similar areas of tumour were reacted for TRAP activity (fig. 5.1 lc) 
and Wrights stain (histology) (fig. 5.1 Id).
Human fetal bone
Histology (fig. 5.12a) of a fetal rib section showed cartilage cells and connective 
tissue. Osteoblasts, derived from the connective tissue by the process of
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intramembranous bone formation, are laying down immature woven bone in a strut- 
like fashion. The anti-sense IL-6  probe hybridised to the newly formed osteoblasts 
with a very intense signal similar to the osteophyte sections (fig. 5.12b). 
Furthermore, more flattened osteoblasts within the same section, although positive, 
did not express as much IL-6  mRNA. Other cells within the tissue were negative 
for EL-6  mRNA, and the sense transcript exhibited no binding (fig. 5.12c).
DISCUSSION
In chapter 4, the production of EL-6  by bioassay and Northern and dot blot analysis 
was demonstrated in human osteoblast-like cells. Furthermore, by employing 
immunostaining techniques in the present chapter, EL-6  protein was shown to be 
present in cultured osteoblasts. As IL-6  is expressed in such high levels in 
osteoblasts, and such a large proportion of cells are expressing the protein, it is 
possible to visualise that the cells in culture exist in a state where EL-6  mRNA and 
protein production are activated permanently. Culture conditions such as adherence 
to plastic or glass may be affecting the phenotype of the cells which results in an 
inaccurate reflection of the in vivo conditions.
Attempts to immunolocalise IL-6  in tissue sections were hindered by high 
non specific background. Many attempts were made to reduce this non specific 
binding, such as increasing levamisole content in the substrate solution; changing 
the species of the secondary antibody and pre-blocking solution, and pre-incubation 
with avidin and biotin. Although some of these treatments lowered the background 
slightly they did not abolish non specific binding. However, omitting a single step 
from the staining process resulted in an absence of binding which suggests that the 
negative control is inappropriate and is likely to be responsible for the non specific 
bindirg. Tissue sections contain proteins which may be interfering with the 
stainirg process by binding the non immune sheep serum which was used as a
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negative control. Therefore studies are required using the specific isotype of the 
sheep anti-human IL-6  antibody for the negative control. Non-immune sheep serum 
is a poor negative control as it contains many of the immunoglobulin subclasses as 
well as serum associated proteins which may be interfering with the specificity of 
this procedure.
In situ hybridisation in developing osteophyte demonstrated that IL-6  mRNA was 
particularly intense in osteoblasts and osteoclasts. The anti-sense probe also 
hybridised to other regions in this tissue such as the marrow and a population of 
chondrocytes.
A striking feature of the in situ hybridisation studies was the high expression of 
IL-6  mRNA in what appears to be newly formed osteoblasts in both the osteophyte 
and the fetal tissue. It is very difficult to identify osteoblast progenitors in situ, 
because as yet there are no specific markers for these cells. Therefore histological 
examination and location of the cells are of critical importance for identification. 
More quiescent osteoblasts lining the bone surface express less IL-6  mRNA activity 
than plump newly formed osteoblasts and this was evident during both 
endochondral and intramembranous bone formation. Therefore, it appears that 
levels of IL-6  mRNA fluctuate within the osteoblasts. Further studies are required 
to investigate the co-expression of IL-6  mRNA with markers of osteoblast 
maturation. Several groups have demonstrated that proteins such as MGP, alkaline 
phosphatase, collagen type I and osteocalcin are expresssed at different stages of 
osteoblast maturation (Fraser et al 1988, Owen et al 1991, Lian et al 1991). 
Therefore the co-localisation of these proteins with IL-6  may possibly indicate 
whether IL-6  mRNA expression is a function of immature osteoblast phenotype. 
IL- 6  mRNA and protein were also localised in osteoclasts derived from 
osteoclastoma tumours. An advantage of using the osteoclastoma tumour for in situ 
hybridisation studies was the fact that negatives (sense RNA probe) were readily
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obtainable. This is in contrast to osteophyte serial sections where the 
corresponding osteoclast was unlikely to be present in both anti-sense and sense 
labelled sections. Similar areas of sections were stained for TRAP activity and 
histologies were also performed in order to aid with the identification of the 
osteoclasts. In accordance with these studies, Ohsaki et al (1991) reported 
preliminary evidence for the presence of IL-6  mRNA in osteoclasts derived from 
osteoclastoma tumour. In a contrasting study, Hoy land et al (1992) demonstrated 
that osteoclasts did not produce EL-6  mRNA but were capable of synthesizing 
TGFp mRNA. The results of Hoyland and co-workers (1992) were also in contrast 
to parallel studies within our laboratories by Merry et al (1991), who demonstrated 
that TGFp and IL-1 mRNA were not expressed in osteoclasts (Merry et al 1991b). 
TNFa and TNFp have been reported to be expressed in 14 day GM-CFC-derived 
osteoclasts (Qi et al 1991). Hence from the data presented within this chapter and 
evidence by other groups, it is likely that osteoclasts are not solely involved in 
resorption, but are probably involved in paracrine/autocrine interactions within the 
bone microenvironment. This is made possible by the expression of various 
cytokines by these osteoclasts. The ability of cells of the osteoclast lineage to 
synthesize factors implicated in local bone remodelling raises the possibility that 
osteoclastic cells could regulate other cells involved in bone turnover. As 
osteoclasts are difficult to isolate for in vitro study, and their phenotype is unstable 
under tissue culture conditions, the in situ hybridisation technique will be a 
valuable tool for investigating osteoclast function.
As IL-6  is produced by many of the cells within the bone microenvironment, it is 
less likely to be involved directly in bone formation and resorption in contrast to 
cytokines such as IL-1. The effects of IL-1 on bone remodelling are very potent 
and rapid. In accordance with this concept, studies within our laboratory have 
demonstrated that compared to IL-6  mRNA expression (Littlewood et al 1991b),
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the expression of IL-1 mRNA is relatively transient (Merry et al 1992a) in human 
osteoblasts. However, the possibility that IL-6  may modulate actions of cytokines 
such as IL-1 can not be excluded. Indeed Black et al (1991b) has reported that the 
presence of IL-6  is critical for resorption in neonatal mouse calvariae stimulated by 
IL-1 and TNF, although others have been unable to demonstrate this same effect in 
a similar system (Al-Humidan et al 1991).
Conversely, it is possible that IL-6  expression within the bone microenvironment 
may need to reach threshold levels in order to exert any influence on bone 
remodelling and fluctuating levels of this cytokine in osteoblasts may be critical. In 
this respect, presence of inhibitors is also of importance when considering available 
IL-6  concentration. So far, no inhibitors for IL-6  have been isolated. This is in 
contrast to the functionally related cytokines TNF and IL-1. TNF inhibitors are 
binding proteins that associate with this cytokine and subsequently inhibit TNF 
function (Nophar et al 1990). In contrast, IL-1 inhibitors are receptor antagonist 
proteins, thereby blocking the association of the ligand with the receptor 
(Seckinger et al 1987a). a2-macroglobulin in the circulation (Matsuda et al 1989), 
and a soluble extracellular form of the IL-6R in urine (Novick et al 1989) have been 
identified as carriers for IL-6  although neither of these carriers inhibit IL-6  activity. 
So far, no natural soluble form of the IL-6 R has been isolated in the circulation. 
Others, by using this truncated soluble IL-6  receptor, and by preparing specific 
antibodies, have established an ELISA (enzyme linked immuno-sorbant assay) 
(Yasukawa et al 1990, Saito et al 1991). This ELISA, although established in the 
murine system, may be useful for the detection of natural forms of the soluble 
IL-6R in the circulation. These potential carriers for IL-6  may protect the IL-6  from 
proteolytic breakdown and this could result in an increased local concentration of 
IL-6 . Therefore, it is necessary to investigate whether inhibitors or carrier proteins 
for IL-6  exist within bone as these may influence the actions of this cytokine.
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Further in situ hybridisation studies will be of value in order to gain a clearer 
understanding of the function of IL-6  in bone remodelling.
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Subcloning IL -6  into blue script vector
Fig. 5.1a - Ten small scale plasmid preparations (IL-6  300 base insert within 
3000 base blue script vector) were linearised by digestion with Eco R l, and 
electrophoresed on a 1% (w/v) agarose gel (see Chapter 2). Lane 1 is the linearised 
vector alone and lane 12 is a molecular weight marker -ADNA cut with Hind IH.
Apart from sample number 6 (lane 7), all the linearised species appear to be larger than 
the 3000 base blue script vector alone.
Fig. 5.1b - The gel in Fig. 5.1a was subjected to Southern blot onto a Hybond N+ 
membrane which was subsequently hybridised with an IL-6  cDNA probe (see 
Chapter 4 methods). All samples, apart from number 6 had incorporated the IL-6  
insert as shown by the autoradiograph.
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Fig. 5.2 Immunolocalisation of IL-6  protein in human osteoblasts and human 
osteoclasts.




Cells were immunostained with the sheep anti-human IL-6 antibody (see methods)
Fig. 5.2a IL-6  staining in human osteoblasts treated with monensin (1 uM) (see methods). 
Fig. 5.2b IL-6  protein is present in human osteoclasts derived from an osteoclastoma.
Fig. 5.2c and 5.2d Negative controls - non immune sheep serum was incubated with 
the cells at the same concentration as the sheep anti-human IL-6 antibody.
163
Fig. 5.3 Colocalisation of IL-6 protein with a marker of osteoblast 
phenotype - alkaline phosphatase.
X  400
Human osteoblast-like cells were reacted for alkaline phosphatase 
(see methods) and subsequently stained for IL-6  protein by using 
the sheep anti-human IL-6  antibody (a). Non immune sheep serum 
was used as the negative control (b).
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Fig. 5.4 Specificity o f the sheen anti-human IL-6 antibody.
Fig. 5.4a and b IL-6 staining in osteoblasts (a) and osteoclasts (b) with sheep 
anti-human IL-6 antibody (1:100).
Fig. 5.4c and d Preadsorption of the anti-IL-6 antibody with 10,000 pg/ml of 
rhIL-6 in order to demonstrate partial inhibition of immunostaining in 
osteoblasts (c) and osteoclasts (d).
Fig. 5.4e and f Total inhibition of staining by preadsorption of the antibody with 
500,000 pg/ml of rhIL-6 in osteoblasts (e) and osteoclasts (f) (compare with 
non immune sheep serum treated cells in Fig. 5.2c and d.
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Fig. 5.5 IL-6 is present in osteoblasts and populations of chondrocytes in the 
PStePPhYtg-
Fig. 5.5a Wrights stain of a section of endochondral bone formation in an osteophyte. 
Cartilage (large arrow) is eroded by osteoclasts and replaced by osteoblasts depositing 
woven bone. Woven bone is subsequently resorbed and replaced with lamellar bone 
closely lined by osteoblasts (small arrow).
Fig. 5.5b Anti-sense section of a similar area of bone showing plump osteoblasts 
expressing large amounts of IL-6 mRNA (small arrow) in comparison to more flattened 
osteoblasts apposed to the bone surface (large arrow). A population of chondrocytes 
also express IL-6 mRNA (double arrow).






Fig. 5.6 IL-6 is present in newlv formed osteoblasts in the osteophyte.
X 200
Fig. 5.6a Wrights stain of an area of intramembranous bone formation in the
developing osteophyte. A Fine layer of osteoblasts (large arrow) derived from the 
surrounding connective tissue (small arrow) are actively laying down woven bone.
Fig. 5.6b Anti-sense section of a similar area showing high expression of IL-6 mRNA 
in the newly formed plump osteoblasts (large arrow) compared to the more mature 
osteoblasts apposed to the bone surface (small arrow).
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Fig. 5.7 IL-6 is present in newlv formed osteoblasts in the tip of 
a developing osteophyte.
Fig. 5.7a Wrights stain of the tip of a developing osteophyte. Both endochondral 
and intramembranous bone formation processes are evident. Cartilage (large 
arrow) is eroded and replaced by woven and subsequently lamellar bone. A thin 
layer of osteoblasts (small arrow) have differentiated from the surrounding 
connective tissue (double arrow).
Fig. 5.7b Anti-sense section showing high expression of IL-6 mRNA
in the newly formed osteoblasts (large arrow) derived from the connective tissue.
Fig. 5.7c Sense probe exhibited no binding.
170





Fig. 5.8 IL-6 is present in cells within the maturing osteophyte.
Fig. 5.8a Histology of a section of osteophyte containing a spicule of newly formed 
bone lined by osteoblasts (large arrow) and osteoclasts (small arrow).
Fig. 5.8b IL-6 mRNA was present in osteoblasts, osteoclasts, marrow cells and a 
population of chondrocytes.




Fig. 5.9 IL-6 is present in osteoclasts within the osteophyte.
/  200
Fig. 5.9a Section of osteophyte reacted for TRAP activity demonstrates the presence 
of osteoclasts within an area of endochondral bone formation.
Fig. 5.9b Similar area of osteophyte showing high levels of IL-6 mRNA expression 
in osteoclasts.
Fig. 5.10 IL-6 is present in osteoclasts within various osteophytes.
X 100
X 4 0 0
Fig. 5.10 Osteoclasts adjacent to the bone surface within different osteophytes 
express high levels of IL-6 mRNA expression.
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Fig. 5.11 IL-6 is present in gstew dasts w ith in gstettclastom a tum our.
X 4 0 0
Fig. 5.11a Osteoclasts and stromal cells within an osteoclastoma express high levels 
of IL-6 mRNA.
Fig. 5.1 lb  Sense probe exhibited no binding.
Fig. 5.11c A similar area of tumour was reacted for TRAP activity to confirm the 
presence of osteoclasts.
Fig. 5.1 Id Histology of the tumour also demonstrates the presence of the 
multinucleated osteoclasts.
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Fig. 5.12 IL-6 is present in osteoblasts within fetal tissue.
Fig. 5.12a Histology of fetal rib showing osteoblasts derived from the 
connective tissue during intramembranous bone formation (large arrow) 
laying down woven bone.
Fig. 5.12b IL-6  mRNA is present in high levels newly formed osteoblasts 
(large arrow).





Alkaline phosphatase substrate solution 
Napthol AS-MX phosphate, free acid 2 mg
N,N-dimethylformamide 
0.1 M Tris buffer pH 8.2 9.8 ml
0 .2  ml
1 M Levamisole 0.04 ml
Fast Red TR salt 10  mg
This solution was made by dissolving Napthol in N,N-dimethylformamide in a 
glass tube. Tris buffer was added followed by the levamisole (blocked 
endogenous bone alkaline phosphatase, but not intestinal calf alkaline 
phosphatase present in streptavidin/alkaline phosphatase). The solution was 
adjusted to pH 8.2. Immediately before use, the fast red TR salt was dissolved 
in this solution and it was filtered onto the slides.
3-aminopropvltriethoxvsilane (TESPA1 coating of slides
Slides were handled with gloves and prepared by dipping into the following
solutions:-
10% (v/v) HC1 in 70% (v/v) alcohol for 10 seconds 
Distilled water for 10 seconds 
95% (v/v) alcohol for 10 seconds
The slides were dried in an oven at 150°C and allowed to cool before dipping
into the following solutions:-
2% (v/v) TESPA in acetone for 10 seconds
100% acetone for 2 X 10 seconds
Distilled water for 10 seconds
The slides were baked dry in an oven at 42°C,transferred to a dessicated box 
and stored at 4°C.
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Different linear species obtained bv cutting the vector/insert intersection with 
two different enzvmess












1 0% dextran sulphate 
lOmMDTT
RNase inhibitor - 0.4 U/ml 
lOUtRNA
1 X denharts solution (see Appendix 3)
200 ug/ml salmon sperm DNA (see Appendix 3)
1 X T4 DNA polymerase buffer 
16.6 mM ammonium sulphate 
37 mM Tris HC1 pH 8 .8
6.7 mM magnesium chloride
10 mM 2-mercaptoethanol
6.7 uM EDTA




EXPRESSION AND MODULATION OF IL-6 R IN HUMAN 
OSTEOBLAST-LIKE CELLS.
ABSTRACT
As shown previously (Chapter 3), IL-6  does not modulate osteoblast function and 
one explanation for this may be related to the lack of IL-6  receptor (IL-6 R) 
expression by these cells. The IL-6 R has been recendy cloned and cDNA probes 
are available for the study of the expression of the IL-6 R. IL-6 R has been shown 
to be expressed in many cell types including myeloma cells, hepatocytes and 
lymphocytes. The expression and modulation of IL-6 R mRNA in human 
osteoblast-like cells has therefore been investigated. Total RNA was extracted from 
unstimulated human osteoblast-like cells and from cultures stimulated with rhIL-la 
(10-H M), rhTNFa (H)’8 M), IL-6  (2000 pg/ml), l,25(OH)2D3 (10'8M) and 
hPTH (1-34) (10-9 M). Northern and dot blots were probed for IL-6 R using a 
specific cDNA probe. The probe annealed to a hybridising species which was 
heavier than the 28S rRNA band and was composed therefore of approximately 
5000 - 6000 nucleotides confirming its identity (Yamasaki et al 1988, M. Baumann 
et al 1990). IL-6 R mRNA was constitutively produced by the human 
osteoblast-like cells and none of the osteotropic agents tested modulated its 
expression over a 24 h incubation period in either serum free or 10% (v/v) FCS- 
containing EMEM. Dexamethasone (10-6 M) exerted no modulatory effect on the 
expression of IL-6 R mRNA either in the presence or absence of rhIL-la (KH1 M) 
or rhTNFa (10' 8 M), unlike its effect on IL-6  mRNA production. These studies 
indicate that cultures of human osteoblast-like cells express EL-6 R mRNA. The 
reason for the potential presence of receptors on osteoblast-like cells is unclear as 
no function for this cytokine has been found in these cells. Whether the mRNA for
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the IL-6 R is subsequently translated into a functionally responsive IL-6R protein is 
not currently known. It is possible that associated components required for 
IL-6 /IL-6 R interactions may be absent or that processes involved in signal 
transduction may be defective. Alternatively, excess IL-6  levels produced by these 
cells (Chapter 4) may exert a desensitising effect on the receptor. Further studies 
are required to address these individual possibilities.
INTRODUCTION
The receptor for IL-6  was first cloned from human leukocytes (Yamasaki et al
1988) and from the nucleotide sequence, its amino acid structure has been 
determined. IL-6 R consists of a 468 amino acid sequence including a hydrophobic 
signal peptide of approximately 19 amino acids and a poly A sequence usually 
associated with mRNA stability on the 3' end. Another hydrophobic area was 
located and this was presumed to be the transmembrane domain which was 
followed by an anchor region (Yamasaki et al 1988). The rat liver IL-6  receptor was 
recently cloned (Baumann et al 1990b). This group observed that the rat IL-6 R 
possessed areas of homology with the human counterpart such as the signal peptide 
region and the transmembrane domain. IL-6 R also shares several structural 
features with a cytokine receptor family which included GM-CSF, murine IL-4 
(mIL-4), mIL-3 and hIL-2 (B chain) (Baumann et al 1990b).
The detection of receptors for IL-6  first was reported by Taga et al (1987). Using 
radio-iodinated EL-6 , they demonstrated the existence of between 200 - 2700IL-6R 
sites on a human B cell line SKW6-CL4, Epstein Barr virus transformed B-cell 
lines, U937 and HL-60 cells. They also located IL-6 R on resting T cells although 
the number of sites per cell decreased upon activation. This correlates well with 
evidence for early effects of IL-6  on T cell proliferation (Ceuppens et al 1988, 
Tosato and Pike 1988; refer to introduction for further references). Evidence for
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the late activation of T cells by IL-6  (Okada et al 1988) may be due to different 
responding subsets of T cells (Garman et al 1987, Hodgkin et al 1988, 
Habetswallner et al 1988).
EL-6 R are not present on resting human B cells in the absence of stimulation 
although receptor number increases upon activation of B cells. This fits in well 
with the late acting function of IL-6  on the terminal differentiation of B cells into 
immunoglobulin producing cells (Takatsuki et al 1988, Muraguchi et al 1988, 
Kishimoto and Hirano 1988 for review).
IL-6R have also been located on a number of other cells including hepatocytes 
(Rose-John et al 1991, M. Baumann et al 1990, Snyers et al 1990, Bauer et al
1989), rat and human skin fibroblasts (Rose-John et al 1991), myeloma cells (Taga 
et al 1987, Yamasaki et al 1988, Taga et al 1989, Kawano et al 1988) and human 
blood mononuclear cells (Bauer et al 1989). Therefore, like IL-6 , the receptor is 
expressed by a number of different cell types. Several groups have demonstrated a 
glucocorticoid up-regulation of IL-6R in hepatoma cell lines which is in accordance 
with an increased acute phase protein production by glucocorticoids (Snyers et al 
1990, Bauer et al 1989). In contrast Bauer et al (1989) described a down regulation 
of IL-6 R by glucocorticoids in human blood monocytes. Bauer et al (1989) also 
observed that IL-6  itself is able to reduce IL-6R mRNA in human monocytes, and 
increase it in human hepatocytes.
IL-6  is also known to be an autocrine growth factor for some myelomas (Klein et al 
1987, Kawano et al 1988, Sidell et al 1991). This would explain the presence of 
IL-6  receptors and production of this cytokine in myeloma.
The observations that no detectable responses to IL-6  can be demonstrated in 
human osteoblast-like cells (Chapter 3) may indicate the absence of receptors for 
this cytokine. In this chapter, the expression of IL-6 R mRNA was examined in
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human trabecular bone cells in response to various osteotropic agents including 
dexamethasone and EL-6 .
METHODS
RNA extraction, Northern and dot blot analysis were conducted as described in 
Chapter 4 methods.
The concentration for each osteotropic agent used was based on IL-6  bioassay data 
with the exception of dexamethasone and IL-6 . In the case of IL-6 , the 
concentration was based on endogenous levels produced by human osteoblast-like 
cells under serum-free conditions measured by bioassay (Chapter 4). The 
concentration of dexamethasone used was obtained from recent work demonstrating 
a dexamethasone down regulation of IL-6  bioactivity in fibroblasts (Waage et al 
1990).
RESULTS
The IL-6R probe was verified by Northern blot analysis using unstimulated human 
osteoblast-like cells. The hybridising species was heavier than the 28S rRNA band 
and corresponded to approximately 5 - 6  kb (fig. 6.1). The receptor for IL-6  is a 
much larger protein than its ligand (80 kDa vs 26 kDa) respectively and this was 
reflected in the different sizes of the mRNA species (approx. 5 kb compared to 1.3 
kb) (fig. 6 .1).
IL-6R mRNA was constitutively expressed in very high levels compared to IL-6  
mRNA in human osteoblast-like cells (fig. 6.1). It was not modulated by rhTNFa 
(10'8 M) in serum-free containing medium over a 24 h time course (fig. 6.2). 
Furthermore, this cytokine did not regulate IL-6 R mRNA levels in EMEM 
containing 10% (v/v) FCS although the time couse was only studied for the first 8 h 
(fig. 6.3). The effects of rhIL-la (10-11 M) over 48 h were studied in EMEM
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containing 10% (v/v) FCS. IL-6 R mRNA remained at constitutive background 
levels throughout the whole culture period (fig. 6.4). When excess exogenous IL-6  
(2 0 0 0  pg/ml) was added to human osteoblast-like cells in serum-free culture, no 
receptor modulation was observed over the 24 h incubation period (fig. 6.5). 
l,25(OH)2D3 at a concentration of 10' 8 M exerted no effect on the EL-6 R mRNA 
levels over 24 h serum-free culture period (fig. 6 .6 ). The paler dot after 2 h 
treatment was due to a loading error - the first 3 rows show clearly a lack of 
modulation by this hormone. hPTH (1-34) at a concentration of 10‘9 M did not 
alter the constitutive expression of IL-6 R mRNA over 24 h serum-free culture 
period (fig. 6.7) and in EMEM containing 10% (v/v) FCS (fig. 6 .8 ). The effect of 
dexamethasone (10-6 M) alone and in combination with rhIL-la (fig. 6.9) and 
rhTNFa (fig. 6.10) on IL-6 R mRNA levels was investigated. Under serum-free 
conditions the glucocorticoid exerted no regulatory effect on the basal IL-6 R mRNA 
levels in the presence or absence of rhIL-la or rhTNFa.
DISCUSSION
These studies indicate that although IL-6R mRNA was present constitutively, none 
of the agents tested modulated the mRNA in human osteoblast-like cells. 
Glucocorticoids and IL-6  neither stimulated nor inhibited IL-6 R mRNA levels in 
osteoblasts which is in contrast to their stimulatory effects on other cells such as 
hepatocytes (Bauer et al 1989, Snyers et al 1990). Bauer et al (1989) also observed 
a down regulation of IL-6 R in human blood monocytes by IL-6 , IL-1 and 
dexamethasone and an upregulation of IL-6 R mRNA in hepatocytes by these 
agents. From these studies they concluded that monocytes bind trace IL-6  
circulating in the serum, but during an inflammatory response, IL-6  binds 
preferentially to hepatocytes and so it therefore follows that the number of IL-6R 
sites/cell will be up regulated. Circulating glucocorticoids have a protective role
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which is mediated by increasing acute phase protein production and IL-6 R number 
which in turn will increase the hepatocyte response to IL-6 . Sanceau et al (1991) 
reported that in human monocytic THP-1 cells, IFNy increases IL-6 R mRNA but 
IFNy and TNFa decrease the levels of IL-6 R mRNA. Since levels of IFNy and 
TNF will be increased during inflammation, the work of Sanceau et al (1991) 
supports that of Bauer et al (1989) in that the target cell for IL-6  may be shifted 
from monocytes to other cells such as hepatocytes. The fact that B-cells acquire 
IL-6 R upon activation, relates to the immunomodulatory function of IL-6  as a B 
cell maturation factor (Takatsuki et al 1988, Muraguchi et al 1988). Therefore in 
the above studies, the up regulation of IL-6 R appears to correlate with an 
immunological role of IL-6 .
In contrast, no function for IL-6  was determined in human osteoblast-like cells 
(chapter 3). This may have been due to the fact that inappropriate parameters were 
studied. Another possibility is evident from the studies presented in this chapter 
which only demonstrate the presence of IL-6 R mRNA and not the mature IL-6 R 
protein. The IL-6 R mRNA may not be translated and expressed as the functional 
membrane receptor. Many other groups have observed the presence of various 
different mRNA species in a number of cells, but have been unable to detect the 
final protein (Garrett et al 1987, McDonald and Tuan 1989, Hakeda et al 1991). In 
order to demonstrate whether the human osteoblast-like cells express IL-6 R protein, 
attempts are in progress to investigate the presence of the IL-6 R protein in these 
cells by the use of immunoprecipitation techniques.
An alternative theory is that the receptor is translated into the final mature protein, 
but the signal transduction mechanism is absent. Interestingly, the IL-6 R 
possesses no tyrosine kinase domain (Yamasaki et al 1988), nor does the ligand 
receptor complex appear to signal through the recognised channels such as 
increased intracellular Ca2+ and phosphoinositide turnover (M. Baumann et al
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1990). Therefore a novel signal transduction mechanism may exist. Evidence for 
this is substantiated by Taga et al (1989) using a human myeloma cell line. Taga et 
al (1989) revealed by immunoprecipitation techniques using a specific anti-IL-6 R 
antibody, that a 130 kDa glycoprotein, gpl30 was capable of associating with the 
receptor after addition of IL-6 . Furthermore, this association was necessary for 
signal transduction. This proposal was further supported by evidence from 
Baumann et al (1990b) who used the rat DL-6 R gene and an acute phase protein 
gene fused to a chloramphenicol acetyltransferase (CAT) reporter construct. These 
were co-transfected into a number of lines including human hepatoma cells, 
monkey COS cells and mouse L cells. Baumann et al (1990b) observed that CAT 
activity was only increased, upon addition of IL-6 , in the human hepatoma lines 
(Hep3B-2 and HepG2). This demonstrates that more than receptor ligand binding 
is required to establish a functional IL-6  signal cascade. A likely candidate for this 
signalling component is gpl30. Taga et al (1989) observed that gp 130 was present 
in all IL-6  responsive cells. Furthermore, Taga et al (1989) using a truncated 
cDNA, expressed a soluble form of the 80 kD IL-6  receptor which was capable of 
binding IL-6  and transducing a functional signal in cells which only contained the 
gp 130 and not the IL-6 R. It is possible that human osteoblast-like cells, even 
though they may possess the 80 kD IL-6 R, lack the signalling transduction 
mechanism involving gpl30. Hibi et al (1990) cloned the 130 kD protein and 
confirmed Taga’s findings that the peptide was present in IL-6  responsive cells. 
There is increasing information about the gp 130 peptide and the nuclear factors 
induced by IL-6 . How the two are linked to transduce the IL-6  signal, remains to 
be discovered although recently, there is a suggestion that a tyrosine 
phosphorylation of a 160 kD protein and a serine kinase are involved in 
intermediate steps leading to activation of the relevant nuclear factors (Kishimoto - 
personal communication). Furthermore, a 61 amino acid region in the cytoplasmic
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section of the gp 130 was reported to be sufficient to transduce the IL-6  signal 
(Murakami et al 1991). In addition, by truncating the gp 130, a loss of signal 
transducing ability was demonstrated to correspond to a lack of tyrosine 
phopshorylation of gp 130 induced by IL-6  (Murakami et al 1991).
Gearing et al (1991) reported that although IL-6  and LIF were structurally distinct, 
there was a degree of homology between the gp 130 and the LIF receptor, with the 
transmembrane and cytoplasmic domains being most closely related. Gearing and 
co workers (1991) suggested that IL-6  and LIF may share common signal 
transduction pathways which would help to explain some of the similar activities of 
the two factors such as induction of differentiation of Ml cells (Miyaura et al 
1989a, Metcalf 1989), stimulation of early hematopoiesis (Murray et al 1990) and 
induction of acute phase proteins from hepatocytes (Baumann et al 1989). Lord et 
al (1991) extended the studies of Gearing et al and investigated the intracellular 
signalling mechanisms induced by IL-6  and LIF during the differentiation of the 
myeloblastic leukemia Ml cells. Lord and co workers (1991) demonstrated that 
LIF and IL-6  shared a common intracellular signalling pathway which was distinct 
from other known mechanisms and involved a tyrosine phosphorylation which lead 
to activation of genes involved in myeloid differentiation.
There are differences between IL-6  and LIF actions on other cells however (see 
Chapter 1) and so the signalling pathways must vary in some respects. Possibly 
these differences may be related to the induction of alternative nuclear factors in 
different cells. The pleiotropic actions of IL-6  on different cell types may therefore 
be due to the expression of IL-6 -inducible nuclear proteins (Baumann et al 1990b). 
IL-6  induces nuclear proteins IL-6DBP (IL-6  DNA binding protein) and NF-IL-6  
(nuclear factor IL-6 ) in IL-6  responsive cells such as hepatocytes (Poli and Cortese 
1989, Akira et al 1990b). In addition, these binding proteins are homologous, but 
distinct (Poli et al 1990). Therefore, some of the many variable actions of IL-6  in
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different cell types may be due to the range of nuclear factors induced by this 
cytokine, as well as due to the presence of appropriate 'IL-6  responsive elements’ 
in the 5' upstream region of IL-6  responsive genes.
Since IL-6 R mRNA levels were not modulated in human osteoblast-like cells by 
any of the agents within this chapter, one, or a combination of these above points 
are possible. Further work is required to address these points.
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Fig.6.1 Constitutive expression of IL-6 R mRNA hv Northern blot
in human osteoblast-like ceils,
10ug of RNA from human trabecular bone cells was loaded for each of the 
2 lanes. The resultant filter was probed for IL-6 R (see Chapter 4 methods). 
The transcript was larger than the 28S ribosomal RNA band and was 
therefore approx. 5000 bases. This is a representative example of the 
twelve patients studied.
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Lack of modulation of IL-6R mRNA by rhTNFrxin human trabecular bone cells
in serum-free (fig. 6.2) or 10% FCS (fig. 6.3) containing EMEM.
C T C T C T
2 2 6 6 24 24
rhTNFcx (10”7M) was incubated with human osteoblast-like cells for various 
time points and the total RNA was subsequently extracted. Serial two-fold 
dilutions of RNA were performed starting with 4ug of RNA as the highest 
concentration. After probing for IL-6 R, the filter was stripped and reprobed 
with the cDNA probe for/3 actin. C = unstimulated osteoblast RNA and T = 
rhTNFK.
t t •
|# •  •  • • • C1 T T T T C1 2 4 8 8
6 3
192
Fig 6.4 Lack of modulation of IL-6R mRNA bv rhIL-liMn human
trabecular bone ceils in 10% FCS containing EMEM,
•  •
Human osteoblast-like cells were treated with rhIL-lc*(10 M) for 4 ,8 , 24 and 
48 h and total RNA was extracted. Serial two-fold dilutions of RNA were 
performed starting with 5ug of RNA. After probing for IL-6 R mRNA, the 
filter was stripped and reprobed with the A actin cDNA probe. C = 
unstimulated osteoblast RNA and T = rhIL-l<* treatment.
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Lack of m odulation of IL-6R mRNA bv rhIL-6 (fig. 6.5) and
1.25(OHU>a (fia. 6.6) in human trabecular bone cells in serum-free
containing EMEM.
C T C T C T
2 2 6 6 24 24
•  •  •
I f *m
•  i *
C T C T C T
2 2 6  6  24 24
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Human osteoblast-like cells were treated with l,25(OH)^D3 (10”%I) or IL-6  
(2000 pg/ml) for 2, 6  and 24 h and total RNA was extracted. Doubling 
dilutions starting at 6 ug of RNA were used and the filter probed for IL-6 R 
and actin mRNA.
C = unstimulated cells (vehicle) and T = treatment.
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Lack of modulation of IL-6R mRNA bv PTH in human trabecular bone
cells in serum-free (fig. 6.7) and 10% FCS (fig. 6 .8 ) containing EMEM.
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2 2 6 6 24 24
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•  • • • • •
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Human osteoblast-like cells were treated with PTH (10 ^V!) for 2, 6  and 24 h and 
total RNA was extracted. Doubling dilutions starting with 3 ug of RNA were 
used. After probing with IL-6 , the filter was stripped and reprobed with/* actin. 
C = unstimulated cells (vehicle) and T = treatment.
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Effect of rhIL-l(x(fig. 6.9) and rhTNFs* (fig. 6.10) alone and in combination with 
dexamethasone on IL-6 R mRNA and protein levels in human trabecular bone cells 
under seruro-free conditions,
C D  T T + D C D T T+D C D T T+D
C D  T T + D C D T T+D C D T T+D
2 2 2 2 6 6 6 6 24  24  24  24
The osteoblasts were treated with rhlL-li^lO'^VI), rhTNF(x(10“7M) alone and in 
combination with dexamethasone (10 6M) for various time points and the total RNA 
was extracted. Doubling dilutions starting with 4ug of RNA were used.
The filter was probed for IL-6 R mRNA followed by^actin. C = unstimulated cells 
(vehicles), D = dexamethasone and T = treatment (rhIL-lcxand rhTNF*).
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CHAPTER 7
THE ROLE OF ENDOGENOUS IL-6 ON HUMAN OSTEOBLAST-LIKE CELL
ACTIVITY.
ABSTRACT
In the work presented in Chapter 3, no potential function of exogenous IL-6 could 
be demonstrated on the activity of human and rat osteoblast-like cells. 
Furthermore, IL-6 did not modulate the activity of any stimulated osteoblast 
parameters measured. However, these cells also produce high basal endogenous 
levels of this cytokine as demonstrated in chapters 4 and 5. This raises the 
possibility that the high endogenous production of IL-6 may have masked the 
potential action of exogenous IL-6 on these cells. Endogenous IL-6 synthesis may 
also mediate the effects of osteotropic agents such as IL -la and TNFa on 
osteoblast-like cells. To investigate this possibility, a sheep anti-human EL-6 
neutralizing antibody was used to clarify the role of endogenous IL-6 on various 
osteoblastic parameters. When added to human osteoblast-like cell cultures at a 
1:1000 dilution, complete neutralization of endogenous IL-6 bioactivity, as 
assessed by the B9 assay, was observed. Various osteoblastic parameters were 
then studied in the presence and absence of this antibody. The contribution of basal 
endogenous IL-6 synthesis to the induction of osteocalcin production and alkaline 
phosphatase activity in response to l,25(OH)2D3 was examined. In addition, the 
involvement of the induction of IL-6 synthesis on the stimulation of cell 
proliferation, TNF and PGE2 production by human bone cells in response to 
rhIL-la was also examined. All of these studies demonstrated that the presence of 
the antibody exerted no detectable effects on any of the parameters measured. 
Furthermore, no effects of endogenous IL-6 were observed on the rhTNFa- 
induced cell proliferation or IL-1 production by human osteoblast-like cells. These 
studies do not support the notion that IL-6 has a role in the basal regulation of 
osteoblast cell activity or is responsible for mediating the actions of other 
osteotropic agents on human osteoblast-like cells.
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INTRODUCTION
IL-6 has been shown to be produced by osteoblast-like cells from a variety of 
species such as rat (Feyen et al 1989; Lowik et al 1989), mouse (Ishimi et al 1990, 
Li et al 1991) and human (Littlewood et al 1991b, Linkhart et al 1991b). In human 
bone cells, IL-6 mRNA is constitutively expressed (Litdewood et al 1991b, 
Linkhart et al 1991b). Furthermore, quantities of bioactive basal endogenous IL-6 
produced by human osteoblast-like cells range from 200 to 2050 pg/ml and 1950 to 
6650 pg/ml in serum-free and 10% (v/v) FCS containing cell conditioned media 
respectively (Chapter 4). These quantities of IL-6 far exceed the levels of many 
other cytokines produced by human osteoblast-like cells such as TNF (Gowen et al
1990) and IL-1 (Hughes et al 1988). The functional significance of such high 
levels of IL-6 production by the human osteoblast-like cells is uncertain since 
addition of exogenous IL-6 appears to exert no effects on these cells. It is possible 
however, that endogenous levels of IL-6 may have a role either in the tonal 
regulation of osteoblast metabolism alone or may mediate the effects of other 
cytokines on a particular aspect of osteoblast function. These possibilities were 
examined by use of a sheep anti-human EL-6 antibody which, at a 1:1000 dilution, 
neutralized all endogenous IL-6 activity. This antibody was specific for IL-6 as 
determined in the B9 assay (see table 7.1). Effects of endogenous basal IL-6 on 
various stimulated and unstimulated osteoblast features were studied. These 
included cytokine production (IL-1 and TNF), PGE2 production, proliferation and 
alkaline phosphatase and osteocalcin expression.
METHODS
Human osteoblast-like cells were plated out at a density of 5000 cells/well in a 
96-well plate for alkaline phosphatase activity determinations and at 10000 
cells/well in a 48-well plate for assessment of cell proliferation, osteocalcin, PGE2 , 
IL-1 and TNF production.
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Cells were allowed to attach to the tissue culture plate for 24 h and then 
preincubated in medium containing 0.1% (w/v) BSA or 10% (v/v) FCS in the 
presence or absence of anti-IL-6 antibody (1:1000 final dilution) for 1-2 h prior to 
addition of appropriate test agents to induce the various parameters studied. The 
antibody was therefore present at 1:1000 dilution in half of the wells throughout the 
whole experiment which neutralized all endogenous IL-6 bioactivity in those wells. 
After an incubation period of 24-72 h, conditioned medium was removed and used 
for appropriate assay.
Assays for cell proliferation, PGE2 , osteocalcin, IL-1 and TNF production were all 
performed as described previously in Chapter 3 (methods).
IL-6 production was determined, by using the B9 assay (Chapter 2), in all wells in 
order to demonstrate that all bioactivity was neutralized in wells containing the 
antibody.
The procedure for the assessment of alkaline phosphatase activity was adapted for 
the 96-well plate micro-assay. Medium was removed from the wells and the cell 
layer washed twice with PBS. 4.64 mg of 4-nitrophenylphosphate was added to 
10 ml of assay buffer (see Appendix 2) immediately prior to use (see Chapter 3 
methods). 200 ul of this solution was then added to each sample and incubated at 
37°C for 30-60 mins, or until optimal yellow/green colour developed. The 
absorbance at 410 nm was then measured on an ELISA platereader and results were 
expressed as a percentage of control absorbance value.
RESULTS
Stimulation of TNF production and cell proliferation induced bv rhlL-lrx (Fig 7.U 
Assessment of TNF production and cell proliferation were both studied in EMEM 
containing 10% (v/v) FCS since this was found to be the optimal condition to study 
these parameters. Under serum-free conditions, human osteoblast-like cells did not 
produce readily detectable levels of TNF using the WEHI cytotoxic assay (refer to 
Chapter 3). These experiments were conducted in the presence of indomethacin
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(1.4 uM) as prostaglandins are known to inhibit cytokine release from various cell 
types (Kunkel and Chensue 1985). After a 72 h incubation, rhIL-la (10_11M) 
significantly enhanced cell proliferation and TNF production in human osteoblast­
like cells. The stimulation of TNF synthesis and cell proliferation by rhIL-la 
(10'iiM) was unaltered by the addition of the anti-IL-6 antibody (1:1000). There 
was also no difference between the levels of basal TNF production and cell 
proliferation in the presence or absence of anti-IL-6 antibody.
It was necessary to demonstrate that all bioactive IL-6 was neutralized in cultures 
containing antibody. A small amount of conditioned medium was retained from 
each experiment for this purpose. All IL-6 activity was consistently and completely 
neutralized when antibody was used at 1:1000 dilution.
Stimulation of PGEo production bv rhIL-la (Fig. 7.21.
rhIL-la was an effective stimulator of PGE2 production in human osteoblast-like 
cells. This was observed in serum-free culture after 72 h with as low a 
concentration as 10'13 M rhIL-la although this effect was not always observed at 
such low concentrations. In this figure, the stimulatory effect was more marked in 
cultures without the presence of antibody. When cultures containing antibody were 
compared with the corresponding wells in the absence of antibody however, there 
were no significant differences. The stimulation of PGE2 activity by 10'11 M 
rhIL-la was very marked for human osteoblast-like cells +/- antibody. Complete 
neutralization of IL-6 bioactivity was observed upon addition of the IL-6 antibody.
Stimulation of cell proliferation bv rhTNFa (fig. 7.3).
TNFa also stimulates proliferation of the human osteoblast-like cells, although it is 
less potent than IL-1 (Gowen 1988). This was reflected by a significant increase in 
cell proliferation first being detected at a concentration of 10'9 M rhTNFa after 
72 h culture in medium containing 10% (v/v) FCS. The effect of TNFa on cell 
proliferation was most pronounced with the highest concentration of rhTNFa
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(10"7 M) used. Presence of anti- IL-6 antibody did not affect TNFa-stimulated, or 
basal cell proliferation.
All IL-6 activity was neutralized in cultures containing the antibody.
Stimulation of IL-1 production bv rhTNFa (fig. 7.4).
After 72 h culture in medium containing 10% (v/v) FCS, rhTNFa at a 
concentration of 10'8 M stimulated the basal IL-1 production although these levels 
were very low, amounting to 0.003 U/ml upon induction. The presence of 
endogenous IL-6 did not appear to affect either basal or TNF-stimulated production 
of IL-1. All endogenous IL-6 was blocked by the specific antibody.
Stimulation of alkaline phosphatase activity bv 1.25(OHl?D^ (fig. 7.51.
In the absence of antibody, alkaline phosphatase levels were consistently induced 
by l,25(OH)2D3 at 10-9 M and 10'8 M after 24 h culture in medium containing 
10% (v/v) FCS. The presence of the antibody did not affect basal alkaline 
phosphatase expression, nor did it modulate the induction of enzyme activity by 
l,25(OH)2D3. Under serum-free conditions, l,25(OH)2D3 did not stimulate the 
basal alkaline phosphatase activity after a 24 h incubation period (data not shown). 
Wells containing antibody did not contain any endogenous IL-6 activity as assessed 
by the B9 assay.
Stimulation of osteocalcin synthesis bv 1.25(OH)?D3 (fig. 7.6).
At a concentration of 10-8 M, l,25(OH)2D3 consistently stimulated osteocalcin 
levels in human osteoblast-like cells after 72 h incubation in serum-free culture. 
The presence or absence of anti-IL-6 antibody did not alter either the basal or 
l,25(OH)2D3-stimulated levels of this bone matrix protein. Furthermore, all IL-6 
activity was neutralized in cultures containing antibody.
201
DISCUSSION
The present studies demonstrate that endogenous production of IL-6 does not affect 
any of the parameters studied either under basal or rhIL-la, rhTNFa or 
l,25(OH)2D3-stimulated conditions. Since ROS 17/2.8 cells are derived from a rat 
osteosarcoma cell line, the sheep anti-human IL-6 antibody was unable to cross 
react with rat IL-6 and therefore only studies with human trabecular bone cells 
could be investigated. The studies presented within this chapter would indicate that 
IL-6 does not influence several aspects of human osteoblast-like cell function 
although this series of experiments does not exclude the possible interactions of 
IL-6 with other factors or that other activities of human osteoblast-like cells are 
similarly unresponsive. The demonstration of the presence of IL-6 receptor mRNA 
(Chapter 6) in human osteoblast-like cells is an interesting observation especially 
since IL-6 seems to exert no effect on the trabecular bone cells. However, the 
possibility that mRNA levels are not converted to the final receptor protein can not 
be eliminated. Alternatively, although human osteoblast-like cells may contain a 
functional receptor, they may lack the gp 130 glycoprotein through which IL-6 
transduces its signal (see Chapter 6 discussion). This aspect is currently being 
investigated. Another possibility is that the high endogenous levels of IL-6 
produced by osteoblasts may be exerting a de-sensitising effect on the cell's 
functional receptor. The lack of effects of IL-6 on basal osteoblast function may 
therefore be due to a number of possibilities.
Furthermore, IL-6 did not modulate the effects of IL-1, TNF or l,25(OH)2D3 with 
respect to the various osteoblast features studied (discussed in chapter 3). The 
theory that IL-6 may be a secondary agent by which IL-1 can mediate its effects 
arise from a number of studies: IL-1, TNF and IL-6 are produced by a wide range 
of cells, and IL-1 and TNF further induce EL-6 production in a number of these cell 
types including fibroblasts (Van Damme et al 1987a, 1987c, Elias and Lentz 1990), 
monocytes (Aarden et al 1987) and osteoblasts (Ishimi et al 1990, Littlewood et al 
1991b, Linkhart et al 1991b). As discussed in previous chapters, these cytokines
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have many pleiotropic actions, many of which overlap, including the induction of 
the acute phase response and proliferation of thymocytes. It is possible that IL-1 
and TNF may be exerting their effects in part at least, via the production of a 
secondary cytokine such as IL-6. Therefore, as well as examining the effects of 
endogenous IL-6 on osteoblast function, this chapter was designed to investigate 
whether the various effects of IL-1 and TNF were mediated via a secondary 
cytokine such as IL-6. Others have observed that IL-6 is able to mediate the IL-1 
response in a number of different environments, although some of the evidence 
presented is circumstantial rather than direct. Gueme et al (1989) observed that 
IL-1 and TNF are important in mediating inflammatory joint destruction through 
their ability to stimulate production of proteases and prostaglandins by 
synoviocytes. Gueme and co workers (1989) in the same report also demonstrated 
that IL-1 and TNF induce IL-6 expression by synoviocytes; hence it is possible that 
IL-1 and TNF are causing joint destruction via IL-6 production. Antibody studies 
are required to address this point. Nietfeld et al (1990) using human cartilage 
demonstrated that IL-1 stimulated IL-6 production and furthermore IL-6 was 
partially responsible for the IL-1 induced inhibition of proteoglycan synthesis. By 
using anti-IL-6 antibody, this group was able to demonstrate that IL-1 was exerting 
its effects partially by induction of IL-6. Black et al (1990,1991b), using neonatal 
mouse calvariae, observed that anti-EL-6 antibody inhibited resoiption due to IL-1 
and TNF. This latter work is controversial however, as other groups have been 
unable to demonstrate any effects of IL-6 on resorption (Barton and Meyer 1990, 
Al-Humidan et al 1991). Furthermore, using anti-IL-6 antibody, Al-Humidan et al 
(1991) demonstrated that EL-6 exerted no effect on IL-1 or TNF- stimulated 
resorption in the same system. Bataille et al (1991) observed that during the early 
stages of multiple myeloma, there was an increase in resorption accompanied by 
increased osteoblast numbers and generation of new osteoclasts. They 
demonstrated the presence of several cytokines in the myeloma milieu including 
EL-1, TNF and EL-6, which they proposed acted in cascade and synergy to enhance
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the pathogenesis of the disease. Obviously antibody studies are required in order to 
investigate which cytokines are mediating the effects of the other factors in the 
milieu.
Hence, although IL-6  is capable of mediating the response of cytokines such as 
IL-1 and TNF in various cells within the bone microenvironment, from the studies 
presented in this chapter, this does not seem to be the case for the human 
osteoblast.
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Fig. 7.1 Effect of endogenous IL-6 production on rhIL-1 -stimulated TNE 
production and proliferation in human osteoblast-like ceils..
Human osteoblast-like cells were incubated with rhIL-1 in the presence or absence of 
sheep anti-human IL-6 antibody for 72 h in 10% (v/v) FCS-containing EMEM. The cell 
layer was subsequently assayed for proliferation (middle graph) and the conditioned 
medium was removed for TNF (top graph) and IL-6 bioassay. Mean ± S.E.M. 
Significant difference from control (- antibody) *p<0.05, **p<0.01, ***p<0.001. 
Significant difference from control (+ antibody) oop<0.01. There was no significant 
difference between wells ± antibody for any of the above parameters investigated. 
Neutralization of IL-6 activity in the cultures containing the sheep anti-human IL-6 
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Fig. 7.2 Effect of endogenous IL-6  on rhIL-lj* stimulated prostaglandin Eg 
levels in human osteoblast-like cells.
Human trabecular bone cells were incubated with rhIL-la in the presence and absence 
of antibody for 72 h in 0.1% BSA-containing EMEM . The bone cell conditioned 
medium was removed and assayed for PGE2 levels (top graph) and IL-6  bioactivity. 
Mean ± S.E.M. Significant difference from control (- antibody) *p<0.05, **p<0.01, 
***p<0.001. Significant difference from control (+ antibody) ooop<0.001. There was no 
significant difference between wells ± antibody.
Neutralization of IL -6  activity in the cultures containing the antibody was determined by 
the B9 assay (bottom graph). Representative experiment (n=3).
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Fig. 7.3 Effect of endogenous IL -6  on rhTNF^stimulated proliferation 
in human osteoblast-like cells.
Human trabecular bone cells were incubated with rhTNFxin the presence or absence of 
sheep anti-human IL -6  antibody for 72 h in 10% (v/v) FCS- containing EMEM. The cell 
layer was assessed for proliferation (top graph) and the conditioned medium was stored 
for IL-6  bioassay. Mean ± S.E.M. Significant difference from control (- antibody) 
*p<0.05, **p<0.01. Significant difference from control (+ antibody) °p<0.05,ooop<0.00I. 
There was no significant difference to wells ± antibody.
Neutralization of IL-6  activity in the cultures containing the antibody was determined by 
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Fig. 7.4 Effect of endogenous IL-6  on rhTNFx- stimulated IL-1 levels Ln_____
human osteoblast-like cells,
Human osteoblast-like cells were treated with rhTNFU in the presence and absence of 
sheep anti-human IL-6  antibody in 10% (v/v) FCS-containing EMEM for 72 h culture. 
The bone cell conditioned medium was removed and assayed for IL-1 and IL-6  
bioactivity. Mean ± S.E.M. Significant difference from control (- antibody) *p<0.05, 
**p<0.01. Significant difference from control (+ antibody) oop<0.01. There was no 
significant difference between wells ± antibody.
Neutralization of IL-6  activity in the cultures containing the antibody was determined 
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Fig. 7.5 The effect of. endogenous IL-6 on J,25(QHU) -stimulated 
alkaline phosphatase lmls in human osteoplast-like
Human osteoblasts were incubated with l,25(OHy)3 in the presence 
and absence of sheep anti-human IL-6  antibody for 24 h in 10% (v/v) 
FCS-containing EMEM. Alkaline phosphatase activity in the cell 
layer was measured on a spectrophotometer at 410 nm (top graph). 
Mean ± SEM. Significant difference from control (- antibody) where 
absorbance at 410 nm was 0.139, **p<0.01, ***p<0.001. Significant 
difference from control (+ antibody) where absorbance at 410 nm was 
0.142 ooop<0.001. There was no significant difference between the 
wells treated with antibody and wells without antibody.
Neutralization of IL-6  activity in the cultures containing the antibody 
was determined by the B9 assay (bottom graph). Representative 
experiment (n=3).
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Fig. 7.6 Effect of endogenous IL-6  on i ,2 5 (QH)2 i^  -stimulated osteocalcin 
levels in human osteoblast-like cells.
Human trabecular bone cells were cultured with l,25(OHy>oin the presence or absence of 
sheep anti-human IL-6  antibody in 0.1% BSA-containing EMEM for 72 h culture. The 
conditioned medium was removed and assessed for osteocalcin content (top graph) and IL-6 
bioactivity. Mean ± S.E.M. Significant difference from control (- antibody) **p<0.01. 
Significant difference from control (+ antibody) ooop<0.001. There was no difference 
between wells ± antibody. Neutralization of IL-6  activity in the cultures containing the 
antibody was determined by the B9 assay (bottom graph). Representative experiment (n=3).
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GENERAL DISCUSSION
From the data presented within this thesis, it can be seen that IL-6  does not affect 
osteoblast function with respect to proliferation, differentiated phenotype, and 
production of cytokines and prostaglandins. This could be due to a number of factors 
such as
a) inappropriate osteoblast parameters studied: -
Others have observed a slight depression in collagen type I production by murine 
osteoblasts (Ishimi et al 1990, Fang and Hahn 1991). Whether this is the case for the 
human osteoblasts remains to be elucidated. In addition, further information may be 
gained by the investigation of whether EL-6  modulates the expression of integrins and 
production of bone matrix proteins such as osteopontin. This study could provide 
information about whether the osteoblasts are induced to interact with the matrix and 
attach to the bone surface. Several bone matrix proteins such as thrombospondin 
(Gehron-Robey et al 1989) and osteopontin (Oldberg et al 1986) contain an RGD 
sequence which is associated with cell attachment and spreading. Furthermore, integrin 
expression by cells also promotes attachment by binding to recognised sequences. The 
RGD sequence is a ligand for some of these integrins for example (Dedhar 1990, 
Ruoslahti and Yamaguchi 1991). Human osteoblasts express the a l  integrin, the 
expression of which is upregulated by the addition of IL-1 (J.Clover, personal 
communication). As this integrin subunit is capable of association with collagen 
(Dedhar 1990), it supports the theory that osteoblasts are capable of attachment to the 
bone surface. In addition, Dedhar (1989) reported that the pi integrin subunit was 
induced in human osteosarcoma lines after exposure to IL-1. Whether EL-6  mimicks 
the IL-1 action in human osteoblasts remains to be studied. Certainly other effects of 
IL-1 on various human osteoblast features such as proliferation and prostaglandin and 
cytokine production, were not shared by EL-6 .
b) osteoblasts in vitro may not behave in the same way as ones in vivo: -
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Little is known about the behaviour of cells in vivo. In vitro study is less complicated 
and can be valuable for demonstration of general trends. An example of this is evident 
by the fact that IL-1 induces proliferation of osteoblasts both in vitro (Gowen 1988) 
and in vivo (Boyce et al 1989). In vitro study does have its limitations however, in that 
generally the system is over simplified and often effects of a single agent on an isolated 
cell type are studied. Therefore, possibility of interaction with other agents, cell types 
and matrix is not explored. It is possible that IL-6  may have effects on osteoblasts in 
combination with other factors produced by some other cell type absent in tissue 
culture. Alternatively, IL-6  may act on another cell type resulting in the release of a 
factor that may affect the osteoblasts. Another problem is encountered by using various 
clonal osteoblast cell lines as a potential model system. They all behave differently in 
culture which can serve to confuse the issue rather than clarify it. The rat osteosarcoma 
line, ROS 17/2.8, exhibits a very different spectrum of actvities to the human trabecular 
bone cells in vitro (Chapter 3). The former cells do not produce bioassayable amounts 
of TNF, exhibit lower prostaglandin and IL-6  levels and higher alkaline phosphatase 
levels. Furthermore, their response to osteotropic agents differ, for example PTH 
stimulates IL-6  production in the rat osteosarcoma line, but not in the human 
osteoblast-like cells. Therefore while these systems are useful for the study of 
osteoblast functions, results must be interpreted with some caution.
Culture on plastic rather than on the bone surface or matrix components also has an 
influence on osteoblast function and cytokine production. For example, adherence of 
macrophages and monocytes to plastic can produce a powerful signal for the production 
of TNFa and IL-1. This apsect, amongst others is reviewed by Nathan and Spom 
1991. Culture of osteoblasts on collagen gels reduces l,25(OH)2D3- induced alkaline 
phosphatase and osteocalcin expression (J. Clover, personal communication). Hence it 
is likely that matrix components have a bearing on remodelling functions (Nathan and 
Spom 1991). They suggested that cytokines are intercellular signal proteins that 
coordinate remodelling of tissues in association with the extracellular matrix. There are 
many ways that the two interact, such as adherence to matrix could induce cells to
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produce cytokines, or cytokines themselves might affect cell adhesion receptors 
(integrins - as discussed earlier). Combined requirement for cytokine and matrix 
signals may be important for localising responses of cells to a cytokine (such as IL-6 ) 
that is widely distributed. Cytokine interactions on cells in vitro need to take into 
account the extracellular milieu of the responding cells in vivo. Nathan and Spom 
(1991) postulated that in vitro tissue culture on isolated cell populations often leads to 
contradictory effects for a particular agent and therefore is a relatively unsatisfactory 
technique.
Future work should take this into consideration, and culture of cells within 3 
dimensional matrices containing components of the bone matrix may provide us with 
more meaningful results.
In situ hybridisation and immunolocalisation, although difficult to quantitate, have the 
potential to provide valuable information about which cells are expressing particular 
proteins at a certain time. Also information on whether expression alters under 
different environmental conditions is relatively easily obtained with these techniques. 
In Chapter 4, it was demonstrated that human osteoblasts produced high constitutive 
levels of IL-6  mRNA in vitro which was in contrast to the fluctuating levels of IL-6  
mRNA expression observed in tissue sections by in situ hybridisation. Therefore, it 
would appear as though the synthesis of IL-6  in vitro does not accurately reflect 
expression in situ. Co-localisation of IL-6  mRNA with the expression of various 
markers of osteoblast differentiation has the potential to provide valuable information as 
to whether the IL-6  gene is regulated at different stages of osteoblast development and 
this may give an indication of the role of IL-6 .
c) osteoblasts do not have functional receptors:-
In Chapter 6 , mRNA for the IL-6 R was constitutively produced by human osteoblast 
like cells. It is possible that the mRNA is not converted to the final mature protein or 
alternatively, the receptor is expressed but associated signalling components such as 
gp 130 (Taga et al 1989) are absent. Another possibility is that the osteoblasts do not 
contain IL-6 -inducible nuclear factors which bind to responsive elements of certain
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genes to alter their transcription as visualised in hepatocytes (Poli et al 1990). These 
possibilities need to be explored by the use of immunoprecipitation techniques, and by 
Northern analysis as cDNA probes for gp 130 (Hibi et al 1990) and nuclear factor 
IL-6DBP (Poli et al 1990) have been isolated.
d) endogenous levels of IL-6  mask exogenous IL-6 :-
In Chapters 4 and 5, it was demonstrated that human osteoblasts produce large 
quantities of IL-6  (B9 bioassay, Northern analysis, immunolocalisation and in situ 
hybridisation). Therefore another explanation for the lack of effects of IL-6  on human 
osteoblasts may be that high endogenous IL-6  levels mask the exogenously added 
cytokine. This possibility was eliminated by use of a monoclonal antibody to IL-6 . 
This neutralised all IL-6  endogenous activity in culture (assessed by the B9 assay). The 
removal of IL-6  did not modulate various basal or stimulated osteoblast parameters 
such as proliferation, cytokine and prostaglandin production, and differentiated 
phenotype such as alkaline phosphatase and osteocalcin expression. Therefore, IL-6  
was not responsible for the modulation of the above parameters in human osteoblasts. 
However, this does not exclude the possibility that endogenous IL-6  levels are 
modulating other functions of osteoblasts not studied in this thesis.
e) The half life of IL-6  in vivo and in vitro is another factor to take into consideration 
and presence of inhibitors or protective carrier proteins will affect this.
a2 macroglobulin is known to associate with IL-6  to form a soluble complex which is 
transported in the circulation (Matsuda et al 1989). This provides a mechanism whereby 
IL-6  is protected from degradation and is transported systemically without inhibiting its 
function. Novick et al (1989) demonstrated the presence of the extracellular portion of 
the IL-6 R in human urine, which was capable of binding EL-6  but did not inhibit IL-6  
activity. Saito et al (1991) developed an ELISA in the murine system for the detection 
of the truncated IL-6  receptor whereas the equivalent ELISA in the human requires 
development. Presence of a2 macroglobulin and soluble EL-6 R would provide 
valuable information as to whether the conditions in vivo and in vitro are different, 
resulting in alterations in the lifespan of IL-6 . It is of interest to note that a soluble form
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of the TNF receptor exists in the circulation which inhibits TNF activity (Nophar et al 
1990). Whether a specific inhibitor for IL-6  exists remains to be elucidated.
The study presented in Chapter 5 has also shown that osteoclasts produce IL-6  mRNA. 
Evidence would suggest that they may produce the IL-6  protein as this was visualised 
by immunolocalisation on isolated osteoclasts derived from osteoclastoma tumour. 
Immunolocalisation studies need to be repeated in tissue sections using a more 
appropriate negative control as the non immune sheep serum used in these studies may 
have contributed to the high non specific background seen in tissue sections.
From evidence presented in this thesis and from other studies (Ohsaki et al 1991, Qi et 
al 1991, Merry et al 1992b, Hoyland et al 1992) it would appear that osteoclasts are 
capable of synthesizing several cytokines and therefore do not exert a purely resorptive 
role. By expressing mRNA for various cytokines, the osteoclasts may signal to other 
cells within the bone microenvironment. For example, it is possible that osteoclasts are 
producing IL-6  in order to maintain hematopoiesis resulting in the promotion of the 
maturation of immature osteoclasts (discussed later). The possible production of 
cytokines such as TNF by the osteoclast (Qi et al 1991) is likely to affect the 
proliferation of the osteoblasts. Gowen (1988) demonstrated that in vitro, TNF 
increased osteoblast proliferation and down-regulated the differentiated phenotype of 
osteoblasts which may serve to increase the available osteoblast pool. As osteoblasts 
are capable of producing TNF themselves (Gowen et al 1990, Merry et al 1990), it 
appears that this cytokine can act in an autocrine as well as a paracrine fashion. It 
therefore seems likely that osteoclasts are capable of modulating osteoblast function in a 
number of ways. Merry et al (1991) was unable to demonstrate the production of 
TGFp in osteoclasts by in situ hybridisation. However, from the work of Oreffo et al 
(1989) and Pfeilschifter et al (1990a 1990b), it is likely that osteoclasts activate the 
latent TGFp complex present in the matrix, which serves as a chemoattractant for 
osteoblasts. Other growth factors and bone matrix proteins will be released during the
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process of resorption and these will also have influences on the osteoblasts as well as 
on the other cells within the vicinity of the resorbing osteoclasts.
Further in situ studies are required to demonstrate the repertoire of factors produced by 
osteoclasts and this will contribute to the understanding of the role of this cell in 
remodelling. In addition, since isolation of osteoclasts is a difficult procedure and their 
phenotype does not appear to be stable in culture, in situ hybridisation is a useful tool 
for studying the osteoclast. There are limitations to in situ hybridisation, as handling 
of the tissue is critical and sections need to be demineralised, resuting in the loss of 
cells and available mRNA. However, in situ hybridisation is particularly valuable for 
the study of the behaviour of cells and is more likely to represent an in vivo situation 
than tissue culture conditions. Whilst tissue culture is useful for the simplified study of 
a particular factor on an isolated cell type, the limitations are numerous as discussed 
earlier. More involved studies are now required to study interactions of cells with 
factors within their local milieu.
From the studies presented within this thesis, it appears that IL-6  is produced by 
osteoblasts and exerts a paracrine role in that it acts on other cells within the tissue. The 
fluctuating levels of this cytokine produced by different populations of osteoblasts seen 
in chapter 5, would indicate that IL-6  expression during remodelling is not at a constant 
level. Furthermore, IL-1 and TNF-stimulated IL-6  mRNA levels were transiendy 
increased in human osteoblasts (Chapter 4) which would support the theory that IL-6  
levels within the bone microenvironment are variable. It is possible that IL-6  
concentrations need to reach a threshold level before its actions become effective in 
vivo. More detailed in situ studies are required to establish whether these ideas have 
foundation.
Whether IL-6  exerts paracrine or autocrine effects on osteoclasts remains to be 
elucidated. The study of the presence of the IL-6  receptor on osteoclasts by in situ and 
immunolocalisation techniques would be useful in this respect. There are several 
conflicting studies concerning the role of IL-6  on bone resorption (Barton and Mayer
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1990, Al-Humidan et al 1991, Black et al 1991b, Ishimi et al 1990, Lowik et al 1989). 
Furthermore, IL-6  is increased by the resorptive agents IL-1 and TNF and may 
therefore serve to prolong resorption (Black et al 1990) or inhibit resorption (Al- 
Humidan et al 1991) by these factors.
The majority of evidence suggests that IL-6  acts at some stage on the immature 
osteoclast precursors to promote osteoclastogenesis. There are several lines of 
evidence to support this theory. Many groups have observed that IL-6  promotes 
maturation of hematopoietic stem cells along the granulocyte/macrophage lineage 
(Ikebuchi et al 1987, Hoang et al 1988, Wong et al 1988, Suda et al 1988, Gardner et 
al 1990). Kurihara et al (1990) demonstrated the induction of osteoclasts by IL-6  in 
long-term human marrow culture and Lowik et al (1989) observed that IL-6  only 
promoted resorption in murine bones containing osteoclast precursors. This suggests 
that IL-6  exerts a permissive role on the promotion of resorption, in that IL-6  increases 
production of osteoclast precursors rather than acting on the mature phenotype.
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